AU2006262275A1

AU2006262275A1 - HIV-1 protease inhibitors, and methods of making and using them

Info

Publication number: AU2006262275A1
Application number: AU2006262275A
Authority: AU
Inventors: Akbar Ali; Michael D. Altman; Saima Ghafoor Anjum; Hong Cao; Sripriya Chellappan; Miguel X. Fernandes; Kiran Kumar Reddy Garudammagari Sai; Michael Gilson; Visvaldas Kairys; Nancy King; Madhavi Nagga Laxmi Nalam; Ellen Nalivaika; Moses Prabu; Tariq M. Rana; Celia A. Schiffer; Bruce Tidor
Original assignee: Massachusetts Institute of Technology; University of Maryland College Park; University of Massachusetts Amherst
Current assignee: Massachusetts Institute of Technology; University of Maryland College Park; University of Massachusetts Amherst
Priority date: 2005-06-22
Filing date: 2006-06-21
Publication date: 2007-01-04
Also published as: EP1937655A1; CA2667449A1; JP2008546790A; WO2007002173A1

Description

WO 2007/002173 PCT/US2006/024109 HIV-1 Protease Inhibitors, and Methods of Malking and Using Them RELATED APPLICATIONS The present application claims priority from U.S. provisional patent application 5 serial No, 60/693,134, filed on June 22, 2005, US. provisional patent appliafion serial No, 60/749,902, filed on December 12, 2005, and U.S. provisional patent application serial No. 60/810,234 filed on June 2, 2006, all of which are expressly incorporated by reference, GOVERNMENT SUPPORT This invention Was made with support provided by the NIH/NIAID (Grant No. 10 PO01GM 066524-01); therefore, the government m4y have crtan rights in the invention. BACKGROUND OF THE INVENTION Human immunodeficiency virus type 1 (HIV-1) protease plays % critical role in the virus life cycle by processing the viral Gag and Gag-Pol polyproteins into strumctural and fmactional proteins essential for vikal maturation. Ithibitioa of IV-1 protease leads to the 15 production ofnoninfeotious virus particles and hence is w promising therapeutic target for auntiviral therapy in AIDS patients. In fact, HIV-1 protease inhibitors represent the most potent anti-AIDS drugs reported to date and are essential components of highly active antiretroviral therapy (HAART). In the last decade, structure based drug design has led to the discovery of eight FDA approved drugs and several others in advanced clinical trials, 20 Currently marketed HIV-I protease inhibitors, saquinavir, indinavir, ritonaviri, nelfinavir, amprenavir, lopinavir, atazanavi-, and tipranavir, are all competitive inhibitors that bind in the active site of the enzyme. Except the newly approved drug tipranavir, all approved inhibitors have been developed based on transition state mimetic concept and contain various nonleavable dipeptide isosteres as core acaffolds to nimio the transition state of 25 HIV-1 prot ease substrates. The development and olinioal. itroduotion of santi-AIDS HIVW-l protease inhibitors is regarded as major success of structure based drug design. Anti-AIDS chenmotherapy based on HIV-1 protease and reverse-franscriptase inhibitors has been remarkably successful in decreasing the mortality rate in HIV-1 infected patients. However, the emergenqw of Hl'V-I mutants that are resistant to ourent drug 30 regimens is a critical factor in the clinical failure of antiviral therapy. In general, drug RECTIFIED SHEET (RULE 91)

ISA/EP

WO 2007/002173 PCT/US2006/024109 resistance occurs when mutations in a target protein allow that protein to retain function while in the presence of a drug. In the case of HIV-1 protease, drug resistence typically occurs when, even in the presence of protease inhibitors, the enzyme is able to cleave the Gal and Pol polypeptides in at least nine different locations, allowing viral mutation. Viral 5 resistance is regarded as a critical factor in clinical failure of antiviral therapy. The relatively rapid appearance of resistant viral mutants among treated HIV patients is attributable to the virus' high rate of replication, coupled with a high intrinsic rate of mutation due to the infidelity of the HIV reverse transcriptase. Further, current HIV-1 protease inhibitors were designed to inhibit a single variant of HIV-1 protease. 10 For most of the currently approved protease inhibitors, the emergence of multi drug resistant (MDR) mutants poses a great challenge to the efficacy of these drugs. (Condra, J. H. et al. Nature 1995, 374, 569-571; and Clavel, F. et al. N. Engl. J. Med. 2004, 350, 1023-1035.) Development of next generation HIV-1 protease inhibitors active against MDR virus has been the focus of intense research efforts in recent years. (Koh, Y. et al. 15 Antnimicrob. Agents Chemother. 2003, 47, 3123-3129; Surleraux, D. L. N. G. et al. J Med. Chem. 2005, 48, 1813-1822; and Surleraux, D. L. N. G. et al.. J Med. Chem. 2005, 48, 1965-1973.) Developing different classes of therapeutic agents is not likely to be an adequate solution to the problem of resistance to protease inhibitors, primarily because the same 20 basic molecular-biological mechanisms will likely also lead to viral strains resistant to the other agents. In fact, resistance is a major clinical problem for the other major classes of HIV drugs, the reverse transcriptase inhibitors, and resistance to newer preclinical agents, such as fusion inhibitors, develops rapidily in vivo. Therefore, the challenge is to develop new classes of protease inhibitors that are less 25 susceptible to drug resistance with an emphasis on broad spectrum activity against MDR mutants. The present invention addresses the challenege. SUMMARY OF THE INVENTION The present invention is based, at least in part, on the discovery of small molecule protease inhibitors (PIs). These inhibitors, and methods of making and using them, are 30 described herein. It is expected that these inhibitors will be less likely to induce the -2- WO 2007/002173 PCT/US2006/024109 development of resistant strains, because when they are bound to HIV-1 protease, these inhibitors appear not to protrude beyond the enzyme's substrate binding envelope. In one aspect, the invention features PIs described herein, or an enantiomer, diastereomer or a pharmaceutically acceptable salt thereof, and pharmaceutical 5 compositions for inhibiting HIV protease that include a pharmaceutical carrier and a therapeutically effective amount of a PI described herein. In another aspect, the invention features methods for treating a viral infection, e.g., an HIV infection or AIDS in a subject, comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition described 10 herein. In some embodiments, the methods further comprise administering a second therapeutic agent, e.g., a non-nucleoside reverse transcriptase inhibitor (NNRTI), such as efavirenz (SustivaTM), nevirapine (ViramuneTM) and delavirdine (RescriptorTM); a nucleoside reverse transcriptase inhibitor (NRTI), such as AZT (zidovudine, RetrovirTM)/3TC (lamivudine, EpivirTM) and d4T (stavudine, ZeritTM)/3TC; and d-drugs 15 (ddl [didanosine, Videx T M /VidexEC T M ], ddC [zalcitabine, HividTM], d4T); a nucleotide reverse transcriptase inhibitor, such as tenofovir (VireadTM); and a fusion inhibitor, such as enfuvirtide (FuzeonTM). In some embodiments, the compound or pharmaceutical composition is administered as part of a highly active antiretroviral therapy (HAART) regimen. 20 Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention relates. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are only illustrative of the invention and, therefore, they 25 are'not intended to be limiting. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control. Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims. -3- WO 2007/002173 PCT/US2006/024109 BRIEF DESCRIPTION OF THE FIGURES Figure 1 depicts the chemical structures of amprenavir (APV) 1, TMC114 2 and selected compounds of the invention 3. Figure 2 depicts a scheme showing the synthesis of intermediates N 5 Phenyloxazolidine-5-carboxylic acids 9 and 10. Key: (a) n-BuLi, THF, -78 'C to r. t. overnight; (b) RuC1 3

.H

2 0, CH 3 CN-CC14-H 2 0 (2:2:3), 0 'C to r. t. 4-10 h. Figure 3 depicts a scheme showing the synthesis of inventive compounds 20-29. Key: (a) EtOH, 80 oC, 3-4 h; (b) aq. Na 2

CO

3 , CH 2 Cl 2 , 0 'C to r. t., 4-8 h; (c) TFA, CH 2 C1 2 , 1 h; (d) (OCOC1) 2 , r. t., overnight; (e) Et 3 N, TIF, 0 oC to r. t., 4-8 h; (f) SnCl 2 .2H 2 0, 10 EtOAc, 70 oC, 2 h. Figure 4 depicts a scheme showing the synthesis of compounds 36-39. Key: (a) iPrOH or EtOH, 80 oC, 3-4 h; (b) aq. Na 2

CO

3 , CH 2 C1 2 , 0 oC to r. t., 4-8 h; (c) TFA,

CH

2 C1 2 , 1 h; (d) (OCOC1) 2 , r. t., overnight; (e) Et 3 N, THF, 0 'C to r. t., 4-8 h. Figure 5 depicts a table showing the inhibitory activities of selected inventive 15 compounds, amprenavir (APV) and lopinavir (LPV) against wild type HIV-1 Protease. Figure 6 depicts selected structure and inhibitory activities of novel protease inhibitors of the invention. Figure 7 depicts a table showing inhibitory activities of selected compounds of the invention against wild type HIV-1 protease. 20 Figure 8 depicts a table of inhibitory activities of selected compounds of the invention, and known inhibitors, against MDR Mutant Proteases (Wt: Q7K; Ml: L10I, G48V, I54V, L63P, V82A; M2: D30N, L63P, N88D; M3: L10I, L63P, A71V, G73S, I84V, L90M; APV: amprenavir; LPV: lopinavir.) Figure 9 depicts a table showing the purity of selected target compounds as 25 determined by HPLC using two different systems. First system: column, Waters Nova-Pak RP-C18 (4 pm, 3.9 mm x 150 mm); mobile phase A, 10 mM ammonium acetate in water; mobile phase B, acetonitrile. Using a flow rate of 0.8 mL/min, gradient elution was performed from 50% B to 100% B over 10 min. Second system: column, Agilent Zorbax 300SB-C8 (5 /m, 4.6 mm x 250 mm); mobile phase A, 0.1% trifluoroacetic acid in water; 30 mobile phase B, 0.1% trifluoroacetic acid in acetonitrile. Gradient elution was performed from 50% B to 100% B over 10 min at a flow rate of 1 mL/min. -4- WO 2007/002173 PCT/US2006/024109 Figure 10 depicts graphically HIV protease kinetics in the absence and presence of an inhibitor (Amprenavir). Figure 11 depicts a graph used for the calculation of initial velocities. Figure 12 depicts a graph and equation used to determine binding dissociation 5 constants. Figure 13 depicts graphically data enabling the calculation of the Ki for an HIV-1 protease inhibitor (KB-19 = 21f) of the present invention. Figure 14 depicts various classes of HIV-1 protease inhibitors of the present invention. 10 Figure 15 depicts various embodiments of the cyclic carbamate portion of the HIV 1 protease inhibitors of the present invention, e.g., those represented by any of Formulas I to IX. The present invention expressly encompasses the combination of any of the embodiments depicted in the Figure with any of the other structural features described herein. 15 Figure 16a-k depicts anti-HIV drugs by class. Figure 17 depicts selected compounds of formula VA/VB and associated Ki values. Figure 18 depicts selected compounds of formula IIIA/IIIB and associated Ki values. Figure 19 depicts selected compounds of formula VIIA/VIIB and associated Ki 20 values. Figure 20 depict possible synthetic routes to selected inventive compounds. DETAILED DESCRIPTION OF THE INVENTION One aspect of the present invention addresses the challenge of developing HIV-1 protease inhibitors that are less vulnerable to drug resistance and/or more active against 25 current protease-resistant HIV-1 isolates than other HIV drugs. The present invention addresses this challenge by integrating clinical data, in vitro virology, and high-throughput chemistry and compound screening. HIV protease is a particularly appealing target because inhibiton of its activity is clinically effective; however, it can evolve to tolerate extensive mutations conferring drug resistance while retaining enzymatic function. -5- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the invention relates to designed inhibitors based on the (R)-(hydroxyethylamino)sulfonamide isostere present in 1 and 2 (Figure 1). Among the approved protease inhibitors, amprenavir (APV) 1 fits reasonably well within the substrate envelope (Figure 1). It has been suggested that the inhibitors designed on the APV template 5 may be less susceptible to drug resistance. (King, N. M. et al. J. Virol. 2004, 78, 12012 12021.) Protease inhibitor TMC114 2, structurally similar to 1, has been recently shown to possess very potent in vitro and in vivo antiviral activity against wild type as well as MDR mutants (Figure 1). (De Meyer, S. et al. Antimicrob. Agents & Chemother. 2005, 49, 2314 2321.) Compared to the THF moiety in 1, the additional interactions of bis-THF moiety in 10 2 with the backbone atoms of fairly conserved Asp29 and Asp30 residues in protease explains its potent and broad spectrum activity against MDR mutants. (Koh, Y. et al. Antimicrob. Agents Chemother. 2003, 47, 3123-3129; and Surleraux, D. L. N. G. et al. J. Med. Chemn. 2005, 48, 1813-1822.) Therefore, it was envisioned that a small heterocyclic moiety with multiple polar 15 atoms located at the P2 position would mimic the critical interactions of the THF/bis-THF moieties present in APV/TMC114. Since the oxygen atom of the carbamate linking THF/bis-THF moieties to the hydroxyethylamine core in 1 and 2 does not make any hydrogen bond contacts with the protease, it was decided to attach the heterocyclic moiety to the core isostere via amide linkage. Previous reports of inhibitors with heteroaryl and 20 other polar heterocyclic groups as P2 ligands directly linked to the (hydroxyethylamino)sulfonamide fragment did not show promising activities. (Ghosh, A. K. et al. Bioorg. Med. Chem. Lett. 1998, 8, 979-982; and Ghosh, A. K. et al. Farmaco 2001, 56, 29-32.) However, inhibitors incorporating substituted hydroxybenzamides as P2 ligands have shown potent inhibitory activities against HIV-1 protease. (Freskos, J. N. et 25 al. Bioorg. Med. Chemn. Lett. 1996, 6, 445-450; Cheng, T.-J. et al. Antimicrob. Agents Chemother. 2004, 48, 2437-2447; Nagarajan, S. R. et al. Bioorg. Med. Chemn. 2003, 11, 4769-4777; and Vazquez, M. L. US Patent 6,046,190, hereby incorporated by reference.) Recently, protease inhibitors incorporating 2,3-dihydroxybenzoic acid derived macrocyclic P l-P2 ligands have been reported to exhibit low nanomolar protease inhibitory activities. 30 (Ghosh, A. K. et al J. Med. Chem. 2005, 48, 3576-3585.) In one embodiment of the invention, N-phenyloxazolidine-5-carboxamides were selected to be utilized as P2 ligands in HIV-1 protease inhibitors. The oxazolidines represent a class of synthetic antimicrobial agents that are highly stable and exhibit -6- WO 2007/002173 PCT/US2006/024109 exceptional bioavailability profiles. (Barbachyn, M. R. et al. Angew. Chem., Int. Ed. 2003, 42, 2010-2023.) For example, Linezolid is an FDA approved antibacterial drug that contains N-phenyloxazolidine nucleus. (Brickner, S. J. et al.. J. Med. Chem. 1996, 39, 673 679.) In addition, N-phenyloxazolidine-5-carboxamides were recently reported to possess 5 better antibacterial activities compared to linezolid with enhanced solubility and bioavailability properties. (Hester, J. B. WO 2003/006440, hereby incorporated by reference; and Thomas, R. C. WO 2003/072553, hereby incorporated by reference). It was reasoned that the carbonyl group of the oxazolidine ring would mimic critical hydrogen bond interactions of THF/bis-THF moieties of APV and TMC114 in the S2 binding pocket 10 of the protease active site. The phenyl group at the ring nitrogen can be utilized to introduce functional groups to make additional contacts with the protease. In addition, the selected heterocyclic moiety can be linked to the (hydroxyethylamino)sulfonamide isostere in stereochemically defined manner using either (R)- or (S)-enantiomer of N phenyloxazolidine-5-carboxylic acids. 15 Remarkably, the N-phenyloxazolidine based cyclic carbamate ligands have not been utilized previously in protease inhibitors. However, there are reports of inhibitors containing other cyclic carbamate ligands, but with poor protease inhibitory activities. (Salituro, F. G. et al. Bioorg. Med. Chem. Lett. 1998, 8, 3637-3642.) On the other hand, cyclic urea based ligands have been widely used in protease inhibitors; approved drug 20 lopinavir contains cyclic urea at P3 position. (Sham, H. L. et al. Antimicrob. Agents Chemother. 1998, 42, 3218-3224.) In addition, substituted imidazolidines have been incorporated as cyclic Pl-P2 scaffolds in protease inhibitors based on hydroxyethylene and hydroxyethylamine isosteres. These conformationally restricted molecules displayed potent inhibitory activities against HIV-1 protease with Ki values in nanomolar range. 25 (Kazmierski, W. M. et al. Bioorg. Med. Chem. Lett. 2004, 14, 5685-5687.) Recently, potent oximinoarylsulfonamide based HIV-1 protease inhibitors that contain N-substituted five membered cyclic urea moiety linked to the hydroxyethylamine core analogous to lopinavir P3 side chain have been reported. (Yeung, C. M. et al. Bioorg. Med. Chem. Lett. 2005, 15, 2275-2278; and Randolph, J. T. et al. Bioorg. Med. Chem. 2006, 14, 4035 30 4046.) In certain embodiments the compounds of the invention are a novel series of HIV-1 protease inhibitors incorporating N-phenyloxazolidine-5-carboxamides as P2 ligands. Certain compounds of the invention are competitive inhibitors that appear to bind in the -7- WO 2007/002173 PCT/US2006/024109 center of the "substate envelope" (i.e., at the active site of the protease). Importantly, the compounds of the invention are designed such that when bound they do not significantly protrude beyond the substrate envelope; therefore, they are less likely to induce escape mutations. The protease inhibitors of the invention are useful in the treatment of HIV in 5 susceptible mammals, e.g., humans and certain other primates. In addition the compounds have shown activity against a panel of multi-drug resistant (MDR) mutant variants of HIV 1 protease. Morover, the inhibitors of the invention can be administered as a monotherapy, or in combination with other therapeutic agents, e.g., as part of a highly active antiretroviral therapy (HAART) regime. 10 Selected Protease Inhibitors of the Invention. One aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula I: 0 R 2 n O O- R1 RS 0 I wherein, independently for each occurrence, 15 nis l or2; R, is -OH, -SH, or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;

R

2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 20 R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

5 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, 25 aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. -8- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 1 is -OH; R 2 is F F 7 ; R 3 is ; and R 4 is CH 3

H

3

.

C

H

3

H

3 C" CH 3 "" CH 3 N ,C, ,,N or CH3; R5 is not CH 3 ,

CH

3 H - S N N-OH

H

3 c

CH

3 , \ , , V , H 3 , H 3 C , \- or Ci. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 1 is -OH; R 2 is '-

C

H

3 - R 3 is -O ; and R4 is -- 2 R is not H 3 C -cH 3 , O 0~" N N-OH 10 ,OH3, H 3 , or Ci. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 1 is -OH; R 2 is - CH 3 ; R 3 is ;and R 4 is H; R 5 is not CH 3 . In certain embodiments, the present invention relates to the aforementioned 15 compound and any of the attendant definitions, provided that when R, is -OH; R 2 is

OCF

3

SCH

3

OCH

3

SS-OF

3 <

;R

3 is , -F, , or HO CH3H

OH

3

\OH

3

H

3 0 I -- OOH 3 H3C CH3; and R4 is 3; Rs is not CH 3 . -9- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 1 is -OH; R 2 is HO

SCH

3 CH3 S CF H3C CH 3 ; R 3 is O , - or H 3 ; andR 4 is O H 3

/COCH

3 H3 ; R 5 is not CH 3 . 5 In certain embodiments, the present invention relates to the aformentioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein R 2 is aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; and A 1 , A 2 , 15 A 3 , A 4 and A 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. 20 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ;, A 2 , A 4 and A 5 are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, - 10- WO 2007/002173 PCT/US2006/024109 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; A 1 , A 2 , A 3 5 and A 5 are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein R 3 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 / \ B 3 compound and any of the attendant definitions, wherein R 3 is B 5

B

4 ; and B 1 , B 2 , 15 B 3 , B 4 and B 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. 20 In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 /\ B 3 compound and any of the attendant definitions, wherein R 3 is B 5

B

4 ; B 1 , B 2 , B 4 and

B

5 are hydrogen; and B 3 is halogen, azide, alkyl, aralkyl, aikenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 25 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. - 11- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned I B 1

B

2 compound and any of the attendant definitions, wherein R 3 is B 5 84 ; B1, B 2 , B 3 and

B

5 are hydrogen; and B 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 5 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein R 4 is aryl. In certain embodiments, the present invention relates to the aforementioned DI D 2 -O D3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; and DI, D 2 ,

D

3 , D 4 and Ds are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 15 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 / D 3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; D 1 , D 2 , D 4 20 and Ds are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. -12- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 DI PD3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; D 1 , D 2 , D 3 and D 5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 5 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R5 is alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. 10 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH; R2 is aralkyl or heteroaralkyl; R3 is aryl or heteroaryl; and R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH; R 2 is aralkyl or 15 heteroaralkyl; R3 is aryl or heteroaryl; and R 5 is alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH; R2 is aralkyl or heteroaralkyl; R 4 is aryl or heteroaryl; and R5 is alkyl, (heterocyclyl)alkyl, aralkyl or 20 heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH; R3 is aryl or heteroaryl;

R

4 is aryl or heteroaryl; and R5 is alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned 25 compound and any of the attendant definitions, wherein RI is OH; R2 is aralkyl; R3 is aryl;

R

4 is aryl; and R5 is alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH; R 2 is aralkyl; R3 is aryl;

R

4 is aryl; and Rs is aralkyl. - 13- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is OH; R 2 is aralkyl; R 3 is aryl;

R

4 is aryl; and R 5 is heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned 5 compound and any of the attendant definitions, wherein R 1 is OH; R 2 is aralkyl; R 3 is aryl;

R

4 is aryl; and R 5 is (heterocyclyl)alkyl. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula II: 0 Re-N N NSO2R4 O 0 H OH R6 10 II wherein, independently for each occurrence,

R

3 is alkyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is aryl, heteroaryl, aralkyl or heteroaralkyl; and 15 R 6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 3 is ; and R 4 F F

OCH

3 is CH 3 , OCH 3 F F /,O CH 3 H3C CH3 C4H3 j"00H O N NH CH- N-OH N or CH3; R 6 is not CH 3 , H, H3 , S 20 or C0. -14- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 3 is - ; and R4 H O0 -"< is / H 2

;R

6 isnot O H3, H3C , or CI. 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 3 is - ; and R 4

CH

3 -Q -NH 2 t is NH2; R 6 is not CH 3 . In certain embodiments, the present invention relates to the aforementioned

OCF

3 compound and any of the attendant definitions, provided that when R 3 is , HO

SCH

3

O

3 1- S-0F 3 ~ C H 3 10 -CF3, -or

H

3 CH3; and R4is / \ OC 3

H

3 OCH3; R5 is not CH3. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 3 is HO

CSCH

3 0C3 or 3 ;ad R4 is OH;R5 is CHs 15 not CH3. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R3 is aryl or heteroaryl. - 15- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 /

\B

3 compound and any of the attendant definitions, wherein R 3 is B 5

B

4 ; and B 1 , B 2 , 5 B 3 , B 4 and Bs are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio,'sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. 10 In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 / \ B 3 compound and any of the attendant definitions, wherein R 3 is B 5

B

4 ; B 1 , B 2 , B 4 and

B

5 are hydrogen; and B 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 15 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 / \ B 3 compound and any of the attendant definitions, wherein R 3 is B 5

B

4 ; B 1 , B 2 , B 3 and

B

5 are hydrogen; and B 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 20 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned 25 compound and any of the attendant definitions, wherein R 4 is aryl. - 16- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned DI D2 D D2 compound and any of the attendant definitions, wherein R4 is 5

D

4 ; and D 1 , D 2 ,

D

3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 5 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned SD1 D2 D3 / o\ compound and any of the attendant definitions, wherein R 4 is 5

D

4 ; D 1 , D 2 , D 4 10 and Ds are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned D1 D2 15 compound and any of the attendant definitions, wherein R 4 is 5 D4 ; D 1 , D 2 , D 3 and D 5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R6 is alkyl, heterocyclyl, aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is alkyl. - 17- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R3 is aryl or heteroaryl; and R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned 5 compound and any of the attendant definitions, wherein R3 is aryl or heteroaryl; and R6 is alkyl, heterocyclyl, aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R4 is aryl or heteroaryl; and R6 is alkyl, heterocyclyl, aryl or heteroaryl. 10 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R3 is aryl or heteroaryl; R 4 is aryl or heteroaryl; and R 6 is alkyl, heterocyclyl, aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl; and R 4 is aryl. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R3 is aryl; and PR6 is alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl; and R 6 is alkyl. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein R 3 is aryl; R 4 is aryl; and R6 is alkyl. In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R3 is , , 0 HF 3CH 3

CH

3

H

3 -18 -OCH 3 WO 2007/002173 PCT/US2006/024109 0

CF

3 - CF 3 N 0 >CH, NH

CH

3 OH NCH 3

CH

3 N

C

H

3 - ,N O+H 3 -or H 3 C H In certain embodiments, the present invention relates to the aforementioned

OCH

3 compound and any of the attendant definitions, wherein R4 is - , F 5 & OCH3 -O F _ NH2 OCH3O F F C FNN CCH 3 OH -H 10 N -N CNH SOH CH 01NNSY W 0 W N -rN O H 3 \/N6 \/J: 0 H N- N CH 3 or ; wherein, independently for each occurrence, W is selected, 10 from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7

)

2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is H 3 - 19 - WO 2007/002173 PCT/US2006/024109 C, H 3

CH

3

CH

3 N OH o 0 j N In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , , 0 SF OCH 3

H

3 5 OH 3 , , OCH 0

F

3 3 OCF 3 0 O CH3 NH

CH

3 /CH3

H

3

H

3 CH3or H 3 C R 4 is F

OCH

3 - ' OCH3 F -NH2 OCH3 F , C CH 3 10 OH, \OH,- N-OH,

-

C H3 /H , N W W H H N N CH 3 N N CH 3 or ; wherein, independently for each - 20 - WO 2007/002173 PCT/US2006/024109 occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7

),

2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. In certain embodiments, the present invention relates to the aforementioned F 5 compound and any of the attendant definitions, wherein R 3 is 0 0 F OCH 3

CH

3

H

3 , \/ / -OCH 3 0 O CF 3 OCF 3 N

CF

3 1 0 ONCH3

CH

3 OH

C

H

3 NH CH3N ,CH3 or H 3 C ; and R 6 is

OH

3 3 N H In certain embodiments, the present invention relates to the aforementioned

OCH

3 F

OH

3

\N

2

OH

3 0 F)NC -0CF H 3 O -OH, compound~~~~~~~~~ ~ 21d an-fteatnatdfntos hri 4i WO 2007/002173 PCT/US2006/024109 -6NI H N W 0 WN N CH 3 ~ ON -- N6N 0 H N N YCH, 3 S 0 or ; wherein, independently for each occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R) 2 ; R 7 is selected from the group 5 consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; p is 1-10 inclusive; and R 6 is In certain embodiments, the present invention relates to the aforementioned F compound and any ofthe attendant definitions, wherein R3 is , ,

FOOCH

3

O

3 O OO

CF

3 0F 3 cC, e, t 1 , 00 0 CCF3 0

-CH

3 CH3 Hor ;I~ N, cH3 __/-N, K-CH3 OC H 3 OC H3 isO F 0CH 3 - /F_ F -22- WO 2007/002173 PCT/US2006/024109 N N-CH3 N N CH3 O OS 0 or ; wherein, independently for each 5 occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH2)pN(R7)2; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; p is CH3 SCH3 1-10 inclusive; and R6 is CH3, CH3 orW 10 Another aspect of the present invention relates to a compound, or pharmaceutically H OH OMe F 01 1 F N N O N Cl-OF \/ - 0 - - , o oj 0 0OH 3 COH OO O O -23 ~S Sr ) \ 1 ~ H H23 WO 2007/002173 PCT/US2006/024109 0 F 'N

OCH

3 -0 ' N HS ~ OH H/ OH/ OH 0 0 -~ OMe N N 0 0~ N -1, 00 F F 0 FN F0 -N/ N 0 J H H FN "'6 F \ /e N N OCH 3 0 - O b 0H OH \ 0 00 OMe 0 0 N 0 - o H N \0 0 1 OMe 0 'N 0\N 0 'N N H~ \\ - \- / 0fO OH 5 0 o~ F N 7 0 0N F FNO~ OH 0 y0 - 24 - WO 2007/002173 PCT/US2006/024109 OMe F 0 N 0 0 0 O H 0H OH O 0/ OMe

-NH

2 MeC 0 F 2 b, /,S -N^ \o\ 0 N ' OH- b )-o H OH y ~0 F

OCH

3 0 F 0 0 0 ' 4-0 OH N0 0H H OHY y 0/\/ 3 0 0 0 U N 0 o0 O H o N OCH 3 0 0 00 0 0 0 0> NH 2 U OH 0N\ 0 F_ H OH 0 F 0 N OH 3

F

3 C N

NH

2 0 \\ F - N j 's, F N N',\ N/ HNO H OH 0H r 0 - 25 - WO 2007/002173 PCT/US2006/024109 O 0 -OF H N Me'o 0I1

C

oH N o OHY pGC 0 OMe o OHN \ O0 '~ OCH 3 0g s 0 K -NH 2 0 0 N H0H 5 0 O K' OH0 0 -a N ONK' \\ 2C o OH 0 0 N/ N "K 'I 0- H N O\ A IT OH 0 0 - 26 - WO 2007/002173 PCT/US2006/024109 00 CN' F3 NO O 0 OOH 0 N OH F H OH o F O 00 N OC F'CNO OC 0OO H OH \/NOH N O O O\ H OH F \/N N 'N F 3 C'N O NH0 ,and H NN OHo N N ' o O OH 0 2 \ fF 3 C / N 'N --

OCH

3 \>0 H NS\ 0 -. 0 0 00 0 OHN \,HNN N d-0 H H OH

F

3 ' ~ OF o / 7- WO 2007/002173 PCT/US2006/024109 Another aspect of the present invention relates to a compound, or pharmaceutically acceptable salt thereof, selected from the group consisting of: O OH 0 0 0 (-j NO N N OOH 00 0 03C O OH N r No 5 OO OH O NOH

F

3 C 0 0 OHr ON, -N N N SO o o N N NNN 0 0 F3 O O N 'sC -N N N S N N N'i 0 o o Y(- 0 on NoN F3CO O NH2 FC S0 _ / N ( I% S f 'S N N N NO O OH -o OH -O2 0

F

3 CO 0NN

N>

3 - 0 " HI N' 0 / , -0 OHYH O -28 - WO 2007/002173 PCT/US2006/024109 I OCH 3

F

3 CO0 N N OHN O N H 0H OHH F3CO 0 O -N/7 0 H OH

F

3 00 NO 0 OH 0/ 00 CiC N~FC

F

3 00\ 0 0 00 0 y N~~\V- H N 0 \> 0,O

F

3 CO 0 s - N ' 0' '~ \' - O/ H OH \ -o OH0 0 5 -OCH 3 N C OH 0 H N- -29O- WO 2007/002173 PCT/US2006/024109 O0 NH 2 \/N N "Ne INOH N 0> -o H N" OH SN /-0 H NH 0/O O N .

0- N N /\,-o HN\\ 0/OH \% \' N ,>-o H N\\ ~ IN 0/ N N~ 00 - H OH \/ N\\ 0 0H O H 00 O OY 0 0 "1 - N N/ N \S 0

F

3 C 0 C - N O I lcs-w N\- N N~ \

F

3 C o '.- N 0 0 -30 WO 2007/002173 PCT/US2006/024109

F

3 CO O N> N N OO S O OH OH W N N N NOO OHO N T H OH 0O

F

3 0 0 N O C H 00 NN NN H OHH CN rO O OHO and ; wherein W is selected, independently for each occurrence, from the group consisting of -NHR 7 or -NHR(CH2)pN(R )2; R 7 is selected, independently for each occurrence, from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. In certain embodiments, the present invention relates to the aforementioned N 0OCH S 1 H OH CI0 10 compound and any ofthe attendant defitions, wherein W is -NHselected, independently for()-alkyl or each occurrence, from the group consisting of -NIIR 7 or -NIIR(CII 2 )pN(R 7

)

2 ; k 7 is selected, independently for each occurrence, from the group consisting of hydrogen, alkyl, aralkyl, -Nheteroaralkyl and acyl; and p is .- 10 inclusive. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein W is -NHC(=O)CH3-alkyl or -NHC(0)-fluoroalkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein W is -NHC(0)CH 3 or

-NHC(=O)CF

3 . -31 - WO 2007/002173 PCT/US2006/024109 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula IIIA: o R 2

R

5

R,

4 R-N N ZN

X

2 O 0

R

1

R

7 0 0 IIIA 5 wherein, independently for each occurrence, n is 1 or 2;

X

2 is absent, -0-, -S- or -NR-;

R

1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; 10 R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or 15 heteroaralkyl;

R

5 is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;

R

7 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture 20 of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R 2 is - 32- WO 2007/002173 PCT/US2006/024109

H

3

CVCH

3

H

3 C3j.CH 3 \ NH "\'NH

R

3 is ; X 2 is absent; R 4 is 0OCH 3 , O <CH 3 or

H

3

CVCH

3 H ;and R 5 is H; R 7 isnot In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is absent. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R, is -OH. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein R 2 is aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; and A, A 2 , 15 A 3 , A 4 and As are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. 20 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is AB A 4 ; A 1 , A 2 , A 4 - 33 - WO 2007/002173 PCT/US2006/024109 and As are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 5 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; A 1 , A 2 , A 3 and As are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 10 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is alkyl, aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein R5 is hydrogen. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 /l~ _-

B

3 compound and any of the attendant definitions, wherein R 7 is B 5

B

4 ; and B 1 , B 2 ,

B

3 , B 4 and B 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 25 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. - 34- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned , BI B 2

B

3 compound and any of the attendant definitions, wherein R 7 is B 5

B

4 ; B 1 , B 2 , B 4 and B 5 are hydrogen; and B 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 5 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 compound and any of the attendant definitions, wherein R 7 is B 5

B

4 ; B 1 , B 2 , B 3 and B 5 are hydrogen; and B 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, 10 hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 7 is alkyl, (cycloalkyl)alkyl, 15 (amino)alkyl, (amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 7 is alkyl, (cycloalkyl)alkyl or aralkyl. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein X 2 is absent; R 1 is -OH; R 2 is aralkyl; R 3 is aryl or heteroaryl; R 4 is alkyl, aryl or heteroaryl; R 5 is hydrogen; and R 7 is alkyl, (cycloalkyl)alkyl or aralkyl. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula IIIB: -35 - WO 2007/002173 PCT/US2006/024109 ,R4 0 R 2

R

5 N R3'XI N

HR

1

R

7 0 IIIB wherein, independently for each occurrence, n is 1 or2; 5 X 1 is absent, -0-, -S- or -NR-;

R

1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;

R

2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 10 R3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

5 is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; 15 R 7 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R 2 is CHe 3 ; X is absent; R 3 is H 3 C or ; R4 is ; and Rs is H; R7 is not -. -36- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R 2 is ; X 1 is -O-; R 3 is 1 ; R 4 is ; and R5 is H; R 7 is not . In certain embodiments, the present invention relates to the aforementioned 5 compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 1 is absent. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is -OH. 10 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl. In certain embodiments, the present invention relates to the aforementioned Al A 2

A

3 15 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; and A 1 , A 2 ,

A

3 , A 4 and A 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, 20 trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A A 4 ; A 1 , A 2 , A 4 and A 5 are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 25 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. - 37 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is alkyl, aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A A 4 ; A, Az, A 3 5 and A 5 are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein R 4 is alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 5 is hydrogen. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 compound and any of the attendant definitions, wherein R 7 is B 5

B

4 ; and B 1 , B 2 ,

B

3 , B 4 and Bs are independently selected from the group consisting of hydrogen, halogen, 20 azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

B

1

B

2 25 compound and any of the attendant definitions, wherein R 7 is B 5

B

4 ; BI, B 2 , B 4 -38 - WO 2007/002173 PCT/US2006/024109 and B 5 are hydrogen; and B 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 5 In certain embodiments, the present invention relates to the aforementioned

B

1

B

2

B

3 compound and any of the attendant definitions, wherein R 7 is B 5

B

4 ; B 1 , B 2 , B 3 and Bs are hydrogen; and B 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 10 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 7 is alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned 15 compound and any of the attendant definitions, wherein R 7 is alkyl, (cycloalkyl)alkyl or aralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein XI is absent; R 1 is -OH; R 2 is aralkyl; R 3 is aryl or heteroaryl; R 4 is alkyl, aryl or heteroaryl; R 5 is hydrogen; and R 7 is 20 alkyl, (cycloalkyl)alkyl or aralkyl. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula IVA: 0 .Ph 0 H NR- N R4 S H OH R 7 0 IVA 25 wherein, independently for each occurrence, -39- WO 2007/002173 PCT/US2006/024109

R

3 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl; 5 R 7 is alkyl, cycloalkyl, (cycloalkyl)alkyl or aralkyl; and the stereochemical configuration at any undefined stereocenter is R or S. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when R 3 is - ; and R 4

H

3 CvCH 3

H

3 CC 3CH 3

H

3 C CH 3 \ NH < NH 0N\ N is 0 CH 3 , 0OCH 3 or H ; R 7 is not 10 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl, (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R7 is alkyl, cycloallkyl or (cycloalkyl)alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, R3 is aryl or heteroaryl; R 4 is aryl, 20 (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl; and R 7 is alkyl, cycloalkyl or (cycloalkyl)alkyl. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 compound and any of the attendant definitions, wherein R3 is D 5

D

4 ; and D 1 , D 2 ,

D

3 , D 4 and Ds are independently selected from the group consisting of hydrogen, halogen, 25 azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, - 40 - WO 2007/002173 PCT/US2006/024109 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned DI D2 _D3 D 02 5 compound and any of the attendant definitions, wherein R3 is D 5 D4 ; D 1 , D 2 , D 4 and D 5 are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 10 In certain embodiments, the present invention relates to the aforementioned. D1 D2 1_0 D3 compound and any of the attendant definitions, wherein R 3 is D5 D4 ; D 1 , D 2 , D 3 and Ds are hydrogen; and D 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 15 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R3 is -Ph. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R7 is 20 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula IVB: 4 Ph ,R4 H N

R

3 N N 0 OH R 7 O IVB -41 - WO 2007/002173 PCT/US2006/024109 wherein, independently for each occurrence, R3 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl;

R

4 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, 5 heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R7 is alkyl, cycloalkyl, (cycloalkyl)alkyl or aralkyl; and the stereochemical configuration at any undefined stereocenter is R or S. In certain embodiments, the present invention relates to the aforementioned

CH

3 compound and any of the attendant definitions, provided that when R3 is H 3 C or 10 0; andR 4 is ; R 7 isnot . In certain embodiments, the present invention relates to the aforementioned 0 compound and any of the attendant definitions, provided that when R3 is \ ; and R 4 is ; R7 is not - . In certain embodiments, the present invention relates to the aforementioned 15 compound and any of the attendant definitions, wherein R3 is (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R4 is aryl or heteroaryl. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R7 is alkyl, cycloalkyl or (cycloalkyl)alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, R4 is aryl or heteroaryl; R3 is aryl, 25 (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl; and R 7 is alkyl, cycloalkyl or (cycloalkyl)alkyl. -42- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned D1 D2 0D3 / 0 compound and any of the attendant definitions, wherein R 4 is D5 D4 ; and D 1 , D 2 ,

D

3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 5 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

D

1 D2 D3 compound and any of the attendant definitions, wherein R 4 is 5 D4 ; D 1 , D 2 , D 4 10 and D 5 are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned D1 .D2 Di 0D3 15 compound and any of the attendant definitions, wherein R 4 is D5 D4 ; D 1 , D 2 , D 3 and D 5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is -Ph. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 7 is -43 - WO 2007/002173 PCT/US2006/024109 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of

CH

3 H N oH 0N ONN N . N O N O O N O H OH 0 H OH O 0 CHH 0 HC-CH, SH - CH, 0 H \ HC N NONO O N O NH CO ' H H O N H OC 51R N OH 0 HO wherei, andep n d 0 Another aspc f h rsent,-,-S ir nvetoeatst-;omono ph rmaeuically, accptbl sal NheReooomlA 0-1P 0 -. I 0 N 0 kH N R 0 0=<D) N NX H ii OH000VAH HN H OH 0 N OH 0or -N 0 C H 3 0 ON- H - 4 H - and Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VA: o R 2 0 R3-jk " N- -r l1XR 4 0 10 VA wherein, independently for each occurrence,

X

2 is absent, -0-, -S- or -NR-; RI is -OH1, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl. or acyl; - 44 - WO 2007/002173 PCT/US2006/024109 R2'is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 5 R4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture 10 of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is absent. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein Ri is -OH. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R2 is aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein R2 is aralkyl. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R2 is A 5

A

4 ; and A 1 , A 2 ,

A

3 , A 4 and As are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 25 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. - 45 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned A, A 2 S A 3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; Al, A?, A 4 and As are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 5 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2 S A 3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; A 2 , A 3 and As are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, 10 hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is alkenyl, (amino)alkyl, 15 (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein R 4 is (heterocyclyl)alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein Rs is alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is absent; R, is -OH; R 2 is 25 aralkyl; R 3 is aryl; R 4 is alkyl, aryl or heteroaryl; and Rs is alkyl. - 46 - WO 2007/002173 PCT/US2006/024109 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VB: 0 R 2 0 R3,. .... 'k _ .LL. n H" Y 1 N-R

R

1 R 5 0O VB 5 wherein, independently for each occurrence, XI is absent, -0-, -S- or -NR-;

R

1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;

R

2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, 10 aralkyl or heteroaralkyl; R3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 15 Rs is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R2 is O H 3 0 not CH3 ; X 1 is -0-; R3 is ; and R 4 is ; Rs is notH 3 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned 25 compound and any of the attendant definitions, wherein X 1 is absent. -47 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is -OH. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R2 is aralkyl or heteroaralkyl. 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R2 is A 5

A

4 ; and A, A 2 ,

A

3 , A 4 and As are independently selected from the group consisting of hydrogen, halogen, 10 azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 15 compound and any of the attendant definitions, wherein R2 is A A 4 ; A, A 2 , A 4 and A 5 are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 20 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; A 1 , A 2 , A 3 and As are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 25 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. -48 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl. 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 5 is alkyl. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein Xi is absent; R 1 is -OH; R 2 is aralkyl; R 4 is aryl; R3 is alkyl, aryl or heteroaryl; and R5 is alkyl. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VIA: 0 Ph R3N N N R 4 H RI R6 15 VIA wherein, independently for each occurrence,

R

1 is -OH or -NH 2 ; R3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 20 R 4 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl;

R

6 is alkyl, cycloalkyl, or aryl; and the stereochemical configuration at any undefined stereocenter is R or S. In certain embodiments, the present invention relates to the aforementioned 25 compound and any of the attendant definitions, wherein R, is -OH. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is -NH 2 . -49 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is -0-. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is heterocyclyl. 5 In certain embodiments, the present invention relates to the aforementioned 0 0. compound and any of the attendant definitions, wherein R 4 is \ or V In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is -0-; and R 4 is heterocyclyl. In certain embodiments, the present invention relates to the aforementioned O 10 compound and any of the attendant definitions, wherein X 2 is -0-; and R 4 is In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 -D3 compound and any of the attendant definitions, wherein R3 is D 5

D

4 ; and D 1 , D 2 , 15 D 3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is _ . In certain embodiments, the present invention relates to the aforementioned

D

1 D2 -D3 compound and any of the attendant definitions, wherein R3 is D5 D 4 ; D 1 , D 2 , D 4 - 50 - WO 2007/002173 PCT/US2006/024109 and D 5 are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 5 In certain embodiments, the present invention relates to the aforementioned D1 D2 -D3 / 0 compound and any of the attendant definitions, wherein R 3 is D 5 D4 ; DI, D 2 , D 3 and D 5 are hydrogen; and D 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 10 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is alkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is -CH(CH 3

)

2 . 15 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VIB: O .Ph X N N O H RIR VIB wherein, independently for each occurrence, 20 R, is -OH or -NH2;

R

3 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 25 R 6 is alkyl, cycloalkyl, or aryl; and -51 - WO 2007/002173 PCT/US2006/024109 the stereochemical configuration at any undefined stereocenter is R or S. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; X 1 is O H 3 C . -- C H 3 O-; R 3 is ;and R4 is ; R6 is not 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein RI is -OH. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 1 is -NH 2 . In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein XI is -0-. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is heterocyclyl. In certain embodiments, the present invention relates to the aforementioned 0 0 compound and any of the attendant definitions, wherein R 3 is or 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein XI is -0-; and R 3 is heterocyclyl. In certain embodiments, the present invention relates to the aforementioned O compound and any of the attendant definitions, wherein X 1 is -0-; and R 3 is -\ . In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2

D

3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; and D 1 , D 2 ,

D

3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, - 52 - WO 2007/002173 PCT/US2006/024109 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned 5 compound and any of the attendant definitions, wherein R 4 is -- 0 . In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 i-O D3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; DI, D 2 , D 4 and D 5 are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 10 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 -O- D3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; D 1 , D 2 , D 3 and D 5 are hydrogen; and D 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, 15 hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is alkyl. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is -CH(CH 3

)

2 . Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of - 53 - WO 2007/002173 PCT/US2006/024109 -Q QO -QO 0 0~- 0 \/ 0o 0 0 ON NO ON NO ON - NO H OH CH, H OH CH 3 H OH CH, CH , CH 3 , CHa , -Q 0 0 N N H OH CHH NH, CH,

CH

3 , and CH 3 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VIIA: 0 R 2 H ,m4 n HI I

R

3 -N HN X - 0O

R

1

R

5 O VIIA wherein, independently for each occurrence,

X

2 is absent, -0-, -S- or -NR-;

R

1 is -OH, -SH or -NHR; 10 R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;

R

2 is hydrogen,alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralklcyl; 15 R 4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture 20 of these configurations. - 54- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R 2 is \'NH H 3 C • notI--) - CH3 ; X 2 is absent; R 3 is - ; and R4 is O OCH 3 ; R 5 is not or . 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is absent. In certain embodiments, the present invention relates to the aforementioned 10 compound and any of the attendant definitions, wherein R 1 is -OH or -NH 2 . In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl. 15 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; and A 1 , A 2 ,

A

3 , A 4 and As are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, 20 alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; A 1 , A 2 , A 4 - 55 - WO 2007/002173 PCT/US2006/024109 and A 5 are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. 5 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A A 4 ; A 1 , A 2 , A 3 and A 5 are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 10 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is (amido)alkyl or heterocyclyl. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 5 is alkyl or aryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is absent; R 1 is -OH; R 2 is aralkyl; R 3 is aryl; R 4 is (amido)alkyl or heterocyclyl; and R5 is alkyl or aryl. 20 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VIIB: n,4 0 H ' N R3'X4 N N 0 H y

R

1

R

5 O VIIB wherein, independently for each occurrence, 25 X 1 is absent, -0-, -S- or -NR-;

R

1 is -OH, -SH or -NHR; -56- WO 2007/002173 PCT/US2006/024109 R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl;

R

2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or 5 heteroaralkyl;

R

5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and 10 the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R 2 is HaCO O HN H3C

H

3 C 3 H 3 ; X 1 is absent; R 3

OH

3 is; R 4 is - ; and R5 is not 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 1 is absent. In certain embodiments, the present invention relates to the aforementioned 20 compound and any of the attendant definitions, wherein R 1 is -OH or -NiH 2 . In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl or heteroaralkyl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is aralkyl. 25 In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A 5

A

4 ; and A 1 , A 2 , - 57- WO 2007/002173 PCT/US2006/024109

A

3 , A 4 and A 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, 5 trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A A 4 ; A 1 , A 2 , A 4 and A 5 are hydrogen; and A 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 10 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

A

1

A

2

A

3 compound and any of the attendant definitions, wherein R 2 is A A 4 ; A 1 , A 2 , A 3 and A 5 are hydrogen; and A 4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, 15 hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is (amido)alkyl or heterocyclyl. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 5 is alkyl or aryl. In certain embodiments, the present invention relates to the aforementioned 25 compound and any of the attendant definitions, wherein X 1 is absent; R 1 is -OH; R 2 is aralkyl; R4 is aryl; R 3 is (amido)alkyl or heterocyclyl; and R 5 is alkyl or aryl. -58- WO 2007/002173 PCT/US2006/024109 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula VIIIA: Ph R3 R o 7, H 4 R3,I/- N A HN' N Y X2 O OH OR60 0 VIIIA 5 wherein, independently for each occurrence,

X

2 is absent or -0-;

R

4 is aryl, heteroaryl, aralkyl or heteroaralkyl; 10 R 6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R or S. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when X 2 is absent; R 3 is

H

3 CC CH 3 \2 NH H 3 C - \

CH

3 \/ / ;andR 4 is O OCH3; R 6 isnot -- or N 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 2 is absent. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 20 compound and any of the attendant definitions, wherein R3 is D 5

D

4 ; and DI, D 2 ,

D

3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, - 59 - WO 2007/002173 PCT/US2006/024109 alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is - . 5 In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 -D3 compound and any of the attendant definitions, wherein R 3 is D 5

D

4 ; D 1 , D 2 , D 4 and Ds are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 10 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 D3 compound and any of the attendant definitions, wherein R 3 is D 5

D

4 ; D 1 , D 2 , D 3 and D 5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 15 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is (amino)alkyl, (amido)alkyl or heterocyclyl. 20 In certain embodiments, the present invention relates to the aforementioned O N compound and any of the attendant definitions, wherein R 4 is W or W and W is aryl or heteroaryl. - 60 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 compound and any of the attendant definitions, wherein W is D 5

D

4 ; and D 1 , D 2 ,

D

3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 5 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein W is . 10 In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 compound and any of the attendant definitions, wherein W is D 5

D

4 ; D 1 , D 2 , D 4 and Ds are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 15 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned

D

1

D

2 D3 compound and any of the attendant definitions, wherein W is D 5

D

4 ; D 1 , D 2 , D 3 and

D

5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 20 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 6 is alkyl or aryl. -61 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned

CH

3 compound and any of the attendant definitions, wherein R6 is CH 3 or

-

N

\ /D 0/ . Another aspect of the present invention relates to a compound, or a 5 pharmaceutically acceptable salt thereof, of formula VIIIB: ,R4 Ph N4 R3'X IN H H H NR60 VIIIB wherein, independently for each occurrence,

X

1 is absent or -0-; 10 R 3 is aryl, heteroaryl, aralkyl or heteroaralkyl;

R

6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R or S. 15 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, provided that when n is 1; R 1 is -OH; R 2 is

H

3 CO O HN

H

3 C

H

3

C-CH

3

/H

3 ; X is absent; R 3 is CH 3 ; R 4 is - ; and R6 is not 1 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein X 1 is absent. 20 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is aryl or heteroaryl. - 62 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned DI D2 -D3 compound and any of the attendant definitions, wherein R 4 is D 5

D

4 ; and D 1 , D 2 ,

D

3 , D 4 and Ds are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, 5 sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 4 is . 10 In certain embodiments, the present invention relates to the aforementioned D1 D 2 i-o D3 compound and any of the attendant definitions, wherein R 4 is D5 D 4 ; D 1 , D 2 , D 4 and Ds are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, 15 heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned D D2 -O D3 compound and any of the attendant definitions, wherein R 4 is D5 D4 ; D 1 , D 2 , D 3 and D 5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, 20 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 3 is (amino)alkyl, (amido)alkyl or heterocyclyl. - 63 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned O N compound and any of the attendant definitions, wherein R 3 is W or W; and W is aryl or heteroaryl. In certain embodiments, the present invention relates to the aforementioned D1 D2 D3 5 compound and any of the attendant definitions, wherein W is 5 D 4 ; and D 1 , D 2 ,

D

3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, 10 trifluoromethyl and cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein W is - . In certain embodiments, the present invention relates to the aforementioned D1 D2 D3 compound and any of the attendant definitions, wherein W is 5 D4 ; D 1 , D 2 , D 4 and 15 D 5 are hydrogen; and D 3 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned D1 D2 D3 20 compound and any of the attendant definitions, wherein W is 5 D4 ; D 1 , D 2 , D 3 and D5 are hydrogen; and D4 is halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, - 64 - WO 2007/002173 PCT/US2006/024109 carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl or cyano. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R6 is alkyl or aryl. 5 In certain embodiments, the present invention relates to the aforementioned

CH

3 compound and any of the attendant definitions, wherein R 6 is CH 3 or - N Another aspect of the present invention relates to a copmpound, or a pharmaceutically acceptable salt thereof, selected from the group consisting of \ H 3 O H HOH,c 0O9 N N HHCC Hz 10 \/ , c Hc and O H 3 CCC 3CH. O=O< N N N' NH N OH 00 OCH 3 N Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula IX: 0 0 N' N N

R

3 H H O O0OH R 2 OH 15 Eg wherein, independently for each occurrence, n is 1 or 2; - 65 - WO 2007/002173 PCT/US2006/024109

R

3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; 5 and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. 10 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , , 0 F

OCH

3 CH 3

OH

3 , , OC-O C OCH 3

O

O 0 CF3

OCF

3 15 CF 3 / F 3 \\/N 0 O CHCH3

CH

3 OHN orH , CH3 pCH3 _ N C H3 C3,, NC3or H3C. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula X: - 66 - WO 2007/002173 PCT/US2006/024109 0 0 0 n N N NHR 4

R

3 -N H

R

7 O OH 7 S

R

7 X wherein, independently for each occurrence, n is 1 or 2; 5 R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

7 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, 10 aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. 15 In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , 0 F OCH CH 3 - 67 - WO 2007/002173 PCT/US2006/024109

CF

3 - OCF 3 CF 3 -N O - cCH, ,,, I ,~ / 0 NH

CH

3 OH 0H 3 CH3 , CH3 ,, - - -

CH

3 or H3C ~ ~N CH H In certain embodiments, the present invention relates to the aforementioned OCH3 compound and any of the attendant definitions, wherein R 4 is , F J0 F__ 'F 0 5 -\/

OCH

3 NH2 OCH3O N W - H C-CH 3 H HH -- - - CF 3 ~ CF 3 ' N S' 0' 0 H - 1 N W -W N N CH 3 H N N CH 3 or S; wherein, independently for each occurrence, W is selected, 10 from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7

)

2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R7 is hydrogen or alkyl. In certain embodiments, the present invention relates to the aforementioned 15 compound and any of the attendant definitions, wherein R7 is methyl. - 68- WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 7 is hydrogen. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula XI: 0

R

3 N N N-R 4 OO OH 5 NHR 2 XI wherein, independently for each occurrence, nis 1 or 2;

R

2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, 10 aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and 15 the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned F 20 compound and any ofthe attendant definitions, wherein R 3 is , , 0 F OCH 3

CH

3 H3 F- /6OCH 3 - 69 - WO 2007/002173 PCT/US2006/024109 0

F

3

CF

3 - NCFN _ C-CF, 16 -0 N 0

CH

3 , orCH3 CH3 OH -N CH3 NH3 N CH3 C3O In certain embodiments, the present invention relates to the aforementioned

OCH

3 compound and any of the attendant definitions, wherein

R

4 is -, F - -F _aF 0 5

OCH

3 NH2 CH 0 N-N N-CHsCH - F' \/ CF2

CF

3 H O N OH H .1N N-T--N- 0 T WN-NCHCH 6 0 0 HH N N CHN SOW or ; wherein, independently for each occurrence, W is selected, 10 from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R)2; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein R 2 is hydrogen. Another aspect of the present invention relates to a compound, or a 15 pharmaceutically acceptable salt thereof, of formula XII: - 70 - WO 2007/002173 PCT/US2006/024109 0 N N Z

R

3

-

0 H OH

NHR

4 XII wherein, independently for each occurrence, nis 1 or2; 5 Z is hydrogen, R 4 , or OR 4 ;

R

4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and 10 the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned 15 compound and any of the attendant definitions, wherein Z is hydrogen. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein Z is R 4 . In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein Z is OR 4 . 20 In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , , 0 SF OCH3 CH 3 H3, , , /OCH 3 -71 - WO 2007/002173 PCT/US2006/024109 0

CF

3 OCF 3

,CF

3

~

, , , , 0 N CH3

CH

3 OH

CH

3 NH ,\, ,

-

CH

3 - Nc ,,r-c CH3 or H3CH 3 In certain embodiments, the present invention relates to the aforementioned

OCH

3 compound and any of the attendant definitions, wherein R4 is F FH -O F_&F 0 5/ OCH 3

NH

2

OCH

3 0 0 N

N-CH

3 CH3 _ ~ CF 3 ~ CF' 1--: NHOH HH 6 0 -6 0 HH N.. N CH 3 SO0 or ; wherein, independently for each occurrence, W is selected, 10 from the group consisting of -NHR 7 or -NHR(CH 2 )pN(RT) 2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula XIII: - 72 - WO 2007/002173 PCT/US2006/024109 0 O OH m

R

3 -N N N on 0 O NHR 4 XIII wherein, independently for each occurrence, nis 1 or2; 5 inm is 1 or2;

R

3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloallkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and 10 the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned 15 compound and any of the attendant definitions, wherein m is 1. In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , , 0 F OCH 3

CH

3

CH

3 , , , / OCH 3 - 73 - WO 2007/002173 PCT/US2006/024109 F3 OCF3 N ,, Cl , , \ , 0 '-CH 3 - H 3 __ OH ,CH 3 NH N, CH 3 N CH 3

CH

3 H, N or H 3 C In certain embodiments, the present invention relates to the aforementioned

OCH

3 compound and any of the attendant definitions, wherein R 4 is , F - _ao F,0 0 5 \/- OCH 3 ' F\/, \ NH 2 ' - \ OCH 3 , 0 NN W W N CCH 3 -- O F' & CF3 -- / CF 3 ' \/-O NH HH 01 N NSW 0WN N CH HH N N CH 3 S O or ; wherein, independently for each occurrence, W is selected, 10 from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7

)

2 ; R7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula XIV: - 74 - WO 2007/002173 PCT/US2006/024109 0 OO- H OH R-N N NoS 0 NHR 4 XIV wherein, independently for each occurrence, n is 1 or 2; 5 R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl;

R

4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture 10 of these configurations. In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , , 0 15 F CH 3

CH

3 OOCH 0

CF

3 - - OCF 3 , / \ O , c , 0 O >-CH3 NH

CH

3 OH C H3 N NN H ,o O H 3 , , _/- 75 CH3 or H 3 - 75 - WO 2007/002173 PCT/US2006/024109 In certain embodiments, the present invention relates to the aforementioned

OCH

3 compound and any of the attendant definitions, wherein R 4 is , F -O F _aF 0a

/OCH

3 F

NH

2 ' OCH 3 ' O / F0 /F CF 3 3 OH, S 00 5 O\N-OHI H /S W _ W N N C 3 H N N CH 3 SO0 or '; wherein, independently for each occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R)2; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. 10 Another aspect of the present invention relates to a compound, or a pharmaceutically acceptable salt thereof, of formula XV: 0 H O OHH

R

3 -N HN N S 0 NHR 4 XV wherein, independently for each occurrence, 15 R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; - 76 - WO 2007/002173 PCT/US2006/024109

R

4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations. 5 In certain embodiments, the present invention relates to the aforementioned compound and any of the attendant definitions, wherein n is 1. In certain embodiments, the present invention relates to the aforementioned F compound and any of the attendant definitions, wherein R 3 is , , 0 - 0 F OOH 3

OH

3 H , , , , F / H 3 0

CF

3

OCF

3 10 CF 3 N O CH NH

CH

3 OH CH 3 ,NC H 3 _ N\ O H 3 S CH 3 CH3or H 3 C In certain embodiments, the present invention relates to the aforementioned

OCH

3 compound and any of the attendant definitions, wherein R 4 is , F - - - F F o'

I

0 \/ OCH 3 F \/ NH 2 , \/O CH 3 ' \/ 15 F3 3,H OH, N N o15 N-OH, , , H, - 77- WO 2007/002173 PCT/US2006/024109 H 0"N "N S W O..r W N N CH 3 \~ / / 0- / N0 0 H N -rN CH 3 S O0 or - ; wherein, independently for each occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7

)

2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. 5 Synthesis ofSelected Compounds of the Invention. The protease inhibitors of the invention can be synthesized using the synthetic schemes outlined herein. The definition of each of the variables may be the same as shown in formulae shown above. Protease inhibitors I, II, V and VI can be prepared using the synthetic scheme shown in Figure 20a (top). As shown therein, an epoxide, for example, can be reacted with 10 an amine in a stereoselective manner to yield amine 2. Amine 2 is reacted with sulfonyl chloride or an acyl chloride to yield 3. Deprotection followed by reaction with an acid chloride, for example, yields inhibitor I, II, V or VI. Protease inhibitor III and IV can be prepared using the synthetic scheme shown in Figure 20a (bottom). Amino acid 5 can be converted to amine 6 using standard synthetic 15 procedures. Reaction with an acid yields amide 7. Deprotection followed by reaction with an acid chloride yields inhibitor III or IV. Protease inhibitor IV can be prepared using the synthetic scheme in Figure 20b. As shown in the scheme, an epoxide, for example, can be reacted with a protected hydrazine in a stereoselective manner to yield hydrazine 9, after deprotection. Hydrazine 9 is reacted 20 with an acid to yield amide 10. Further deprotection yields amine 11 followed by reaction with acid chloride yields inhibitor VII or VIII. As can be seen from Figures 20a and 20b, the R groups of the inhibitors are determined by choosing suitable reagents and starting material. Similarly, the stereochemistry of the inhibitors is determined by choosing appropriate starting material 25 and reagents. For example, chiral N-phenyloxazolidine-5-carboxylic acids 9 and 10 used in the synthesis of designed inhibitors, were prepared following the literature procedure as outlined in Figure 2. (Brickner, S. J. et al. J. Med. Chem. 1996, 39, 673-679; Hester, J. B. - 78 - WO 2007/002173 PCT/US2006/024109 WO 2003/006440, hereby incorporated by reference; and Thomas, R. C. et al. WO 2003/072553, hereby incorporated by reference). The intermediate chiral alcohols, 5 (hydroxymethyl)-3-aryl-oxazolidine-2-ones 7-8, were obtained from substituted anilines in two steps. The reaction of CBZ protected anilines 4a-g with either (R)- or (S)-enantiomer 5 of glycidyl butyrate promoted by n-BuLi provided chiral alcohols 7a and 8a-g. This one pot, three step cascade reaction involves the initial ring opening of chiral epoxide with N lithium species followed by an intramolecular cyclization and finally an in situ ester hydrolysis. (Brickner, S. J. et al. J. Med. Chemn. 1996, 39, 673-679.) Oxidation of the resulting chiral alcohols using catalytic ruthenium chloride provided the desired N 10 phenyloxazolidine-5-carboxylic acids 9a and 10a-g (Scheme 1). In case of unsubstituted phenyloxazolidines, both (R)- and (S)- enantiomers, 9a and 10a respectively, were prepared from the corresponding chiral epoxide. All other compounds with substituted phenyl ring, 10b-g, were prepared only as (S)-enantiomers. The synthetic route applied for the preparation of designed protease inhibitors is 15 illustrated in Figure 3. The Boc protected intermediate (R) (hydroxyethylamino)sulfonamides 14-19 were prepared following literature procedure. (Koh, Y. et al. Antimicrob. Agents Chemother. 2003, 47, 3123-3129; and Surleraux, D. L. N. G. et al. J. Med. Chem. 2005, 48, 1813-1822.) Briefly, ring opening of commercially available chiral epoxide, (1S,2S)-(1 -oxiranyl-2-phenylethyl)carbamic acid tert-butyl ester, 20 11 with isobutylamine provided the amino alcohol 12. Reactions of substituted phenylsulfonyl chlorides with 12 afforded the sulfonamides 14-19 that were coupled with phenyloxazolidine fragments. Initially, four compounds were synthesized using either unsubstituted (R)- or (S)-3-phenyloxazolidinie-5-carboxylic acid 9a or 10a attached to the (R)-(hydroxyethylamino)-sulfonamide isostere at P2 position. Previously optimized 25 phenylsulfonamides, 4-methoxyphenylsulfonamide and 4-aminophenylsulfonamide, were utilized as P2' ligands. Thus, removal of the Boc protection of sulfonamides 14-15 followed by the reactions of the resulting amino alcohols with either (R)- or (S)-enantiomer of the activated carboxylic acids 9a or 10a provided the target compounds 20a-23a (Figure 3). In the case of compounds 22a and 23a, the nitro group was reduced using tin chloride to 30 afford the corresponding amino derivatives 24a and 25a. It has to be noted that attempts to use the standard amide coupling conditions, EDCI/HOBt/DIEA, were not very successful and resulted in poor yields mainly because of very slow reactions even with DMF as - 79 - WO 2007/002173 PCT/US2006/024109 solvent. In all subsequent reactions the carboxylic acids 9 and 10 were converted to the corresponding acid chlorides using oxalyl chloride. Series of inhibitors were synthesized using substituted (S)-phenyloxazolidines at P2 and different phenylsufonamide groups at P2' position for structure-activity relationship 5 (SAR) studies. Following the deprotection of sulfonamide intermediates 14-19, the resulting amines were reacted with (S)-N-phenyloxazolidine-5-carbonyl chlorides obtained by the activation of the corresponding carboxylic acids 10b-g to afford the target compounds 21 and 25-29 (Figure 3). The compounds 23b-f containing 4 nitrophenylsulfonamide group at P2' position were transformed to the corresponding 4 10 aminophenylsulfonamide derivatives 25b-f by the reduction of the nitro group. In addition to the compounds described above, series of compounds were prepared with variations at three different positions. The isobutyl group at Pl' position was replaced with three cyclic primary amines. Again, starting from commercially available chiral epoxide 11, the target compounds were synthesized using an analogous synthetic route 15 (Figure 4). In brief, ring opening of epoxide 11 with primary amines 30a-c provided amino alcohols 31a-c. Reactions of various substituted phenylsulfonyl chlorides with 31a-c provided sulfonylamides 32-35. After deprotection of intermediate compounds 32-35, the resulting amines were reacted with (S)-N-phenyloxazolidine-5-carbonyl chlorides prepared from the corresponding carboxylic acids 10 to afford the target compounds 36-39 (Figure 20 4). Pharmaceutical Compositions. The methods described herein include the manufacture and use of pharmaceutical compositions, which include the protease inhibitors described herein as active ingredients. Also included are the pharmaceutical compositions themselves. These compositions can be administered using routes of administration and 25 dosages similar to those used for known HIV protease inhibitors. It will also be appreciated that certain of the compounds of present invention can exist in free form for treatment, or where appropriate, as a pharmaceutically acceptable derivative thereof. According to the present invention, a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of 30 such esters, or a pro-drug or other adduct or derivative of a compound of this invention which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof. - 80 - WO 2007/002173 PCT/US2006/024109 As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically 5 acceptable salts of amines, carboxylic acids, and other types of compounds, are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences 1977, 66: 1-19, incorporated herein by reference. The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting a free base or free acid function with a suitable 10 reagent, as described generally below. For example, a free base function can be reacted with a suitable acid. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may, include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts. Examples of pharmaceutically acceptable, nontoxic acid addition salts are 15 salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, 20 benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, 25 nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic anunmmonium, 30 quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate. Additionally, as used herein, the term "pharmaceutically acceptable ester" refers to esters that hydrolyze in vivo and include those that break down readily in the human body - 81 - WO 2007/002173 PCT/US2006/024109 to leave the parent compound or a salt thereof Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each alkyl or alkenyl moiety advantageously has not more than 6 carbon atoms. Examples of particular esters 5 include formates, acetates, propionates, butyrates, acrylates and ethylsuccinates. Furthermore, the term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the issues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a 10 reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. 15 Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. Methods of formulating pharmaceutical compositions are known in the art; see, e.g., Remington: The Science and Practice of Pharmacy, 20th Ed. (Baltimore, MD: Lippincott 20 Williams & Wilkins, 2000). Pharmaceutical compositions typically include a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" includes saline, solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds can also be incorporated 25 into the compositions. Pharmaceutical compositions are typically formulated to be compatible with their intended route(s) of administration. Examples of routes of administration include parenteral, e.g., by intravenous, intradermal, or subcutaneous injection; or mucosal (e.g., by oral ingestion, inhalation, or rectal or vaginal administration) administration. Compositions 30 intended for parenteral administration can include the following components: a sterile diluent, such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants, such as ascorbic acid or sodium bisulfite; - 82- WO 2007/002173 PCT/US2006/024109 chelating agents, such as ethylenediaminetetraacetic acid; buffers, such as acetates, citrates or phosphates and agents for the adjustment of tonicity, such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide, as appropriate. A parenteral preparation can be enclosed in ampoules, 5 disposable syringes or multiple dose vials made of glass or plastic. Pharmaceutical compositions suitable for injectable use can include sterile aqueous solutions (where the active ingredient is water soluble) or dispersions and sterile powders for the preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, 10 Cremophor ELTM (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent necessary to allow administration via syringe. It should be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for 15 example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyetheylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal 20 agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols, such as mannitol, sorbitol, and/or sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and 25 gelatin. Sterile injectable solutions can be prepared by incorporating the active compound in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle, which contains a basic 30 dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying, which yield a powder of the - 83 - WO 2007/002173 PCT/US2006/024109 active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof. Oral compositions generally include an inert diluent or an edible carrier. For the purpose of oral therapeutic administration, the active compound can be incorporated with 5 excipients and used in the form of tablets, troches, or capsules, e.g., gelatin capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder, such as 10 microcrystalline cellulose, gum tragacanth or gelatin; an excipient, such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant, such as colloidal silicon dioxide; a sweetening agent, such as sucrose or saccharin; or a flavoring agent, such as peppermint, methyl salicylate, or orange flavoring. 15 For administration by inhalation, the compounds can be delivered in the form of an aerosol spray from a pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer. Such methods include those described in U.S. Patent No. 6,468,798; hereby incorporated by reference. Systemic administration of a therapeutic compound as described herein can also be 20 by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For 25 transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art. The pharmaceutical compositions can also be prepared in the form of suppositories (e.g., with conventional suppository bases, such as cocoa butter and other glycerides) or retention enemas for rectal delivery. In one embodiment, the therapeutic compounds are prepared with carriers that will 30 protect the therapeutic compounds against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, - 84- WO 2007/002173 PCT/US2006/024109 polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Such formulations can be prepared using standard techniques. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to 5 viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811; hereby incorporated by reference. The pharmaceutical compositions can be included in a container, kit, pack, or dispenser, optionally with instructions for administration. A kit may comprise one or more 10 compounds described herein and/or one or more other therapeutic compounds and/or a device for their administration, e.g., a syringe. Biological Evaluation of Selected Compounds of the Invention. HIV protease inhibitor activities were determined by fluorescence resonance energy transfer (FRET) method. (Matayoshi, E. D. et al. Science 1990, 247, 954-958.) Protease substrate (Arg 15 Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro-Ile-Val-Gln-Lys(DABCYL)-Arg) was labeled with the energy transfer donor (EDANS) and acceptor (DABCYL) dyes at its two ends to perform FRET. Inhibitor binding dissociation constant (Ki value) was obtained by nonlinear regression fitting to the plot of initial velocity as a function of inhibitor concentration based on Morrison equation. (Greco, W. R. et al. J. Biol. Chem. 1979, 254, 12104-12109.) The 20 activities of all the synthesized inhibitors against wild type HIV-1 protease (Q7K) were determined in triplicate. Chemical structures of inhibitors and their inhibitory activities (Ki values) are presented in Figure 5. In addition, a small set of protease inhibitors with potent activities against wild type protease was studied against a panel of multidrug-resistant (MDR) mutants of HIV-1 25 proteases each representing different paradigms of resistance. The mutant variants were selected by examining the Stanford HIV-1 Drug Resistance Database (http://hivdb.stanford.edu) of HIV-1 infected-patient sequences of viral isolates. The three selected protease variants represent the pattern of resistance mutations that occur under the selective pressure of three or more currently prescribed protease inhibitors. (Wu, T. D. et 30 al. J. Virol. 2003, 77, 4836-4847.) These MDR mutant variants are L10I, G48V, I54V, L63P, V82A (Ml), D30N, L63P, N88D (M2), and L10I, L63P, A71V, G73S, 184V, L90M (M3). The inhibitory activities of selected protease inhibitors against M1-M3 mutant HIV-1 - 85 - WO 2007/002173 PCT/US2006/024109 proteases were examined. For comparison two currently marketed drugs amprenavir (APV) and lopinavir (LPV) were also studied against the selected panel of mutant proteases. To test the design concept, protease inhibitors based on hydroxyethylamine isostere incorporating unsubstituted N-phenyloxazolidine-5-carboxamide were prepared and tested 5 for their inhibitory activities against wild type HIV-1 protease. It was also critical to determine which stereoisomer of phenyloxazolidine based P2 ligand will bind more favorably to the protease. For these preliminary investigations, two pairs of compounds containing either (R)- or (S)-N-phenyloxazolidine-5-carboxylic acid, (5R)-9a or (5S)-10a, and two phenylsulfonamide groups, 4-methoxy- and 4-aminophenylsulfonamide, were 10 prepared and tested (Figure 6). The inhibitors 20a and 24a containing (5R)-9a attached at P2 and both 4-methoxy and 4-amino substituted phenylsulfonamides at P2' position exhibited nanomolar inhibitory activities against wild type HIV-1 protease with Ki = 10.7 and Ki = 37.4 nM, respectively. When (5S)-10a was attached at P2 position, there was significant improvement in the inhibitory activities with both phenylsulfonamide groups. 15 Interestingly, the compound 21a with 4-methoxybenzenesulfonamide as P2' ligand was more potent (Ki = 0.1 nM) than the 4-aminobenzenesulfonamide analog 25a (Ki= 0.53 nM). The protease inhibitory activities of compounds 21a and 25a are comparable to that of structurally related drug amprenavir (APV) 1 with Ki = 0.10 nM. These results clearly show that hydroxyethylamine isostere based inhibitors 20 incorporating N-phenyloxazolidine-5-carboxamides as P2 ligands exhibit potent HIV-1 protease inhibitory activities. These studies also suggest that compounds containing (5S)-N phenyloxazolidine-5-carboxamides are more potent inhibitors of HIV-1 protease compared to the corresponding (5R)-inhibitors. Thus, in subsequent SAR studies only (S)-N phenyloxazolidine-5-carboxylic acids, 10a-g, were used. 25 Structure-Activity Relationship Studies. To explore the possibilities of enhancing the potency of 21a and 25a, we synthesized and tested series of analogs with variations at both P2 and P2' positions. The inhibitor series 21 and 25-29 were prepared using small set of mainly substituted (S)-N-phenyloxazolidine-5-carboxylic acids 10b-g, linked to the (R) (hydroxyethylamino)sulfonamides 14-19 as P2 ligands (Figure 3). All the compounds were 30 evaluated for their activities against wild type HIV-1 protease and Ki values are presented in Figure 5; Ki values of 21a and 25a are also included. The inhibitory activities of amprenavir (APV) and lopinavir (LPV) were also determined using the same assay conditions and Ki data is included in Figure 5 for comparison. - 86- WO 2007/002173 PCT/US2006/024109 In the first series of inhibitors, the 4-methoxybenzenesulfonamide group at P2' was kept constant and substituted N-phenyloxazolidines 10b-g were attached to the (R) (hydroxyethylamino)sulfonamide isostere 14 as P2 ligands. Compared to 21a, all the compounds with substituted phenyl ring 21b-g exhibited improved inhibitory activities 5 against HIV-1 protease (Figure 5, entries 1-7). For the inhibitors with 3-fluoro and 3,4 difluoro groups on the phenyl ring, 21b and 21c, the improvement was relatively minor; Ki values of 21b and 21c are 80 pM and 66 pM, respectively. Introduction of polar groups, trifluoromethyl, acetyl and methoxy, at positions 3 and 4 of the phenyl ring resulted in significant increase in the potency of the inhibitors. The Ki value of compound 21d with 3 10 trifluoromethyl group is 6 pM and the 3-methoxy analog 21g showed Ki value of 45 pM. Inhibitors 21e and 21f with 3- and 4-acetyl groups are the most potent HIV-1 protease inhibitors discovered in our studies with Ki values of 0.8 pM and 4 pM, respectively. The protease inhibitors 25b-f with 4-aminobenzenesulfonamide at P2' did not show much improvement in the protease inhibitory activities as was observed in the 15 corresponding 4-methoxy analogs 21. Only the inhibitors with 3-trifluoromethyl and 3 acetyl substituted phenyl ring, 25d (Ki = 42 pM) and 25e (Ki= 32 pM), exhibited significant increase in potency compared to the unsubstituted analog 25a. Inhibitors with 3 fluoro (25b), 3,4-di-fluoro (25c) and 4-acetyl (25f) groups at the phenyl ring showed relatively small improvement in activities compared to 25a (Figure 5, entries 9-10 & 13). 20 Compounds 26b-f with another commonly used P2' ligand, 1,3-[benzo]dioxolane sulfonamide, also showed very potent inhibitory activities. Again, inhibitors with 3 trifluoromethyl (26d), 3-acetyl (26e) and 4-acetyl (26f) groups at the phenyl ring of oxazolidine were the most potent against HIV-1 protease with Ki values of 16 pM, 6 pM and 16 pM, respectively. 25 The introduction of disubstituted 3-fluoro-4-methoxyphenylsulfonamide at P2' (26b-f) showed mixed results with different substituted phenyloxazolidines at P2. It appears that the addition of 3-fluoro group on the phenyl ring at P2' is not well tolerated. Relatively low Ki values were observed for derivatives with 3-fluoro (27b, Ki = 70 pM), 3 trifluoromethyl (27d, Ki= 72 pM), and 4-acetyl (27f, Ki = 80 pM), groups compared to 30 derivatives with 3,4-difluoro (27c, Ki= 343 pM), and 3-acetyl (27e, Ki = 133 pM) groups. The replacement of 4-methoxyphenyl with 4-trifluoromethoxyphenyl resulted in the complete loss of activity (inhibitors 28d-e). Changing the position of the methoxy group from 4- to 3-position in 29a and 29f also resulted in significant loss of protease inhibitory - 87- WO 2007/002173 PCT/US2006/024109 activity (Figure 5, entries 26 & 27). These results suggest that inhibitors with electron donating substituents, methoxy, dioxolane and amino, at P2' phenylsulfonamide group exhibit potent HIV-1 protease inhibitory activities. Other substitutions and modifications are not well tolerated and could result in significant loss ofprotease inhibitory activity. 5 In addition to the variations at P2 and P2' positions, SAR effort was extended to replace the isobutyl group at Pl' with cyclic groups. Selected primary amines 30a-c include small hydrophobic group cyclopropylmethylamine as well as polar saturated (S)-(2 tetrahydrofuranyl)methylamine and unsaturated 2-(thiophenyl)methylamine heterocyclic groups. Again, sulfonyl chlorides utilized at R' position are all substituted benzene 10 derivatives containing functional groups at various positions. A small set of compounds with variations at all three R', R 2 and R 3 positions, corresponding to P2', P2 and P 1', were prepared and tested (Figure 7). Suprisingly, replacing the isobutyl group at Pl' with cyclopropylmethyl resulted in significantly lower inhibitory activities. The Ki values of 36b (257 pM), 36c (580 pM) and 36f (80 pM) are about 3, 9 and 200 fold higher than the 15 corresponding inhibitors with isobutyl group at P 1' position. Inhibitors 37-39 with (2 thiophenyl)methyl, and (S)-(2-tetrahydrofuranyl)methyl groups at Pl' position all showed very weak inhibitory activities against HIV-1 protease (Table 2 entries 4-11). Selected Inhibitor Activities against MDR Mutants. Selected inhibitors that exhibited potent activities against wild type HIV-1 protease were further evaluated for their 20 activities against a panel of MDR mutant variants. At least one compound was selected from each of the series incorporating different phenyloxazolidine based P2 ligands. In some cases, different functional group variations on benzenesulfonamide fragment were selected in preference to compounds with lowest Ki values in that series. The Ki values of selected inhibitors against M1-M3 MDR mutant protease are presented in Figure 8. Two known 25 drugs, amprenavir (APV, a structurally related compound) and lopinavir (LPV) were also studied for comparisons. The data show that all protease inhibitors loose affinity against mutant variants compared to the wild type protease. However, the relative loss of activity is different in different class of inhibitors. While LPV significantly loses activity against mutants M1 and M3 but, it still retains high affinity against M2 mutant. In case of APV, the 30 relative loss of activity is not that significant against all mutants but, its Ki value for wild type is also relatively high. The protease inhibitors with oxazolidine at P2 showed some loss of activities against M1 mutant, significant loss against M3 mutant, but still retained potent inhibitory activities against M2 mutant. The activity of the most potent protease - 88 - WO 2007/002173 PCT/US2006/024109 inhibitor from this series, 21e (Ki = 0.8 pM against wild type) was less affected by drug resistance mutations and showed quite potent activity against Ml and M2 MDR enzymes and inhibited M1 and M2 MDR enzymes with a Ki values of 160 pM and 39 pM, respectively. 5 Methods of Treatment. The methods described herein include methods for the treatment or prevention of a viral infection, e.g., an HIV, infection and Acquired Immunodeficiency Syndrome (AIDS) or AIDS Related Complex (ARC). Generally, the methods include administering a therapeutically effective amount of a protease inhibitor described herein, to a subject (e.g., a human or other primate) in need thereof, or who has 10 been determined to be in need of, such treatment, e.g., a subject who is (or is determined to be) infected with HIV. A subject who is likely to be infected with HIV, e.g., a person in a high risk group, may also be treated as indicated herein. Subjects also include women who are expecting a child (pregnant women) and in whom a treatment reduces the liklihood of transmission of HIV to the child. 15 In addition to HIV-1 infections, the methods described herein are also expected to be beneficial for treating or preventing HIV-2 infections. Among HIV-1 viruses, it is expected that the methods will be effective against any HIV-1 strain, such as those of group M, O and N, and subtypes A, B, C, D, E, F, G, H, I, J and K and "circulating recombinant forms" or CRFs thereof. The compounds described herein may also be used for treating any other 20 viral infections in which the viral agent has a protease inhibitor that can be inhibited by the compounds described herein. As used in this context, to "treat" means to ameliorate at least one clinical symptom or parameter of HIV infection or preventing it from worsening or preventing the transmission of HIV, e.g., from mother to child. For example, a treatment can result in a 25 reduction in viral load, and/or an increase in number of CD4+ T cells ("CD4 count"). When a subject has achieved a reduction in viral load, and/or an increase in CD4 count, then treatment may also include maintaining the reduction in viral load, and/or the increased CD4 count, e.g., preventing a resurgence of viral load and/or a decrease in CD4 count. These, and other clinically relevant parameters, can be measured using methods 30 known in the art. For example, viral load can be measured, e.g., using PCR or branched DNA (bDNA) assays known in the art. CD4 counts can be measured, e.g., using hematology, DYNAbeads T M (Dynal Biotech/Invitrogen Corp., Brown Deer, WI), flow cytometry (e.g., FACSCountTM, BD Biosciences, Franklin Lakes, NJ) or enzyme-linked - 89 - WO 2007/002173 PCT/US2006/024109 immunosorbent assay (ELISA) methods (see, e.g., Lyamuya et al., J. Immunol. Methods 195(1-2):103-12 (1996); Paxton et al., Clin. Diagn. Lab. Immunol. 2(1):104-114 (1995); Saah et al. Arch. Pathol. Lab. Med. 121(9):960-2 (1997); Mwaba et al., Lancet 362 1459-60 (2003)). Healthy adults and teenagers generally have a CD4 count of at least 800 cells per 5 cubic millimeter of blood; a CD4 count below 200 is associated with severe risk of illness (e.g., AIDS-related diseases, such as Kaposi's sarcoma or pneumocystic pneumonia). Current guidelines suggest treatment for HIV should be started when the CD4 count is less than about 350 and/or the viral load is greater than about 50,000. A "therapeutically effective amount" is an amount sufficient to effect a desired 10 therapeutic effect, e.g., a reduction in viral load, and/or an increase in number of CD4+ T cells. An effective amount can be administered in one or more administrations, applications or dosages. A therapeutically effective amount of a composition may depend on the composition selected. The compositions can be administered once, one or more times per day, and/or one or more times per week; including once every other day. In 15 certain embodiments, the compositions will be administered two or three times per day. The skilled artisan will appreciate that certain factors may influence the dosage and timing required to treat effectively a subject, including but not limited to the severity of the disease or disorder, previous treatments, the general health and/or age of the subject, and any other indications present. Treatment of a subject with a therapeutically effective amount of a 20 protease inhibitor described herein can include a single treatment or a series of treatments. Dosage, toxicity and therapeutic efficacy of the compounds can be determined, e.g., by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and 25 therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds that exhibit high therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to select a dose and administration schedule that minimizes severe side effects while maximizing therapeutic efficacy. 30 The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form - 90- WO 2007/002173 PCT/US2006/024109 employed and the route of administration utilized. For any compound used in a method described herein, a therapeutically effective dosage range can be estimated initially from cell culture assays. A dose can be further formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the 5 test compound that achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to determine more accurately useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography. In some embodiments, a therapeutically effective amount of a new protease inhibitor described herein ranges from about 0.1 to 10 mg per day, or about 0.3 to 10 5 mg/day. In some embodiments, one or more of the protease inhibitors described herein will be administered in combination with one or more other therapeutic agents, e.g., as part of a highly active antiretroviral therapy (HAART) regimen that includes one or more other anti retroviral agents. For example, the methods may include administration of one or more of a 15 non-nucleoside reverse transcriptase inhibitor (NNRTI), such as efavirenz (SustivarM), nevirapine (ViramuneTM) and delavirdine (RescriptorTM), 8 and 9-Cl TIBO (tivirapine), loviride, TMC-125, dapivirine, MKC-442, UC 781, UC 782, Capravirine, DPC 961, DPC963, DPCO82, DPC083, calanolide A, SJ-1366, TSAO, 4"-deaminated TSAO, MV150 and MV026048; a nucleoside reverse transcriptase inhibitor (NRTI), such as AZT 20 (zidovudine, RetrovirTM)/3TC (lamivudine, EpivirM), emtricitabine (EmtrivaTM) and d4T (stavudine, Zerit T M )/3TC, and d-drugs (ddl [didanosine, Videx T M /VidexEC

TM

], ddC [zalcitabine, HividTM], d4T), Abacavir, FTC, DAPD, dOTC, and DPC 817; a nucleotide reverse transcriptase inhibitor, such as tenofovir (VireadTM) and PMEA; a fusion inhibitor, such as enfuvirtide (FuzeonTM), T20, T1249, 5-helix and D-peptide ADS-J1; an entry 25 inhibitor; a co-receptor binding inhibitor, such as AMD 3100, AMD-3465, AMD7049, AMD3451 (Bicyclams), TAK 779; SHC-C (SCH351125), SHC-D, PRO-140RT inhibitors, such as foscarnet and prodrugs; an RNAse H inhibitor, such as SP1093V and PD126338; a TAT inhibitor, such as RO-5-3335, K12 and K37; an integrase inhibitor, such as L 708906, L 731988 and S-1360; another protease inhibitor, such as amprenavir and prodrug GW908, 30 nelfinavir, saquinavir, indinavir, lopinavir, palinavir, BMS 186316, atazanavir, DPC 681, DPC 684, tipranavir, AG1776, mozenavir, GS3333, KNI-413, KNI-272, L754394, L756425, LG-71350, PD161374, PD173606, PD177298, PD178390, PD178392, PNU 140135, TMC114 maslinic acid and U-140690; a glycosylation inhibitor, such as -91 - WO 2007/002173 PCT/US2006/024109 castanospermine, deoxynojirimycine; or a binding inhibitor, such as dextran sulfate, suramine, polyanions, soluble CD4, PRO-542 and BMS-806. Other drugs include those set forth at http://aidsinfo.nih.gov/, hereby incorporated by reference. Other therapeutic agenets that may be coadministered with with one or more agents 5 described herein are agents that inhibit metabolic enzymes, e.g., inhibitors of cytochrome P450 (CYP450) enzymes. For example, a compound described herein may be administered, simultaneously or not, with an inhibitor of CYP3A4, e.g., Ritonavir, or an inhibitor ofCYP2C19, CYP1A2, CYP2D6, or CYP2C9. Exemplary inhibitors of 2C9 are described, e.g., in U.S. publication No. 2006.0069042, hereby incorporated by reference. 10 The compounds of the present invention may also be administered in combination with immunomodulators (e.g., bropirimine, anti-human alpha interferon antibody, IL-2, methionine enkephalin, interferon alpha, HE-2000 and naltrexone), antibiotics (e.g., pentamidine isothiorate), cytokines (e.g. Th2), modulators of cytokines, chemokines or the receptors thereof (e.g. CCR5) or hormones (e.g. growth hormone), to ameliorate, combat, 15 or eliminate HIV infection and its symptoms. In some embodiments, the methods further comprise administering a second therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of amprenavir (Agenerase®; APV), tipranavir (Aptivus®; TPV), indinavir (Crixivan®; IDV), saquinavir (Invirase®; SQV), lopinavir and ritonavir (Kaletra®; LPV), 20 fosamprenavir (Lexiva®; FPV), ritonavir (Norvir®; RTV), atazanavir (Reyataz®; ATZ), nelfinavir (Viracept®; NFV), brecanavir, and darunavir. In some embodiments, the methods further comprise administering a second therapeutic agent, wherein the second therapeutic agent is ritonavir (Kaletra®; LPV). In some embodiments, the methods further comprise administering a second 25 therapeutic agent, wherein the second therapeutic agent is selected from the group consisting of zidovudine (AZT; Azidothymidine; Retrovir®), didanosine (Dideoxyinosine; ddl; Videx®), zalcitabine (Dideoxycytidine; ddC; Hivid®), lamivudine (3TC; Epivir®), stavudine (2',3'-didehydro-3'-deoxythymidine; D4T; Zerit®), abacavir succinate (1592U89 succinate; Ziagen® ABC), Combivir® (lamivudine & zidovudine; (-)-3TC & AZT), and 30 Trizivir® (abacavir & lamivudine & zidovudine; ABC & (-)-3TC & AZT). In some embodiments, the methods further comprise administering a second therapeutic agent, wherein the second therapeutic agent is selected from the group - 92 - WO 2007/002173 PCT/US2006/024109 consisting of nevirapine (BI-RG-587; Viramune@), delavirdine (BHAP; U-90152; Rescriptor®), and (efavirenz; DMP-266; Sustiva®). In some embodiments, the methods further comprise administering a second therapeutic agent, wherein the second therapeutic agent is T-20 (Fuzeon®; Enfuvirtide; DP 5 178; Pentafuside; GP41 127-162 AA). In some embodiments, the methods further comprise administering a second therapeutic agent, wherein the second therapeutic agent is TMCC114, or TMCC114 in combination with a reverse transcriptase inhibitor. In some embodiments, the methods further comprise administering a second therapeutic agent, wherein the second therapeutic 10 agent is Lipinavir, or Lupanivir in combination with a reverse transcriptase inhibitor. Combination therapy in different formulations may be administered simultaneously, separately or sequentially. Alternatively, such combination may be administered as a single formulation, whereby the active ingredients are released from the formulation simultaneously or separately. Compositions comprising at least two inhibitors described 15 herein and/or one or more other protease inhibitors and/or other therapeutic agents are also provided herein. In certain embodiments the compounds of the invention can be combined with one or more of any anti-HIV compounds (e.g. those listed in Figure 16). Additional compounds which may be combined with one or more of the inventive compounds, and further discussion of combination therapy can be found in Yeni, P. G. et al. JAMA 2004, 20 292(2), 251-265; Pozniak, A. et al. Business Briefing: Clinical Virology & Infectious Disease 2004, 1-7; and Chittick, G. E. et al. Antimicrobial Agents and Chemotherapy 2006, 1304-1310; all of which are hereby incorporated by reference. Definitions. All definitions, as defined and used herein, should be understood to control over dictionary definitions, definitions in documents incorporated by reference, 25 and/or ordinary meanings of the defined terms. The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one." The term "HIV" is known to one skilled in the art to refer to Human 30 Immunodeficiency Virus. There are two types ofHIV: HIV-1 and HIV-2. There are many different strains of HIV-1. The strains of HIV-1 can be classified into three groups: the "major" group M, the "outlier" group O and the "new" group N. These three groups may - 93 - WO 2007/002173 PCT/US2006/024109 represent three separate introductions of simian immunodeficiency virus into humans. Within the M-group there are at least ten subtypes or clades: e.g., clade A, B, C, D, E, F, G, H, I, J, and K. A "clade" is a group of organisms, such as a species, whose members share homologous features derived from a common ancestor. Any reference to HIV in this 5 application includes all of these tupes and strains. As known to one skilled in the art, "retroviruses" are diploid positive-strand RNA viruses that replicate through an integrated DNA intermediate (proviral DNA). In particular, upon infection by the RNA virus, the lentiviral genome is reverse-transcribed into DNA by a virally encoded reverse transcriptase that is carried as a protein in each 10 retrovirus. The viral DNA is then integrated pseudo-randomly into the host cell genome of the infecting cell, forming a "provirus" which is inherited by daughter cells. The retrovirus genome contains at least three genes: gag codes for core and structural proteins of the virus; pol codes for reverse transcriptase, protease and integrase; and env codes for the virus surface proteins. Within the retrovirus family, HIV is classified as a lentivirus, having 15 genetic and morphologic similarities to animal lentiviruses such as those infecting cats (feline immunodeficiency virus), sheep (visna virus), goats (caprine arthritis-encephalitis virus), and non-human primates (simian immunodeficiency virus). The term "heteroatom" is art-recognized and refers to an atom of any element other than carbon or hydrogen. Illustrative heteroatoms include boron, nitrogen, oxygen, 20 phosphorus, sulfur and selenium. The term "alkyl" is art-recognized, and includes saturated aliphatic groups, including straight-chain alkyl groups, branched-chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In certain embodiments, a straight chain or branched chain alkyl has about 30 or fewer carbon 25 atoms in its backbone (e.g., C 1

-C

30 for straight chain, C 3

-C

3 0 for branched chain), and alternatively, about 20 or fewer. Likewise, cycloalkyls have from about 3 to about 10 carbon atoms in their ring structure, and alternatively about 5, 6 or 7 carbons in the ring structure. Unless the number of carbons is otherwise specified, "lower alkyl" refers to an alkyl 30 group, as defined above, but having from one to about ten carbons, alternatively from one to about six carbon atoms in its backbone structure. Likewise, "lower alkenyl" and "lower alkynyl" have similar chain lengths. - 94 - WO 2007/002173 PCT/US2006/024109 The term "aralkyl" is art-recognized and refers to an alkyl group substituted with an aryl group (e.g., an aromatic or heteroaromatic group). The terms "alkenyl" and "alkynyl" are art-recognized and refer to unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, 5 but that contain at least one double or triple bond respectively. The term "aryl" is art-recognized and refers to 5-, 6- and 7-membered single-ring aromatic groups that may include from zero to four heteroatoms, for example, benzene, naphthalene, anthracene, pyrene, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like. Those aryl 10 groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles" or "heteroaromatics." The aromatic ring may be substituted at one or more ring positions with such substituents as described herein, for example, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, 15 sulfonamido, ketone, aldehyde, ester, heterocyclyl, aromatic or heteroaromatic moieties, CF 3 , -CN, or the like. The term "aryl" also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings (the rings are "fused rings") wherein at least one of the rings is aromatic, e.g., the other cyclic rings may be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls. 20 The terms ortho, meta and para are art-recognized and refer to 1,2-, 1,3- and 1,4 disubstituted benzenes, respectively. For example, the names 1,2-dimethylbenzene and ortho-dimethylbenzene are synonymous. The terms "heterocyclyl", "heteroaryl", or "heterocyclic group" are art-recognized and refer to 3- to about 10-membered ring structures, alternatively 3- to about 7-membered 25 rings, whose ring structures include one to four heteroa toms. Heterocycles may also be polycycles. Heterocyclyl groups include, for example, thiophene, thianthrene, furan, pyran, isobenzofuran, chromene, xanthene, phenoxanthene, pyrrole, imidazole, pyrazole, isothiazole, isoxazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthyridine, 30 quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, pyrimidine, phenanthroline, phenazine, phenarsazine, phenothiazine, furazan, phenoxazine, pyrrolidine, oxolane, thiolane, oxazole, piperidine, piperazine, morpholine, - 95 - WO 2007/002173 PCT/US2006/024109 lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like. The heterocyclic ring may be substituted at one or more positions with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, 5 carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic moiety, -CF 3 , -CN, or the like. The terms "polycyclyl" or "polycyclic group" are art-recognized and refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are "fused 10 rings". Rings that are joined through non-adjacent atoms are termed "bridged" rings. Each of the rings of the polycycle may be substituted with such substituents as described above, as for example, halogen, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, ketone, aldehyde, ester, a heterocyclyl, an aromatic or heteroaromatic 15 moiety, -CF 3 , -CN, or the like. The term "carbocycle" is art-recognized and refers to an aromatic or non-aromatic ring in which each atom of the ring is carbon. The term "nitro" is art-recognized and refers to -NO 2 ; the term "halogen" is art recognized and refers to -F, -Cl, -Br or -I; the term "sulfhydryl" is art-recognized and refers 20 to -SH; the term "hydroxyl" means -OH; and the term "sulfonyl" is art-recognized and refers to -S0 2 -. "Halide" designates the corresponding anion of the halogens, and "pseudohalide" has the definition set forth on page 560 of "Advanced Inorganic Chemistry" by Cotton and Wilkinson. The terms "amine" and "amino" are art-recognized and refer to both unsubstituted 25 and substituted amines, e.g., a moiety that may be represented by the general formulas: -N(R51)(R50) or [-N(R50)(R52)(R53)]

+

, wherein R50, R51, R52 and R53 each independently represent a hydrogen, an alkyl, an alkenyl, -(CH 2 )m-R61, or R50 and R51 or R52, taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R61 represents an aryl, a cycloalkyl, a 30 cycloalkenyl, a heterocycle or a polycycle; and m is zero or an integer in the range of 1 to 8. In other embodiments, R50 and R51 (and optionally R52) each independently represent a hydrogen, an alkyl, an alkenyl, or -(CH2)m-R61. Thus, the term "alkylamine" includes an - 96 - WO 2007/002173 PCT/US2006/024109 amine group, as defined above, having a substituted or unsubstituted alkyl attached thereto, i.e., at least one of R50 and R51 is an alkyl group. The term "acylamino" is art-recognized and refers to a moiety that may be represented by the general formula: -N(R50)-C(=O)R54, wherein R50 is as defined above, 5 and R54 represents a hydrogen, an alkyl, an alkenyl or -(CH 2 )m-R61, where m and R61 are as defined above. The term "amido" is art recognized as an amino-substituted carbonyl and includes a moiety that may be represented by the general formula: -C(=O)N(R50)(R51), wherein R50 and R51 are as defined above. Certain embodiments of the amide in the present invention 10 will not include imides which may be unstable. The term "alkylthio" refers to an alkyl group, as defined above, having a sulfur radical attached thereto. In certain embodiments, the "alkylthio" moiety is represented by one of-S-alkyl, -S-alkenyl, -S-alkynyl, and -S-(CH 2 )m-R61, wherein m and R61 are defined above. Representative alkylthio groups include methylthio, ethyl thio, and the like. 15 The term "carboxyl" is art recognized and includes such moieties as may be represented by the general formulas: -C(=O)-X50-R55 or -X50-C(=O)-R56, wherein X50 is a bond or represents an oxygen or a sulfur, and R55 and R56 represents a hydrogen, an alkyl, an alkenyl, -(CH 2 )m-R61 or a pharmaceutically acceptable salt, R56 represents a hydrogen, an alkyl, an alkenyl or -(CH2)m-R61, where m and R61 are defined above. 20 Where X50 is an oxygen and R55 or R56 is not hydrogen, the formula represents an "ester". Where X50 is an oxygen, and R55 is as defined above, the moiety is referred to herein as a carboxyl group, and particularly when R55 is a hydrogen, the formula represents a "carboxylic acid". Where X50 is an oxygen, and R56 is hydrogen, the formula represents a "formate". In general, where the oxygen atom of the above formula is replaced by sulfur, 25 the formula represents a "thiolcarbonyl" group. Where X50 is a sulfur and R55 or R56 is not hydrogen, the formula represents a "thiolester." Where X50 is a sulfur and R55 is hydrogen, the formula represents a "thiolcarboxylic acid." Where X50 is a sulfur and R56 is hydrogen, the formula represents a "thiolformate." On the other hand, where X50 is a bond, and R55 is not hydrogen, the above formula represents a "ketone" group. Where X50 30 is a bond, and R55 is hydrogen, the above formula represents an "aldehyde" group. The term "carbamoyl" refers to -O(C=O)NRR', where R and R' are independently H, aliphatic groups, aryl groups or heteroaryl groups. - 97 - WO 2007/002173 PCT/US2006/024109 The term "oxo" refers to a carbonyl oxygen (=0). The terms "oxime" and "oxime ether" are art-recognized and refer to moieties that may be represented by the general formula: -C(R75)(=NOR), wherein R75 is hydrogen, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, or -(CH 2 )m-R61. The moiety is an "oxime" 5 when R is H; and it is an "oxime ether" when R is alkyl, cycloalkyl, alkenyl, alkynyl, aryl, aralkyl, or -(CH 2 )m-R61. The terms "alkoxyl" or "alkoxy" are art-recognized and refer to an alkyl group, as defined above, having an oxygen radical attached thereto. Representative alkoxyl groups include methoxy, ethoxy, propyloxy, tert-butoxy and the like. An "ether" is two 10 hydrocarbons covalently linked by an oxygen. Accordingly, the substituent of an alkyl that renders that alkyl an ether is or resembles an alkoxyl, such as may be represented by one of -O-alkyl, -O-alkenyl, -O-alkynyl, -O-(CH 2 )m-R61, where m and R61 are described above. The term "sulfonate" is art recognized and refers to a moiety that may be represented by the general formula: -S(=0) 2 0R57, in which R57 is an electron pair, 15 hydrogen, alkyl, cycloalkyl, or aryl. The term "sulfate" is art recognized and includes a moiety that may be represented by the general formula: -OS(=0) 2 0R57, in which R57 is as defined above. The term "sulfonamido" is art recognized and includes a moiety that may be represented by the general formula: -N(R50)-S(=0) 2 0R56, in which R50 and R56 are as 20 defined above. The term "sulfamoyl" is art-recognized and refers to a moiety that may be represented by the general formula: -S(=0) 2 N(R50)(R51), in which R50 and R51 are as defined above. The term "sulfonyl" is art-recognized and refers to a moiety that may be represented 25 by the general formula: -S(=0) 2 R58, in which R58 is one of the following: hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl. The term "sulfoxido" is art-recognized and refers to a moiety that may be represented by the general formula: -S(=O)R58, in which R58 is defined above. Analogous substitutions may be made to alkenyl and alkynyl groups to produce, for 30 example, aminoalkenyls, aminoalkynyls, amidoalkenyls, amidoalkynyls, iminoalkenyls, iminoalkynyls, thioalkenyls, thioalkynyls, carbonyl-substituted alkenyls or alkynyls. - 98 - WO 2007/002173 PCT/US2006/024109 The definition of each expression, e.g., alkyl, m, n, and the like, when it occurs more than once in any structure, is intended to be independent of its definition elsewhere in the same structure. The abbreviations Me, Et, Ph, Tf, Nf, Ts, and Ms represent methyl, ethyl, phenyl, 5 trifluoromethanesulfonyl, nonafluorobutanesulfonyl, p-toluenesulfonyl and methanesulfonyl, respectively. A more comprehensive list of the abbreviations utilized by organic chemists of ordinary skill in the art appears in the first issue of each volume of the Journal of Organic Chemistry; this list is typically presented in a table entitled Standard List of Abbreviations. 10 It will be understood that "substitution" or "substituted with" includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, or other reaction. 15 The term "substituted" is also contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. Illustrative substituents include, for example, those described herein above. The permissible substituents may be one or more and the same or 20 different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. This invention is not intended to be limited in any manner by the permissible substituents of organic compounds. 25 For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, "Handbook of Chemistry and Physics", 67th Ed., 1986-87, inside cover. EXEMPLIFICATION The invention now being generally described, it will be more readily understood by 30 reference to the following examples which are included merely for purposes of illustration - 99 - WO 2007/002173 PCT/US2006/024109 of certain aspects and embodiments of the present invention, and are not intended to limit the invention General Experimental Procedures. 'H and 13C NMR spectra were recorded on a Varian 400 MHz NMR spectrometer, operating at 400 MHz for 1 H and 100 MHz for 1 3 C. 5 Chemical shifts are reported in ppm relative to the solvent signal, and coupling constant (J) values are reported in Hertz (Hz). Thin-layer chromatography (TLC) was performed on E. Merck silica gel 60-F-254 plates and spots were visualized with UV light. Flash column chromatography was performed using 230-400 mesh silica gels (E-Merck). High resolution mass spectra (HRMS) were recorded on Waters Q-TOF Premier mass spectrometer by 10 direct infusion of solutions of each compound using electrospray ionization (ESI) in positive mode. Low resolution mass spectra were obtained using Waters Alliance HT/Micromass ZQ system (ESI). Tetrahydrofuran was distilled from sodium/benzophenone. Anhydrous Dichloromethane, N,N-dimethylformamide, benzene, and toluene were purchased from Aldrich and used as such. All reagents and chemicals 15 were purchased from commercial vendors and used as received. Analytical reversed-phase high performance liquid chromatography (HPLC) was performed on a Waters Separation Module 2695 system equipped with an auto sampler and a Waters 996 photodiode array detector. Purity of the final compounds was determined using two different chromatographic systems. First system: column, Waters Nova-Pak RP 20 C18 (4 pm, 3.9 mm x 150 mm); mobile phase A, 10 mM ammonium acetate in water; mobile phase B, acetonitrile. Using a flow rate of 0.8 mL/min, gradient elution was performed from 50% B to 100% B over 10 min. Second system: column, Agilent Zorbax 300SB-C8 (5 Om, 4.6 mm x 250 mm); mobile phase A, 0.1% trifluoroacetic acid in water; mobile phase B, 0.1% trifluoroacetic acid in acetonitrile. Gradient elution was performed 25 from 50% B to 100% B over 10 min at a flow rate of 1 mL/min. A table containing the retention time and purity of each final compound is shown in Figure 9. EXAMPLE 1 GENERAL PROCEDURE FOR THE CBZ PROTECTION OF SUBSTITUTED ANILINES 30 Solid NaHCO 3 (32.65 g, 388.5 mmols) was added to an ice-cooled solution of aniline derivative (185 mmols) in acetone-water mixture (2:1) (300 mL) followed by the slow addition of benzyl chloroformate (27 mL, 190 mmols). The resulting slurry was - 100- WO 2007/002173 PCT/US2006/024109 warmed to ambient temperature and stirred overnight. Reaction mixture was poured onto ice and the resulting precipitate was filtered, washed with water and dried. Product was purified by recrystallization from a mixture of hexanes and ethylacetate to provide the pure product as crystalline solid. Compounds 4a-g were prepared following this general 5 procedure. EXAMPLE 2 GENERAL PROCEDURE FOR THE SYNTHESIS OF 5-(HYDROXYMETHYL) OXAZOLIDINONES 7 AND 8 A solution of CBZ protected aniline derivative 4 (34.7 rnmols) in dry THF (150 mL) 10 was cooled to -78 oC under dry N 2 atmosphere. A solution of n-BuLi (1.6 M in hexanes; 25 mL, 40 mmols) was slowly added keeping the temperature below -70 oC. After stirring the reaction mixture at -78 'C for 45 minutes, a solution of chiral glycidyl butyrate (5 g, 34.7 mmols) in dry THF was slowly added. The resulting mixture was stirred at -78 'C for 2 hours and then slowly warmed to room temperature and stirred overnight. Reaction was 15 quenched by the addition of saturated aqueous NH 4 C1 solution. Ethyl acetate and water were added and layers separated. The aqueous layer was further extracted with ethyl acetate (3 times). Combined organic extract was washed with saturated aqueous NaCl solution, dried (Na 2

SO

4 ), filtered and evaporated to yield a pale yellow solid. This solid was triturated with a mixture of chloroform and hexanes and filtered to provide pure alcohol as 20 off white solid. Compounds 8a-g were prepared following this general procedure. (R)-5-(Hydroxymethyl)-3-phenyloxazolidine-2-one (7a). 1H NMR (400 MHz,

CD

3 OD) 87.55 (min, 2H), 7.35 (m, 2H), 7.12 (min, 1H), 4.71 (m, 1H), 4.10 (t, J= 9.2 Hz, 1H), 3.91 (dd, J= 8.8, 6.8 Hz, 1H), 3.82 (dd, J= 12.8, 3.6 Hz, 1H), 3.67 (dd, J= 12.4, 4.0 Hz, 1H); 13 C NMR (100 MHz, CD 3 OD) 4 139.76, 129.97, 125.14, 119.72, 95.67, 75.05, 63.29, 25 47.78. EXAMPLE 3 GENERAL PROCEDURE FOR THE SYNTHESIS OF PHENYLLOXAZOLIDINONE-5 CARBOXYLIC ACIDS 9 AND 10. To an ice-cooled solution of NaIO 4 (35 mmols) in water (75 mL) was added a 30 solution of the alcohol 7 or 8 (10 mmols) in a mixture of CH 3 CN and CC1 4 (1:1) (100 mL). Solid RuC1 3

.H

2 0 (0.5 mmol) was added and the reaction mixture was stirred at 0 oC for 30 minutes, warmed to room temperature and stirred for 4-6 hours. Reaction was quenched by - 101 - WO 2007/002173 PCT/US2006/024109 adding CH 2

C

2 and layers were separated. The aqueous layer was further extracted with

CH

2 C1 2 , combined organic extract was dried (Na 2

SO

4 ) and evaporated to provide a gummy solid. Crude product was purified by column chromatography on silica gel using a mixture of 25% CH 3 CN in CH 2 C1 2 + 1% HCO 2 H as eluent. This method provided the desired 5 phenyloxazolidine-5-carboxylic acids as solids in excellent yields. The following compounds were prepared by this general procedure: (R)-2-Oxo-3-phenyloxazolidine-5-carboxilic acid (9a). 'H NMR (400 MHz, CDC1 3 ) 37.48 (min, 2H), 7.36 (min, 2H), 7.15 (m, 1H), 5.89 (br. s, 1H), 5.09 (dd, J= 10.0, 5.2 Hz, 1H), 4.33 (t, J= 9.6 Hz, 1H), 4.16 (dd, J= 8.8, 4.8 Hz, 1H). 10 (S)-2-Oxo-3-phenyloxazolidine-5-carboxilic acid (10a). 1H NMR (400 MHz, CDC1 3 ) 37.50 (min, 2H), 7.36 (min, 2H), 7.16 (min, 1H), 5.80 (br. s, 1H), 5.07 (dd, J= 10.0, 5.2 Hz, 1H), 4.32 (t, J= 9.6 Hz, 1H), 4.15 (dd, J= 9.2, 4.4 Hz, 1H). (S)-3-(3-Fluorophenyl)-2-oxo-oxazolidine-5-carboxylic acid (10b). 1 H NMR (400 MHz, CD 3 OD) 3 7.51 (min, 1H), 7.37 (in, 1H), 7.27 (dd, J= 8.4, 2.4 Hz, 1H1), 6.88 (dt, J= 15 8.0, 2.4 Hz, 1H), 5.16 (dd, J= 10.0, 5.6 Hz, 1H), 4.38 (t, J= 9.6 Hz, lH), 4.14 (dd, J= 9.2, 5.2 Hz, 1H). (S)-3-(3,4-Difluorophenyl)-2-oxo-oxazolidine-5-carboxylic acid (10c). 'H NMR (400 MHz, CD 3 OD) 37.72-7.66 (min, 1H), 7.27-7.24 (min, 2H), 5.16 (dd, J= 10.0, 5.6 Hz, 1H), 4.37 (t, J= 9.6 Hz, 1H), 4.14 (dd, J= 9.2, 5.6 Hz, 1H). 20 (S)-2-Oxo-3-[(3-trifluoromethyl)phenyl]oxazolidine-5-carboxilic acid (10d). 'H NMR (400 MHz, CDC1 3 ) 37.75 (d, J= 8.0 Hz, 1H), 7.72 (s, 1H), 7.50 (t, J= 8.0 Hz, 1H), 7.41 (d, J= 8.0 Hz, 1H), 6.24 (br. s 1H), 5.15 (dd, J= 9.6, 5.2 Hz, 1H), 4.38 (t, J= 9.6 Hz, 1H), 4.21 (dd, J= 9.2, 5.2 Hz, 1H). (S)-3-(3-Acetylphenyl)-2-oxo-oxazolidine-5-carboxilic acid (10e). 1H NMR (400 25 MHz, CD 3 0D) 38.15 (s, 1H), 7.83 (dd, J= 8.0, 2.4 Hz, 1H), 7.78 (d, J= 8.0 Hz, 1H), 7.52 (t, J= 8.4 Hz, 1H), 5.19 (dd, J= 9.6, 5.2 Hz, 1H), 4.45 (t, J= 9.2 Hz, 1H), 4.20 (dd, J= 9.6, 5.6 Hz, 1H), 2.61 (s, 3H). (S)-3-(4-Acetylphenyl)-2-oxo-oxazolidine-5-carboxilic acid (10f). 1'H NMR (400 MHz, DMSO) 37.97 (dd, J= 7.6, 1.6 Hz, 2H), 7.69 (dd, J= 7.6, 1.6 Hz, 2H), 5.20 (dd, J= 30 10.0, 5.6 Hz, 1H), 4.39 (t, J= 9.6 Hz, 1H), 4.16 (dd, J= 9.2, 5.2 Hz, 1H), 2.53 (s, 3H). -102- WO 2007/002173 PCT/US2006/024109 (S)-3-(3-Methoxyphenyl)-2-oxo-oxazolidine-5-carboxilic acid (10g). 'H NMR (400 MHz, CDC1 3 ) 67.27 (t, J= 8.0 Hz, 1H), 7.21 (t, J= 2.4 Hz, 1H), 6.98 (dd, J= 8.8, 2.8 Hz, 1H), 6.71 (dd, J= 8.4, 2.4 Hz, 1H), 5.09 (dd, J= 10.0, 5.6 Hz, 1H), 4.33 (t, J= 9.6 Hz, 1H), 4.18-4.07 (min, 2H), 3.81 (s, 3H). 5 EXAMPLE 4 GENERAL PROCEDURE FOR THE RING OPENING OF EPOXIDE WITH AMINES. A solution of the chiral epoxide 11 (1-Oxiranyl-2-phenylethyl)carbamic acid tert butyl ester) (10 mmol) in EtOH (75 mL) was added to isobutyl amine (10 mL; large excess) and the mixture was heated at 80 oC for 3 hours. After cooling to room temperature, 10 solvents were removed under reduced pressure. Product was purified by recrystallization from ethyl acetate-hexanes mixture to provide the product as white solid in excellent yield. EXAMPLE 5 GENERAL PROCEDURE FOR THE SYNTHESIS OF (HYDROXYETHYLAMINO) SULFONAMIDES 15 To an ice-cooled solution of the secondary amine 12 (5 mmol) in CH 2

C

2 (20 mL) was added an aqueous solution of Na 2

CO

3 (8 mmol in 5 mL H20) followed by the slow addition of sulfonyl chloride (5 mmol) solution in CH 2

C

2 (5 mL). After 15 minutes the reaction mixture was warmed to ambient temperature and stirred till no starting material was detected by tic. Reaction mixture was diluted with CH 2 C1 2 and layers were separated. 20 Organic extract was washed with saturated aqueous NaC1 solution, dried (Na 2

SO

4 ), filtered and evaporated. Product was purified by flash chromatography on silica gel using mixture of ethyl acetate and hexanes as eluent to afford pure product. The following compounds were prepared by this general procedure: N-[(1S,2R)-l Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl]amino]propyl]carbamic acid 25 tert-butyl ester (14); N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[isobutyl[(4-nitrophenyl)sulfonyl] amino]propyl]carbamic acid tert-butyl ester (15); N-[(1S,2R)-3-[[(Benzo-[1,3]-dioxole-5 sulfonyl)](isobutyl)amino]- 1 -benzyl-2-hydroxypropyl]carbamic acid tert-butyl ester (16); N-[( 1 S,2R)- 1 -Benzyl-3-[[(3-fluoro-4-methoxyphenyl)sulfonyl](isobutyl)amino]-2 hydroxypropyl]-carbamic acid tert-butyl ester (17); N-[(1S,2R)-l1-Benzyl-2-hydroxy-3 30 [isobutyl[[(4-trifluoro-methoxy)phenyl]sulfonyl]amino]propyl]carbamic acid tert-butyl ester (18); N-[(1S,2R)-l1-Benzyl-2-hydroxy-3-[isobutyl[(3 methoxyphenyl)sulfonyl]amino]propyl]carbamic acid tert-butyl ester (19); N-[(1S,2R)-1 - 103 - WO 2007/002173 PCT/US2006/024109 Benzyl-3-[(cyclopropylmethyl)[(3-methoxyphenyl)sulfonyl]-amino]-2 hydroxypropyl]carbamic acid tert-butyl ester (32); N-[(1S,2R)-1l-Benzyl-2-hydroxy-3-[[(3 methoxyphenyl)sulfonyl](2-thiophenylmethyl)]amino]propyl]carbamic acid tert-butyl ester (33); N-[(1S,2R)- 1-Benzyl-2-hydroxy-3-[(2-thiophenylmethyl)[(2,4,5 5 trifluorophenyl)sulfonyl]-amino]propyl]carbamic acid tert-butyl ester (34); and N-[(1S,2R) 1 -Benzyl-2-hydroxy-3-[[(3-methoxyphenyl)sulfonyl][(R)-(tetrahydro-2 furanyl)methyl]amino]propyl]carbamic acid tert-butyl ester (35). EXAMPLE 6 GENERAL PROCEDURE FOR THE COUPLING REACTION. 10 Excess oxalyl chloride was added to solid phenyloxazolidinone-5-carboxylic acid (0.5 mmols) and the resulting mixture was stirred at room temperature overnight. Oxalyl chloride was removed by distillation under reduced pressure and residue dried under high vacuum for 30 minutes. A solution of the resulting acid chloride in dry THF (5 mL) was used in the coupling reaction. 15 To an ice-cooled mixture of the Boc deprotected amine (0.5 mmols) in dry THF (5 mL) was added Et 3 N (1.1 mmols) followed by slow addition of the acid chloride solution. After 15 minutes the reaction mixture was warmed to room temperature and stirred until reaction was complete (monitored by tic). Small amount of water and ethyl acetate were added and layers were separated. The organic extract was washed with saturated aqueous 20 NaCl solution, dried (Na 2

SO

4 ), filtered and evaporated. Flash chromatography on silica gel using mixture of ethyl acetate and hexanes (in some cases, methanol/chloroform mixture) as eluent, provided the target compound as solid. EXAMPLE 7 GENERAL PROCEDURE FOR THE REDUCTION OF THE NITRO GROUP 25 A mixture of the nitro compound (0.4 mmols) and SnCl 2 .2H 2 0 (0.45 g, 2 mmols) in ethyl acetate (10 mL) was heated at 80 'C for 2-3 hours. Reaction mixture was allowed to cool to ambient temperature and treated with saturated aqueous NaHCO 3 solution (10 m). It was diluted with ethyl acetate and layers were separated, aqueous layer was further extracted with ethyl acetate (2 x). Combined organic extract was washed with saturated 30 aqueous NaC1 solution, dried (Na 2

SO

4 ) and evaporated to yield a foamy solid. Flash chromatography on silica gel using mixture of methanol in chloroform as eluent, provided the target compound as solid. - 104- WO 2007/002173 PCT/US2006/024109 EXAMPLE 8 SELECTED SPECTRAL DATA FOR DESIGNED PROTEASE INHIBITOR General experimental procedures for the synthesis of intermediates, phenyloxazolidines (9-10) and (R)-(hydroxyethylamino)sulfonamides (14-19 and 32-35) 5 and for the coupling reactions to provide the target compounds (20-29 and 36-39) are provided above. (5R)-N-[(1S,2R)-l1-Benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)sulfonyl]amino]-propyl]-2-oxo-3-phenyloxazolidine-5-carboxamide (20a). 'H NMR (400 MHz, CDC1 3 ) 8 7.67 (d, J= 8.8 Hz, 2H), 7.46 (d, J= 8.4 Hz, 2H11), 7.35 (t, J 10 = 7.6 Hz, 2H), 7.24-7.13 (m, 6H), 6.92 (d, J= 8.8 Hz, 2H), 6.75 (d, J= 8.4 Hz, 1H), 4.71 (dd, J= 10.0, 6.0 Hz, 1H), 4.17 (m, 2H), 4.07 (dd, J= 9.2, 6.0 Hz, 1H), 3.91 (m, 1H), 3.84 (m, 1H11), 3.82 (s, 3H), 3.10-2.77 (m, 6H), 1.76 (m, 1H), 0.84 (d,J = 6.4 Hz, 3H11), 0.79 (d,J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) 6168.98, 163.23, 153.06, 137.49, 137.46, 129.91,129.67 (2C), 129.44 (2C), 129.41 (2C), 128.79 (2C), 126.96, 124.95, 118.55 (2C), 15 114.54 (2C), 72.28, 70.03, 58.90, 55.80, 54.41, 53.56, 48.19, 35.05, 27.46 20.25, 20.11. HRMS (ESI) m/z: C 3 1

H

3 8N 3 0 7 S (M + H) + calcd, 596.2430; found, 596.2421. (5S)-N-[(1S,2R)- 1-Benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)sulfonyl]amino]propyl]-2-oxo-3-phenyloxazolidine-5-carboxamide (21a). 1H NMR (400 MHz, CDC1 3 ) 87.74 (d, J= 8.8 Hz, 2H), 7.45-7.38 (m, 4H), 7.19 (t, J= 7.2 20 Hz, 1H), 7.12 (d, J= 7.2 Hz, 2H), 7.04-6.98 (m, 4H), 6.89 (t, J= 7.6 Hz, 1H11), 6.69 (d, J= 9.6 Hz, 1H), 4.77 (dd, J= 9.6, 5.6 Hz, 1H), 4.22 (m, 1H), 4.04 (t, J= 9.6 Hz, 1H), 3.90 (m, 1H), 3.87 (s, 3H), 3.78 (d, J= 2.4 Hz, 1H), 3.36 (dd, J= 9.2, 6.0 Hz, 1H), 3.23 (dd, J= 15.2, 9.2 Hz, 1H), 3.11 (dd , J= 13.6, 4.4 Hz, 1H), 3.02 (dd, J= 13.6, 8.8 Hz, 1H), 2.96 (dd, J= 15.2, 2.8 Hz, 1H), 2.81 (dd, J= 13.6, 6.8 Hz, 1H), 2.73 (dd, J= 14.0, 10.8 Hz, 1H), 25 1.84 (m, 1H), 0.96 (d, J= 6.8 Hz, 3H), 0.90 (d, J= 6.4 Hz, 3H); 13 C NMR (100 MHz, CDC1 3 ) .168.86, 163.25, 153.12, 137.52, 137.49, 129.94, 129.68 (2C), 129.50 (2C), 129.26 (2C), 128.50 (2C), 126.61, 124.76, 118.47 (2C), 114.56 (2C), 72.46, 69.87, 58.91, 55.79, 53.78, 53.52, 48.29, 35.64, 27.44, 20.31, 20.07. HRMS (ESI) m/z: C 3 1

H

38

N

3 0 7 S (M + H) calcd, 596.2430; found, 596.2438. 30 (5S)-N-[(1S,2R)-1l-Benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)sulfonyl]amino]-propyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine-5 carboxamide (21b). 1H NMR (400 MHz, CDC1 3 ) 87.74 (d, J= 8.8 Hz, 2H11), 7.39-7.33 (m, - 105 - WO 2007/002173 PCT/US2006/024109 2H), 7.10 (m, 3H), 7.04-6.98 (m, 4H), 6.93-6.85 (mn, 2H), 6.68 (d, J= 9.6 Hz, 1H), 4.78 (dd, J= 10.2, 6.0 Hz, 1H), 4.23 (m, 1H), 4.01 (t, J= 9.6 Hz, 1H), 3.91 (rn, 1H), 3.88 (s, 3H), 3.68 (br. s, 1H), 3.32 (dd, J= 9.2, 6.0 Hz, 1H), 3.23 (dd, J= 14.8, 9.2 Hz, 1H), 3.10 (dd, J= 13.6, 4.4 Hz, 1H), 3.03 (dd, J= 13.2, 8.8 Hz, 1H), 2.97 (dd, J= 15.2, 2.4 Hz, 1H), 5 2.81 (dd, J= 13.6, 6.8 Hz, 1H), 2.73 (dd, J= 14.0, 10.4 Hz, 1H), 1.84 (m, 1H), 0.96 (d, J= 6.4 Hz, 3H), 0.90 (d, J= 6.4 Hz, 3H); 1 3 C NMR (100 MHz, CDC1 3 ) Mo168.60, 163.29, 163.18 (d, J= 244.2 Hz), 152.82, 138.98 (d, J= 10.6 Hz), 137.48, 130.48 (d, J= 9.1 Hz), 129.91, 129.70 (2C), 129.50 (2C), 128.49 (2C), 126.60, 114.58 (2C), 113.52 (d, J= 2.3 Hz), 111.49 (d, J= 21.2 Hz), 106.06 (d, J= 27.3 Hz), 72.47, 69.82, 58.95, 55.82, 53.79, 10 53.44, 48.20, 35.56, 27.46, 20.31, 20.08. HRMS (ESI) m/z: C 31

H

37

FN

3 0 7 S (M + H) + calcd, 614.2336; found, 614.2357. (5S)-N-[(1S,2R)- 1l-Benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)sulfonyl] amino]-propyl]-3-(3,4-difluorophenyl)-2-oxo-oxazolidinone-5 carboxamide (21c). 'H NMR (400 MHz, CDC1 3 ) 67.74 (m, 2H), 7.54-7.48 (m, 1H), 7.19 15 (dd, J= 18.4, 8.8 Hz, 1H), 7.12 (d, J= 6.8 Hz, 2H), 7.05-6.97 (m, SH), 6.89 (t, J= 7.6 Hz, 1H), 6.75 (d, J= 10.0 Hz, 1H), 4.78 (dd, J= 9.6, 5.6 Hz, 1H), 4.25 (m, 1H), 3.99 (t, J= 9.2 Hz, 1H), 3.92 (m, 1H), 3.87 (s, 3H), 3.69 (d, J= 3.2 Hz, 1H), 3.31 (dd, J= 9.2, 6.0 Hz, 1H), 3.22 (dd, J= 15.2, 9.6 Hz, 1H), 3.12-2.97 (m, 3H), 2.82 (dd, J= 13.2, 6.8 Hz, 1H), 2.74 (dd, J= 14.0, 11.2 Hz, 1H), 1.84 (m, 1H), 0.95 (d, J= 6.4 Hz, 3H), 0.90 (d, J= 6.8 Hz, 3H); 20 " 3 C NMR (100 MHz, CDC1 3 ) .168.45, 163.35, 152.78, 150.49 (dd, J= 246.4, 13.6 Hz), 147.41 (dd, J= 245.0, 12.1 Hz), 137.46, 134.03 (m), 129.87, 129.72 (2C), 129.55 (2C), 128.53 (2C), 126.61, 117.62 (d, J= 18.2 Hz), 114.62 (2C), 113.85 (q, J= 3.0 Hz), 108.37 (dd, J= 22.8 Hz), 72.47, 69.70, 59.05, 55.84, 53.86, 53.39, 48.25, 35.51, 27.54, 20.34, 20.08. HRMS (ESI) m/z: C 31

H

36 FzN 3 0 7 S (M + H) + calcd, 632.2242; found, 632.2251. 25 (5S)-N-[( 1S,2R)- 1 -Benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)sulfonyl]amino]-propyl]-2-oxo-3-[(3-trifluoromethyl)phenyl]oxazolidine 5-carboxamide (21d). 1H NMR (400 MHz, CDC1 3 ) 17.74 (dd, J= 10.0, 2.4 Hz, 2H), 7.70 (dd, J= 8.8, 1.6 Hz, 1H), 7.64 (s, 1H), 7.54 (t, J= 8.0 Hz, 1H), 7.46 (d, J= 8.0 Hz, 1H), 7.12 (dd, J= 8.4, 1.6 Hz, 2H), 7.01-6.96 (m, 4H), 6.83 (t, J= 7.2 Hz, 1H), 6.79 (d, J= 10.0 30 Hz, 1H), 4.81 (dd, J= 10.0, 6.0 Hz, 1H), 4.27 (m, 1H), 4.04 (t, J= 9.6 Hz, 1H), 3.94 (m, 1H), 3.87 (s, 3H), 3.69 (br. s, 1H), 3.33 (dd, J= 9.2, 5.6 Hz, 1H), 3.22 (dd, J= 15.6, 9.6 Hz, 1H), 3.10 (dd, J= 14.0, 4.4 Hz, 1H), 3.04-2.98 (m, 2H), 2.83 (dd, J= 13.2, 6.8 Hz, 1H), 2.74 (dd, J= 14.0, 10.8 Hz, 1H), 1.85 (m, 1H), 0.95 (d, J= 6.4 Hz, 3H), 0.90 (d, J= 6.8 Hz, - 106- WO 2007/002173 PCT/US2006/024109 3H); 3 C NMR (100 MHz, CDC1 3 ) 8168.49, 163.34, 152.83, 138.19, 137.43, 131.76 (d, J= 32.6 Hz), 129.93, 129.87, 129.72 (2C), 129.53 (2C), 128.52 (2C), 126.58, 121.40, 121.24 (q, J= 3.8 Hz), 115.02 (q, J= 3.8 Hz), 114.61 (2C), 72.50, 69.86, 59.03, 55.83, 53.84, 53.36, 48.10, 35.56, 27.52, 20.34, 20.08. HRMS (ESI) m/z: C 32

H

37

F

3

N

3 0 7 S (M + H) calcd, 5 664.2304; found, 664.2316. (5S)-3-(3-Acetylphenyl)-N-[(1S,2R)-1l-benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)-sulfonyl]amino]propyl]-2-oxo-oxazolidine-5-carboxamide (21e). 'H NMR (400 MHz, CDC1 3 ) 67.89 (t, J= 1.6 Hz, 1H), 7.80-7.74 (m, 2H), 7.71 (d, J= 9.2 Hz, 2H), 7.50 (t, J= 8.0 Hz, 1H), 7.10 (d, J= 7.2 Hz, 2H), 6.98 (m, 4H), 6.83 (m, 2H), 4.78 (dd, J= 10 10.0, 6.0 Hz, 1H), 4.23 (m, 1H), 4.05 (t, J= 9.6 Hz, 1H), 3.93 (m, 1H), 3.84 (s, 3H), 3.46 (s, 1H), 3.36 (dd, J= 9.2, 5.6 Hz, 1H), 3.19 (dd, J= 15.2, 9.6 Hz, 1H), 3.09 (dd, J= 14.0, 4.4 Hz, 1H), 3.01-2.95 (m, 2H), 2.82 (dd, J= 13.2, 6.8 Hz, 1H), 2.73 (dd, J= 14.0, 10.8 Hz, 1H), 2.63 (s, 3H), 1.84 (m, 1H), 0.92 (d, J= 6.4 Hz, 3H), 0.88 (d, J= 6.4 Hz, 3H); 3 C NMR (100 MHz, CDC1 3 ) 197.59, 168.59, 163.31,153.07, 138.10, 138.04, 137.52, 129.91, 15 129.71 (2C), 129.65, 129.55 (2C), 128.53 (2C), 126.62, 124.71, 123.01, 117.58, 114.60 (2C), 72.54, 69.93, 59.01, 55.82, 53.85, 53.44, 48.23, 35.63, 27.50, 26.90, 20.33, 20.08. HRMS (ESI) m/z: C 33 H4 0

N

3 0 8 S (M + H) + calcd, 638.2536; found, 638.2544. (5S)-3-(4-Acetylphenyl)-N-[( 1S,2R)- 1 -benzyl-2-hydroxy-3-[isobutyl[(4 methoxyphenyl)-sulfonyl]amino]propyl]-2-oxo-oxazolidine-5-carboxamide (21f). 'H NMR 20 (400 MHz, CDC1 3 ) 87.99 (d, J= 9.2 Hz, 2H), 7.72 (d, J= 8.8 Hz, 2H), 7.53 (d, J= 9.2 Hz, 2H), 7.10 (d, J= 7.2 Hz, 2H), 6.98-6.93 (m, 4H), 6.86 (d, J= 10.0 Hz, 1H), 6.80 (t, J= 7.6 Hz, 1H), 4.80 (dd, J= 10.0, 6.0 Hz, 1H), 4.24 (m, 1H), 4.05 (t, J= 9.6 Hz, 1H), 3.95 (m, 1H), 3.85 (s, 3H), 3.33 (dd, J= 9.6, 6.0 Hz, 1H), 3.19 (dd, J= 14.8, 8.8 Hz, 1H), 3.10-2.94 (m, 3H), 2.83 (dd, J= 13.2, 6.4 Hz, 1H), 2.73 (dd, J= 14.0, 11.2 Hz, 1H), 2.60 (s, 3H), 25 1.84 (m, 1H), 0.92 (d, J= 6.4 Hz, 3H), 0.88 (d, J= 6.8 Hz, 3H); 3 C NMR (100 MHz, CDC1 3 ) 8196.99, 168.46, 163.29, 152.75, 141.55, 137.51,133.13, 129.86, 129.78 (2C), 129.68 (2C), 129.52 (2C), 128.44 (2C), 126.58, 117.57 (2C), 114.58 (2C), 72.47, 69.85, 58.95, 55.81, 53.78, 53.43, 48.0, 35.49, 27.46, 26.65, 20.31, 20.07. HRMS (ESI) nm/z:

C

33

H

40

N

3 0 8 S (M + H) called, 638.2536; found, 638.2545. 30 (5S)-N-[(1S,2R)- 1l-Benzyl-2-hydroxy-3-[isobutyl[(4-methoxyphenyl)sulfonyl] amino]propyl]-3-(3-methoxyphenyl)-2-oxo-oxazolidine-5-carboxamide (21g). 1H NMR (400 MHz, CDC1 3 ) 87.73 (m, 2H), 7.29 (t, J= 8.8 Hz, 1H), 7.14 (d, J= 2 Hz, 1H), 7.11 (m, -107- WO 2007/002173 PCT/US2006/024109 2H), 7.03 (t, J= 7.2 Hz, 2H), 6.98 (m, 2H), 6.92-6.88 (m, 2H), 6.73 (ddd, J= 8.4, 2.8, 0.8 Hz, 1H), 6.70 (d, J= 9.6 Hz, 1H), 4.75 (dd, J= 10.4, 6.4 Hz, 1H), 4.21 (m, 1H), 4.01 (t, J= 9.6 Hz, 1H), 3.89 (m, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.68 (br. s, 1H), 3.32 (dd, J= 9.6, 6.4 Hz, 1H), 3.21 (dd, J= 15.2, 9.2 Hz, 1H), 3.10 (dd, J= 14.0,4.8 Hz, 1H), 3.01 (dd, J= 5 13.2, 8.8 Hz, 1H), 2.96 (dd, J= 15.2, 2.4 Hz, 1H), 2.80 (dd, J= 13.6, 6.4 Hz, 1H), 2.73 (dd, J= 13.6, 10.4 Hz, 1H), 1.83 (m, 1H), 0.95 (d, J= 6.4 Hz, 3H), 0.89 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) .68.86, 163.37, 160.45, 152.94, 138.72, 137.39, 130.08, 129.87, 129.76 (2C), 129.55 (2C), 128.65 (2C), 126.79, 114.66 (2C), 110.61, 110.33, 104.73, 72.49, 69.77, 59.12, 55.89, 55.65, 53.97, 53.52, 48.41, 35.76, 27.60, 20.40, 20.11. HRMS (ESI) 10 m/z: C 32

H

40

N

3 0 8 S (M + H) + called, 626.2536; found, 626.2546. (5R)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2 hydroxypropyl]-2-oxo-3-phenyloxazolidine-5-carboxamide (24a). 'H NMR (400 MHz, CDC1 3 ) 87.52-7.47 (m, 4H), 7.38 (t, J= 8.4 Hz, 2H), 7.24-7.15 (m, 7H), 6.86 (d, J= 8.8 Hz, 1H), 6.61 (d, J= 8.8 Hz, 2H), 4.72 (dd, J= 9.6, 6.4 Hz, 1H), 4.23-4.11 (m, 2H), 4.05 15 (dd, J= 9.2, 6.0 Hz, 1H), 3.95 (m, 1H), 3.87 (br. s, 1H), 3.14-2.96 (m, 3H), 2.89-2.80 (m, 3H), 1.78 (m, 1H), 0.86 (d, J= 6.8 Hz, 3H), 0.82 (d, J= 6.4 Hz, 3H); ' 3 C NMR (100 MHz, CDC1 3 ) 8168.79, 153.29, 150.81,137.68, 137.56, 129.61 (2C), 129.43 (2C), 129.34 (2C), 128.65 (2C), 126.79, 126.20, 124.83, 118.61 (2C), 114.32 (2C), 72.29, 70.12, 58.80, 54.30, 53.53, 48.18, 35.19, 27.33, 20.23, 20.12. HRMS (ESI) m/z: C 30

H

37

N

4 0 6 S (M + H) + called, 20 581.2434; found, 581.2430. (5S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]- 1 -benzyl-2 hydroxypropyl]-2-oxo-3-phenyloxazolidine-5-carboxamide (25a). 'H NMR (400 MHz, CDC1 3 ) 87.56 (d, J= 8.4 Hz, 2H), 7.43-7.37 (m, 5H), 7.18 (t, J= 6.8 Hz, 1H), 7.10 (d, J= 7.6 Hz, 2H), 6.98 (m, 3H), 6.87 (t, J= 7.6 Hz, 1H), 6.69 (d, J= 8.0 Hz, 2H), 4.77 (dd, J= 25 9.6, 6.0 Hz, 1H), 4.23 (m, 1H), 4.02 (t, J= 9.6 Hz, 1H), 3.93 (m, 1H), 3.31 (dd, J= 9.2, 6.4 Hz, 1H), 3.19-3.0 (m, 3H), 2.93 (dd, J= 13.6, 8.8 Hz, 1H), 2.82 (dd, J= 13.2, 6.8 Hz, 1H), 2.71 (t, J= 13.2 Hz, 1H), 1.83 (m, 1H), 0.91 (d, J= 6.4 Hz, 3H), 0.88 (d, J= 6.4 Hz, 3H); 1 3 C NMR (100 MHz, CDC1 3 ) 8168.82, 153.25, 150.64, 137.60, 137.47, 129.68 (2C), 129.51 (2C), 129.26 (2C), 128.46 (2C), 126.55, 126.41, 124.77, 118.49 (2C), 114.57 (2C), 30 72.45, 69.91, 58.89, 53.74, 53.50, 48.32, 35.63, 27.42, 20.32, 20.10. HRMS (ESI) m/z:

C

30

H

37

N

4 0 6 S (M + H) calcd, 581.2434; found, 581.2438. - 108- WO 2007/002173 PCT/US2006/024109 (5S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-l1-benzyl-2 hydroxypropyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine-5-carboxamide (25b). 'H NMR (400 MHz, CDC1 3 ) 87.58 (d, J= 8.8 Hz, 2H), 7.38-7.33 (m, 2H), 7.12-7.08 (m, 3H), 7.01 (t, J= 8.0 Hz, 2H), 6.93-6.85 (m, 2H), 6.70 (d, J= 8.8 Hz, 3H), 4.78 (dd, J= 10.0, 6.0 Hz, 1H), 5 4.22 (m, 2H), 4.01 (t, J= 9.2 Hz, 1H), 3.91 (m, 1H), 3.73 (br. s, 1H), 3.30 (dd, J= 9.2, 5.6 Hz, 1H), 3.22 (dd, J= 14.8, 9.2 Hz, 1H), 3.07 (dd, J= 13.6, 4.4 Hz, 1H), 3.0 (dd, J= 13.6, 8.8 Hz, 1H), 2.95 (dd, J= 14.8, 2.4 Hz, 1H), 2.79 (dd, J= 13.6, 6.8 Hz, 1H), 2.72 (dd, J= 14.0, 10.8 Hz, 1H), 1.83 (m, 1H), 1.60 (br. s, 1H), 0.95 (d, J= 6.4 Hz, 3H), 0.89 (d, J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) ~168.51, 163.22 (d, J= 244.2 Hz), 152.72, 150.92, 10 139.0 (d, J= 10.6 Hz), 137.43, 130.50 (d, J= 9.10 Hz), 129.77 (2C), 129.53 (2C), 128.54 (2C), 126.64, 126.33, 114.37 (2C), 113.50 (d, J= 3.0 Hz), 111.52 (d, J= 21.2 Hz), 106.06 (d, J= 27.3 Hz), 72.46, 69.75, 59.11, 53.92, 53.40, 48.17, 35.62, 27.58, 20.38, 20.10. HRMS (ESI) m/z: C 30

H

36

FN

4 0 6 S (M + H) + called, 599.2339; found, 599.2340. (5S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]- 1l-benzyl-2 15 hydroxypropyl]-3-(3,4-difluorophenyl)-2-oxo-oxazolidine-5-carboxamide (25c). 'H NMR (400 MHz, CDC1 3 ) 87.56 (d, J= 8.4 Hz, 2H), 7.54-7.48 (m, 1H), 7.19 (q, J= 9.2 Hz, 1H), 7.11 (d, J= 7.6 Hz, 2H), 7.02-6.96 (m, 3H), 6.90-6.85 (m, 2H), 6.68 (d, J= 8.8 Hz, 2H), 4.78 (dd, J= 10.0, 5.6 Hz, 1I), 4.28-4.21 (m, 2H), 3.98 (t, J= 9.6 Hz, 1H), 3.94 (m, 1H), 3.76 (hr. s, 1H), 3.27 (dd, J= 9.2, 6.0 Hz, 1H), 3.17 (dd, J= 15.2, 8.8 Hz, 1H), 3.08 (dd, J= 20 14.0, 4.4 Hz, 1H), 2.99 (dd, J= 14.8, 2.4 Hz, 1H), 2.95 (dd, J= 13.6, 8.4 Hz, 1H), 2.81 (dd, J= 13.2, 6.8 Hz, 1H), 2.73 (dd, J= 14.0, 10.8 Hz, 1H), 1.83 (m, 1H), 0.92 (d, J= 6.4 Hz, 3H), 0.89 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) 3.168.41, 152.92, 151.02, 150.44 (dd, J= 246.5, 13.6 Hz), 147.36 (dd, J= 245.0, 12.4 Hz), 137.59, 134.06 (m), 129.72 (2C), 129.55 (2C), 128.45 (2C), 126.52, 126.14, 117.59 (d, J= 18.2 Hz), 114.32 25 (2C), 113.88 (q, J= 3.8 Hz), 108.36 (d, J= 22.0 Hz), 72.491, 69.75, 59.01, 53.81, 53.36, 48.27, 35.48, 27.48, 20.34, 20.10. HRMS (ESI) nm/z: C 3 0

H

35

F

2

N

4 0 6 S (M + H) + calcd, 617.2245; found, 617.2246. (5S)-N-[(1S,2R)-3-[[(4-Aminophenyl)sulfonyl](isobutyl)amino]-1 -benzyl-2 hydroxypropyl]-2-oxo-3-[(3-trifluoromethyl)phenyl]oxazolidine-5-carboxamide (25d). 'H 30 NMR (400 MHz, CDC1 3 ) 87.68 (d, J= 8.0 Hz, 1H), 7.61 (s, 1H), 7.55 (d, J= 8.8 Hz, 2H), 7.52 (t, J= 8.0 Hz, 1H), 7.45 (d, J= 7.6 Hz, 1H), 7.09 (d, J= 7.2 Hz, 2H), 6.96 (t, J= 7.6 Hz, 2H), 6.81 (t, J= 7.6 Hz, 1H), 6.77 (d, J= 10.4 Hz, 1H), 6.67 (d, J= 8.8 Hz, 2H), 4.78 - 109- WO 2007/002173 PCT/US2006/024109 (dd, J= 10.4, 6.0 Hz, 1H), 4.24 (m, 1H), 4.16 (br. s, 1H), 4.02 (t, J= 9.6 Hz, 1H), 3.91 (m, 1H), 3.73 (br. s, 1H), 3.30 (dd, J= 9.2, 6.0 Hz, 1H), 3.19 (dd, J= 15.2, 9.2 Hz, 1H), 3.07 (dd, J= 14.0, 4.4 Hz, 1H), 3.0-2.93 (m, 2H), 2.78 (dd, J= 13.2, 6.8 Hz, 1H), 2.70 (dd, J= 13.6, 10.8 Hz, 1H), 1.82 (m, 1H), 0.93 (d, J= 6.8 Hz, 3H), 0.88 (d, J= 6.8 Hz, 3H); 1 3 C 5 NMR (100 MHz, CDC1 3 ) .168.44, 152.86, 150.98, 138.13, 137.50, 131.77 (d, J= 32.6 Hz), 129.94, 129.77 (2C), 129.55 (2C), 128.50 (2C), 126.55, 126.24, 121.40, 121.23 (q, J= 3.8 Hz), 115.02 (q, J= 3.8 Hz), 114.35 (2C), 72.50, 69.85, 59.09, 53.89, 53.32, 51.06, 48.10, 35.57, 27.56, 20.37, 20.11. HRMS (ESI) m/z: C 3 1

H

3 6

F

3

N

4 0 6 S (M + H) + calcd, 649.2307; found, 649.2291. 10 (5S)-3-(3-Acetylphenyl)-N-[(IS,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino] 1-benzyl-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (25e). 'H NMR (400 MHz, CDC1 3 ) 37.91 (t, J= 2.0 Hz, 1H), 7.80-7.74 (m, 2H), 7.54 (d, J= 8.8 Hz, 2H), 7.50 (t, J= 7.6 Hz, 1H), 7.10 (d, J= 7.2 Hz, 2H), 6.97 (t, J= 7.2 Hz, 2H), 6.92 (d, J= 10.0 Hz, 1H), 6.83 (t, J= 7.2 Hz, 1H), 6.65 (d, J= 8.8 Hz, 2H), 4.78 (dd, J= 10.0, 6.0 Hz, 1H), 4.22 (m, 15 2H), 4.03 (t, J= 9.6 Hz, 1H), 3.94 (m, 1H), 3.79 (br. s, 1H), 3.34 (dd, J= 9.2, 6.0 Hz, 1H), 3.15 (dd, J= 15.2, 9.2 Hz, 1H), 3.08 (dd, J= 14.0, 4.4 Hz, 1H), 3.01-2.90 (m, 2H), 2.80 (dd , J= 13.6, 6.8 Hz, 1H), 2.72 (dd, J= 13.6, 11.2 Hz, 1H), 2.62 (s, 3H), 1.82 (m, 1H), 0.91 (d, J= 6.4 Hz, 3H), 0.87 (d, J= 6.4 Hz, 3H); " 3 C NMR (100 MHz, CDC1 3 ) Mo97.64, 168.54, 153.15, 151.03,138.12, 138.01,137.62, 129.72 (2C), 129.63, 129.56 (2C), 128.47 (2C), 20 126.55, 126.14, 124.69, 123.0, 117.61, 114.30 (2C), 72.55, 69.94, 59.02, 53.84, 53.41, 48.23, 35.65, 27.47, 26.90, 20.34, 20.10. HRMS (ESI) m/z: C 3 2

H

39

N

4 0 7 S (M + H) calcd, 623.2539; found, 623.2543. (5S)-3-(4-Acetylphenyl)-N-[(1 S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino] 1-benzyl-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (25f). 1H NMR (400 MHz, 25 CDC1 3 ) 38.04-8.01 (m, 2H), 7.59-7.53 (m, 4H), 7.11 (d, J= 6.8 Hz, 2H), 6.98 (t, J= 7.6 Hz, 2H), 6.81 (t, J= 7.2 Hz, 1H), 6.72-6.66 (m, 3H), 4.80 (dd, J= 9.6, 5.6 Hz, 1H), 4.24 (m, 1H), 4.16 (br. s, 2H), 4.06 (t, J= 9.6 Hz, 1H), 3.91 (mi, 1H), 3.74 (br. s, 1H), 3.35 (dd, J = 9.6, 6.4 Hz, 1H), 3.24 (dd, J= 15.2, 9.6 Hz, 1H), 3.08 (dd, J= 14.0, 4.8 Hz, 1H), 3.01 (dd, J= 13.6, 8.8 Hz, 1H), 2.94 (dd, J= 14.8, 2.4 Hz, 1H), 2.79 (dd, J= 13.2, 6.0 Hz, 1H), 30 2.73 (dd, J= 14.0, 11.2 Hz, 1H), 2.63 (s, 3H), 1.83 (m, 1H), 0.96 (d, J= 6.8 Hz, 3H), 0.90 (d, J= 6.4 Hz, 3H); '3C NMR (100 MHz, CDC1 3 ) .

5 1 97 .0, 168.39, 152.73, 151.0, 141.58, 137.52, 133.17, 129.81(2C), 129.75 (2C), 129.55 (2C), 128.46 (2C), 126.60, 126.22, 117.58 - 110- WO 2007/002173 PCT/US2006/024109 (2C), 114.34 (2C), 72.47, 69.84, 59.08, 53.88, 53.40, 48.0, 35.54, 27.55, 26.68, 20.37, 20.11. HRMS (ESI) nzm/z: C 32

H

39

N

4 0 7 S (M + H) + calcd, 623.2539; found, 623.2532. (5S)-N-[(1S,2R)-3-[[(Benzo-[ 1,3]-dioxole-5-sulfonyl)](isobutyl)amino]-1-benzyl-2 hydroxypropyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine-5-carboxamide (26b). 1H NMR (400 5 MHz, CDC1 3 ) 87.38-7.30 (min, 3H), 7.20 (s, 1H), 7.13-7.08 (m, 3H), 7.02 (t, J= 8.0 Hz, 2H), 6.92-6.86 (m, 3H), 6.75 (d, J= 9.6 Hz, 1H), 6.09 (s, 2H), 4.78 (dd, J= 10.0, 6.0 Hz, 1H), 4.23 (m, 1H), 4.02 (t, J = 9.6 Hz, 1H), 3.93 (m, 1H), 3.64 (br. s, 1H), 3.32 (dd, J= 8.8, 5.6 Hz, 1H), 3.20 (dd, J= 15.2, 9.2 Hz, 1H), 3.10 (dd, J= 14.0, 4.4 Hz, 1H), 3.03-2.98 (m, 2H), 2.83 (dd, J= 13.6, 6.4 Hz, 1H), 2.74 (dd, J= 14.0, 10.8 Hz, 1H), 1.85 (m, 1H), 0.96 10 (d, J= 6.8 Hz, 3H), 0.91 (d, J= 6.0 Hz, 3H); " 3 C NMR (100 MHz, CDC1 3 ) 3168.63, 163.19 (d, J= 243.4 Hz), 152.81,151.77, 148.56, 139.01 (d, J= 10.6 Hz), 137.45, 131.57, 130.48 (d, J= 9.1 Hz), 129.49 (2C), 128.52 (2C), 126.63,123.35, 113.52 (d, J= 3.1 Hz), 111.50 (d, J= 21.3 Hz), 108.58, 107.71, 106.06 (d, J= 27.3 Hz), 102.56, 72.52, 69.81, 59.04, 53.87, 53.47, 48.20, 35.58, 27.48, 20.31, 20.07. HRMS (ESI) mn/z: C 3 1H 3 5

FN

3 0 8 S (M + H) 15 calcd, 628.2129; found, 628.2127. (5S)-N-[(1S,2R)-3-[[(Benzo-[1,3]-dioxole-5-sulfonyl)](isobutyI)amino]-1-benzyl-2 hydroxypropyl]-3-(3,4-difluorophenyl)-2-oxo-oxazolidine-5-carboxamide (26c). 'H NMR (400 MHz, CDC1 3 ) 67.54-7.48 (m. 1H), 7.36 (dd, J= 8.0, 1.6 Hz, 1H), 7.22-7.11 (m, 4H), 7.04-6.98 (m, 3H), 6.89 (t, J= 4.0 Hz, 2H), 6.81 (d, J= 9.6 Hz, 1H), 6.08 (s, 2H), 4.79 (dd, 20 J= 10.0, 5.6 Hz, 1H), 4.25 (m, 1H), 4.0 (t, J= 9.6 Hz, 1H), 3.95 (m, 1H), 3.64 (br. s, 1H), 3.30 (dd, J= 9.2, 6.0 Hz, 1H), 3.17 (dd, J= 15.2, 9.2 Hz, 1H), 3.10 (dd, J= 13.6, 4.4 Hz, 1H), 3.05-2.95 (m, 2H), 2.85 (dd, J= 13.6, 6.4 Hz, 1H), 2.74 (dd, J= 13.6, 10.8 Hz, 1H), 1.85 (m, 1H), 0.94 (d, J= 6.0 Hz, 3H), 0.90 (d, J= 6.8 Hz, 3H). 13C NMR (100 MHz, CDC1 3 ) .8168.49, 152.84, 151.79, 150.45 (dd, J= 246.3, 12.9 Hz), 148.57, 147.39 (dd, J= 25 245.0, 12.9 Hz), 137.49, 134.05 (m), 131.53, 129.53 (2C), 128.51 (2C), 126.59, 123.36, 117.60 (d, J= 18.2 Hz), 113.86 (d, J= 3.8 Hz), 108.59, 108.37 (d, J= 22.0 Hz), 107.71, 102.58, 72.54, 69.74, 59.07, 53.87, 53.42, 48.26, 35.50, 27.49, 20.31, 20.07. HRMS (ESI) z/z: C 31

H

3 4F 2

N

3 08S (M + H) + called, 646.2034; found, 646.2037. (5S)-N-[(1S,2R)-3-[[(Benzo-[1,3]-dioxole-5-sulfonyl)](isobutyl)amino]-1 -benzyl-2 30 hydroxypropyl]-2-oxo-3-[(3-trifluoromethyl)phenyl]oxazolidine-5-carboxamide (26d). 'H NMR (400 MHz, CDC1 3 ) 87.70 (dd, J= 8.0, 1.2 Hz, 1H), 7.63 (s, 1H), 7.54 (t, J= 8.4 Hz, 1H), 7.46 (d, J= 7.6 Hz, 1H), 7.37 (dd, J= 8.4, 2.0 Hz, 2H), 7.20 (d, J= 2.0 Hz, 1H), 7.11 -111- WO 2007/002173 PCT/US2006/024109 (dd, J= 8.4, 1.6 Hz, 1H), 6.99 (t, J= 7.2 Hz, 2H), 6.90 (d, J= 8.0 Hz, 1H), 6.85-6.80 (m, 2H), 6.09 (s, 2H), 4.81 (dd, J= 10.0, 5.6 Hz, 1H), 4.26 (m, 1H), 4.05 (t, J= 9.6 Hz, 1H), 3.94 (m, 1H), 3.65 (br. s, 1H), 3.34 (dd, J= 9.6, 6.4 Hz, 1H), 3.20 (dd, J= 14.8, 8.8 Hz, 1H), 3.11 (dd, J= 13.6, 4.4 Hz, 1H), 3.04-2.97 (m, 2H), 2.84 (dd, J= 13.6, 7.2 Hz, 1H), 5 2.73 (dd, J= 13.6, 11.2 Hz, 1H), 1.86 (m, 1H), 0.95 (d, J= 6.8 Hz, 3H), 0.91 (d, J= 6.8 Hz, 3H); 1 3 C NMR (100 MHz, CDC1 3 ) 6168.54, 152.83, 151.82, 148.60, 138.11,137.42, 131.78 (d, J= 32.6 Hz), 131.52, 129.94, 129.52 (2C), 129.54 (2C), 126.61, 123.38, 121.40, 121.27 (q, J= 3.8 Hz), 115.02 (q, J= 3.8 Hz), 108.62, 107.73, 102.59, 72.57, 69.86, 59.14, 53.94, 53.39, 51.05, 48.11, 35.58, 27.54, 20.34, 20.08. HRMS (ESI) m/z: C 32

H

35

F

3

N

3 0sS (M + 10 H) + calcd, 678.2097; found, 678.2101. (5S)-3-(3-Acetylphenyl)-N-[(1S,2R)-3-[[(benzo-[1,3]-dioxole-5 sulfonyl)](isobutyl)amino]-1-benzyl-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (26e). 'H NMR (400 MHz, CDC1 3 ) 37.95 (s, 1H), 7.77 (dd, J= 7.6, 1.6 Hz, 2H), 7.52 (t, J = 8.0 Hz, 1H), 7.36 (dd, J= 8.0, 2.0 Hz, 1H), 7.19 (d, J= 2.0 Hz, 1H), 7.13 (d, J= 6.8 Hz, 15 2H), 6.99 (t, J= 7.6 Hz, 3H), 6.89-6.83 (m, 2H), 6.07 (d, J= 2 Hz, 2H), 4.82 (dd, J= 10.0, 6.0 Hz, 1H), 4.24 (m, 1H), 4.07 (t, J= 9.6 Hz, 1H), 3.98 (m, 1H), 3.77 (br. s, 1IH), 3.38 (dd, J= 9.2, 6.4 Hz, 1H), 3.20-3.11 (m, 2H), 3.06 (dd, J= 15.2, 4.6 Hz, 1H), 2.97 (dd, J = 13.2, 8.0 Hz, 1H), 2.87 (dd, J= 13.2, 6.8 Hz, 1H), 2.75 (dd, J= 14.0, 11.0 Hz, 1H), 2.64 (s, 3H), 1.87 (m, 1H), 0.93 (d, J= 6.8 Hz, 3H), 0.90 (d, J= 6.4 Hz, 3H); 1 3 C NMR (100 MHz, 20 CDC1 3 ) 8197.64, 168.68, 153.16, 151.72, 148.52, 138.10, 138.01, 137.61, 131.59, 129.62, 129.54 (2C), 128.50 (2C), 126.58, 124.71,123.33, 123.0, 117.64, 108.56, 107.72, 102.55, 72.65, 69.96, 59.02, 53.86, 53.49, 48.25, 35.67, 27.44, 26.89, 20.29, 20.08. HRMS (ESI) nm/z: C 33

H

3 8N 3 0 9 S (M + I-I) + calcd, 652.2329; found, 652.2324. (5S)-3-(4-Acetylphenyl)-N-[(1S,2R)-3-[[(benzo-[1,3]-dioxole-5-sulfonyl)](isobutyl) 25 amino]-1 -benzyl-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (26f). H NMR (400 MHz, CDC13) 68.01 (d, J= 8.8 Hz, 2H), 7.54 (d, J= 8.8 Hz, 2H), 7.36 (dd, J= 8.4, 2.0 Hz, 1H), 7.19 (d, J= 1.6 Hz, 1H), 7.11 (d, J= 7.2 Hz, 2H), 6.98 (t, J= 7.6 Hz, 2H), 6.89 (d, J= 8.0 Hz, 1H), 6.83-6.79 (m, 2H), 6.08 (s, 2H), 4.81 (dd, J= 9.6, 5.6 Hz, 1H), 4.24 (m, 1H), 4.07 (t, J= 9.6 Hz, 1H), 3.95 (m, 1H), 3.64 (br. s, 1H), 3.35 (dd, J= 9.2, 6.0 Hz, 1H), 3.19 30 (dd, J= 15.2, 9.2 Hz, 1H), 3.10 (dd, J= 13.6, 4.4 Hz, 1H), 3.05-2.96 (m, 2H), 2.84 (dd, J = 13.2, 6.4 Hz, 1H), 2.73 (dd, J= 13.6, 10.8 Hz, 1H), 2.62 (s, 3H), 1.86 (m, 1H), 0.94 (d, J= 6.8 Hz, 3H), 0.90 (d, J= 6.8 Hz, 3H); 1 3 C NMR (100 MHz, CDC1 3 ) 8196.97, 168.48, -112- WO 2007/002173 PCT/US2006/024109 152.71, 151.79, 148.57, 141.55, 137.46, 133.17, 131.53, 129.80 (2C), 129.52 (2C), 128.49 (2C), 126.64, 123.36, 117.58 (2C), 108.60, 107.71, 102.58, 72.53, 69.84, 59.09, 53.90, 53.46, 48.0, 35.53, 27.51, 26.66, 20.32, 20.08. HRMS (ESI) m/z: C 33

H

3 8N 3 0 9 S (M + H) calcd, 652.2329; found, 652.2325. 5 (5S)-N-[(1S,2R)- 1 -Benzyl-3-[[(3-fluoro-4 methoxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-(3-fluorophenyl)-2-oxo oxazolidine-5-carboxamide (27b). 1H NMR (400 MHz, CDC1 3 ) 87.58 (m, 1H), 7.51 (dd, J = 10.4, 2.4 Hz, 1H), 7.38-7.32 (m, 2H), 7.13-7.05 (m, 4H), 7.02 (t, J= 7.6 Hz, 2H), 6.92 6.86 (m, 2H), 6.83 (d, J= 10.0 Hz, 1H), 4.80 (dd, J= 10.0, 6.0 Hz, 1H), 4.24 (m, 1H), 4.03 10 (t, J= 9.6 Hz, 1H), 3.95 (s, 3H, overlapping signal), 3.94 (m, 1H, overlapping signal), 3.61 (d, J= 3.2 Hz, 1H), 3.32 (dd, J= 9.6, 6.0 Hz, 1H), 3.20 (dd, J= 15.2, 9.2 Hz, 1H1), 3.11 (dd, J= 13.6, 4.4 Hz, 1H), 3.05 (dd, J= 15.2, 2.8 Hz, 1H11), 2.99 (dd, J= 13.2, 8.4 Hz, 1H11), 2.86 (dd, J= 13.2, 6.4 Hz, 1H), 2.74 (dd, J= 14.0, 10.8 Hz, 1H), 1.86 (m, 1H), 0.93 (d, J= 6.4 Hz, 3H), 0.90 (d,J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) .M168.67, 163. 21 (d, J= 15 244.2 Hz), 152.80, 151.95 (d, J= 250.2 Hz), 151.83 (d, J= 9.8 Hz), 139.0 (d,J = 10.6 Hz), 137.37, 130.51 (d, J= 9.1 Hz), 130.34 (d, J= 4.5 Hz), 129.49 (2C), 128.56 (2C), 126.69, 124.89 (d, J= 3.8 Hz), 115.60 (d, J= 20.5 Hz), 113.53 (d, J= 3 Hz), 113.19, 111.54 (d, J= 21.2 Hz), 106.08 (d, J= 26.6 Hz), 72.48, 69.81, 58.91, 56.63, 53.78, 53.50, 48.21, 35.59, 27.46, 20.29, 20.06. HRMS (ESI) m/z: C3 1

H

3 6

F

2

N

3 0 7 S (M + H) + calcd, 632.2242; found, 20 632.2258. (5S)-N-[(1S,2R)-l1-Benzyl-3-[[(3-fluoro-4 methoxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-3-(3,4-difluorophenyl)-2-oxo oxazolidine-5-carboxamide (27c). 'H NMR (400 MHz, CDC1 3 ) 87.59-7.55 (m, 1H11), 7.54 7.48 (m, 2H), 7.18 (q, J= 9.2 Hz, 1H), 7.12 (d, J= 7.2 Hz, 2ff), 7.07-6.97 (m, 4H), 6.90 (t, 25 J= 7.2 Hz, 1H), 6.86 (d, J= 10.0 Hz, 1H), 4.80 (dd, J= 10.0, 6.0 Hz, 1H), 4.26 (m, 1H), 4.0 (t, J= 9.2 Hz, 1H), 3.96 (m, 1H, overlapping signal), 3.95 (s, 3H), 3.62 (d, J= 316 Hz, 1H1), 3.31 (dd, J= 9.2, 6.0 Hz, 1H11), 3.18 (dd, J= 15.2, 9.2 Hz, 1H), 3.21-3.04 (m, 2H11), 2.97 (dd, J= 13.6, 8.0 Hz, 1H11), 2.87 (dd, J= 13.6, 6.8 Hz, 1H1), 2.74 (dd, J= 13.6, 10.8 Hz, 1H11), 1.86 (m, 1H11), 0.92 (d, J= 6.4 Hz, 3H), 0.89 (d, J= 6.4 Hz, 3H); 1 3 C NMR (100 MHz, 30 CDC1 3 ) 168.55, 152.88, 151.92 (d, J= 250.2 Hz), 151.82 (d, J= 10.6 Hz), 150.45 (dd, J= 246.4, 12.9 Hz), 147.39 (dd, J= 245.7, 12.9 Hz), 137.46, 134.03 (m), 130.32 (d, J= 3.8 Hz), 129.51 (2C), 128.52 (2C), 126.61, 124.88 (d, J= 3.8 Hz), 117.61 (d, J= 18.2 Hz), 115.58 (d, J= 21.2 Hz), 113.88 (q, J= 3.8 Hz), 113.18, 108.37 (d, J= 22.0 Hz), 72.50, -113- WO 2007/002173 PCT/US2006/024109 69.76, 58.86, 56.62, 53.72, 53.47, 48.28, 35.49, 27.42, 20.27, 20.06. HRMS (ESI) m/z:

C

31

H

35

F

3

N

3 0 7 S (M + H) + called, 650.2148; found, 650.2151. (5S)-N-[(1S,2R)-1 -Benzyl-3-[[(3-fluoro-4 methoxyphenyl)sulfonyl](isobutyl)amino]-2-hydroxypropyl]-2-oxo-3-[(3 5 trifluoromethyl)phenyl)]oxazolidine-5-carboxamide (27d). 'H NMR (400 MHz, CDC1 3 ) 8 7.69 (d, J= 8 Hz, 1H), 7.64 (br. s, 1H), 7.59-7.49 (m 3H), 7.45 (d, J= 7.6 Hz, 1H), 7.12 (d, J= 6.8 Hz, 2H), 7.05 (t, J= 8.4 Hz, 1H), 6.99 (t, J= 7.6 Hz, 2H), 6.87-6.82 (m, 2H), 4.81 (dd, J= 10.0, 5.6 Hz, 1H), 4.27 (m, 1H), 4.06 (t, J= 10.0 Hz, 1H), 3.96 (m, 1H, overlapping signal), 3.95 (s, 3H), 3.61 (br. s, 1H), 3.35 (dd, J= 9.2, 5.6 Hz, 1H), 3.20 (dd, J 10 = 15.2, 9.2 Hz, 1H), 3.11 (dd, J= 14.0, 4.4 Hz, 1H), 3.05 (dd, J= 15.2, 3.2 Hz, 1H), 2.98 (dd, J= 13.2, 8.0 Hz, 1H), 2.87 (dd, J= 13.2, 6.8 Hz, 1H), 2.74 (dd, J= 14, 10.8 Hz, 1H), 1.87 (m, 1H), 0.94 (d, J= 6.4 Hz, 3H), 0.90 (d, J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) 6168.59, 152.88, 151.95 (d, J= 250.9 Hz), 151.84 (d, J= 10.7 Hz), 138.09, 137.40, 131.76 (d, J= 32.5 Hz), 130.30, 129.94, 129.50 (2C), 128.54 (2C), 126.62, 124.89 (d, J= 15 3.8 Hz), 121.40, 121.25 (q, J= 3.8 Hz), 115.60 (d, J= 20.5 Hz), 115.04 (q, J= 3.8 Hz), 113.19, 72.53, 69.88, 58.92, 56.63, 53.78, 53.43, 48.13, 35.56, 27.46, 20.29, 20.06. HRMS (ESI) m/z: C 32

H

36

F

4

N

3 0 7 S (M + H) + called, 682.2210; found, 682.2203. (S)-3-(3-Acetylphenyl)-N-[(1S,2R)- 1-Benzyl-3-[[(3-fluoro-4-methoxyphenyl) sulfonyl](isobutyl)amino]-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (27e). 1H 20 NMR (400 MHz, CDC1 3 ) 8 7.96 (m, 1H), 7.78-7.73 (mi, 2H), 7.59-7.48 (m, 3H), 7.13 (d, J = 7.2 Hz, 2H), 7.07-6.98 (m, 4H), 6.85 (t, J= 8.0 Hz, 1H), 4.82 (dd, J = 9.6, 5.6 Hz, 1H), 4.25 (m, 1H), 4.07 (t, J= 9.6 Hz, 1H), 3.99 (br. s, 1H), 3.94 (s, 3H), 3.75 (m, 1H), 3.41 3.37 (m, 1H), 3.21-3.06 (m, 3H), 3.0-2.86 (m, 2H), 2.76 (dd, J= 14.0, 11.2 Hz, 1H), 2.64 (s, 3H), 1.88 (m, 1H), 0.92 (d, J= 6.8 Hz, 3H), 0.89 (d, J= 6.4 Hz, 3H); " 3 C NMR (100 25 MHz, CDC1 3 ) 8197.65, 168.71,153.18, 151.90 (d, J= 251.0 Hz), 151.74 (d, J= 9.9 Hz), 138.09, 138.01, 137.59, 130.46 (d, J= 4.5 Hz), 129.62, 129.53 (2C), 128.51 (2C), 126.61, 124.86 (d, J= 3.8 Hz), 124.74, 122.98, 117.64, 115.58 (d, J= 20.4 Hz), 113.17, 72.60, 69.98, 58.82, 56.60, 53.69, 53.55, 48.26, 35.68, 27.38, 26.88, 20.25, 20.06. HRMS (ESI) m/z: C 33

H

39

FN

3 0 8 S (M + H) + calcd, 656.2442; found, 656.2441. 30 (S)-3-(4-Acetylphenyl)-N-[(1S,2R)- 1l-Benzyl-3-[[(3-fluoro-4-methoxyphenyl) sulfonyl](isobutyl)amino]-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (27f). 1H NMR (400 MHz, CDC1 3 ) 88.01 (d, J= 8.8 Hz, 2H), 7.58-7.52 (m, 3H), 7.50 (dd, J= 10.4, -114- WO 2007/002173 PCT/US2006/024109 2.4 Hz, 1H), 7.11 (d, J= 8.0 Hz, 2H), 7.04 (t, J= 8.4 Hz, 1H), 6.97 (t, J= 7.6 Hz, 2H), 6.92 (d, J= 9.6 Hz, 1H), 6.82 (t, J= 7.2 Hz, 1H), 4.82 (dd, J= 9.6, 5.6 Hz, 1H), 4.26 (m, 1H), 4.08 (t, J= 10.0 Hz, 1H), 3.98 (m, 1H), 3.94 (s, 3H), 3.68 (br. s, 1H), 3.35 (dd, J= 9.6, 6.4 Hz, 1H), 3.18 (dd, J= 15.2, 8.8 Hz, 1H), 3.13-3.06 (m, 2H), 2.97 (dd, J= 13.2, 8.0 Hz, 5 1H), 2.89 (dd, J= 13.6, 6.8 Hz, 1H), 2.74 (dd, J= 14.0, 11.2 Hz, 1H), 2.61 (s, 3H), 1.87 (m, 1H), 0.91 (d, J= 6.4 Hz, 3H), 0.89 (d, J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) 3197.0, 168.55, 152.78, 151.90 (d, J= 251.0 Hz), 151.78 (d, J= 10.7 Hz), 141.54, 137.46, 133.15, 130.31,129.78 (2C), 129.50 (2C), 128.47 (2C), 126.63, 124.86 (d, J= 3.0 Hz), 117.58 (2C), 115.56 (d, J= 20.5 Hz), 113.18, 72.49, 69.88, 58.83, 56.60, 53.69, 53.50, 10 48.01, 35.49, 27.39, 26.64, 20.26, 20.06. HRMS (ESI) m/z: C 33

H

39

FN

3 0 8 S (M+ H) + called, 656.2442; found, 656.2448. (5S)-N-[(1S,2R)-1 -Benzyl-2-hydroxy-3-[isobutyl[[(4 trifluoromethoxy)phenyl]sulfonyl]-amino]propyl]-2-oxo-3-[(3 trifluoromethyl)phenyl]oxazolidine-5-carboxamide (28d). 'H NMR (400 MHz, CDC1 3 ) . 15 7.88-7.85 (m, 2H), 7.70 (d, J= 8.0 Hz, 1H), 7.63 (s, 1H), 7.54 (dt, J= 8.0, 2.4 Hz, 1H), 7.46 (d, J= 8.0 Hz, 1H), 7.37 (dd, J= 7.6, 1.2 Hz, 2H), 7.12 (dd, J= 7.6, 1.2 Hz, 2H), 7.03-6.98 (m, 2H), 6.85 (dt, J= 8.0, 2.4 Hz, 1H), 6.70 (d, J= 8.0 Hz, 1H), 4.81 (dd, J= 9.6, 6.0 Hz, 1H), 4.26 (m, 1H), 4.06 (t, J= 10.0 Hz, 1H), 3.94 (m, 1H), 3.54 (br. s, 1H), 3.37 (dd, J= 10.0, 6.0 Hz, 1H), 3.25 (dd, J = 15.6, 9.2 Hz, 1H), 3.13-3.02 (m, 3H), 2.87 (dd 20 , J= 13.6, 6.0 Hz, 1H), 2.71 (dd, J= 13.6, 9.6 Hz, 1H), 1.87 (m, 1H), 0.96 (d, J= 6.4 Hz, 3H), 0.91 (d, J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) .168.61,152.78, 152.57, 138.06, 137.26, 136.82, 131.81 (d, J= 32.6 Hz), 129.96 129.71 (2C), 129.48 (2C), 128.61 (2C), 126.69, 121.40, 121.33, 121.27 (2C), 115.02 (m), 72.50, 69.84, 58.90, 53.79, 53.47, 51.07, 48.10, 35.56, 27.49, 20.28, 20.02. HRMS (ESI) mI/z: C 32

H

34

F

6

N

3 0 7 S (M + H) + calcd, 25 718.2021; found, 718.2028. (5S)-3-(3-Acetylphenyl)-N-[(1S,2R)- 1-benzyl-2-hydroxy-3-[isobutyl[[(4-trifluoro methoxy)phenyl]sulfonyl]amino]propyl]-2-oxo-oxazolidine-5-carboxamide (28e). 1H NMR (400 MHz, CDC1 3 ) 37.90-7.77 (m, 5H), 7.53 (t, J= 8.0 Hz, 1H), 7.36 (d, J= 8.8 Hz, 2H), 7.13 (d, J= 8.0 Hz, 2H), 7.03 (t, J= 8.0 Hz, 2H), 6.87 (t, J= 7.6 Hz, 1H), 6.83 (d, J= 9.6 30 Hz, 1H), 4.82 (dd, J= 9.6, 5.6 Hz, 1H), 4.25 (m, 1H), 4.09 (t, J= 10.0 Hz, 1H), 3.94 (m, 1H), 3.59 (d, J= 3.2 Hz, 1H), 3.42 (dd, J= 9.6, 6.0 Hz, 1H), 3.25 (dd, J= 15.2, 9.2 Hz, 1H), 3.13 (dd, J= 14.4, 4.8 Hz, 1H), 3.07-3.02 (m, 2H), 2.88 (dd, J= 13.2, 6.4 Hz, 1H), 2.75 (dd, J= 13.6, 10.8 Hz, 1H), 2.65 (s, 3H), 1.87 (m, 1H), 0.95 (d, J= 6.8 Hz, 3H), 0.90 - 115- WO 2007/002173 PCT/US2006/024109 (d, J= 6.8 Hz, 3H); 3C NMR (100 MHz, CDC1 3 ) o197.53, 168.68, 152.95, 152.55, 138.06, 137.27, 136.85, 129.72 (2C), 129.68, 129.50 (2C), 128.65 (2C), 126.77, 124.79, 123.01, 121.27 (2C), 117.53, 72.52, 69.89, 58.93, 53.84, 53.54, 48.21, 35.65, 27.51, 26.90, 20.29, 20.03. HRMS (ESI) inm/z: C 33

H

37

F

3

N

3 0sS (M + H) + calcd, 692.2253; found, 692.2244. 5 (5S)-N-[(1S,2R)- 1-Benzyl-2-hydroxy-3-[isobutyl[(3 methoxyphenyl)sulfonyl]amino]-propyl]-2-oxo-3-phenyloxazolidine-5-carboxamide (29a). 'H NMR (400 MHz, CDC1 3 ) 87.46-7.36 (m, 6H), 7.31 (t, J= 2.8 Hz, 1H), 7.20 (m, 1H), 7.12 (min, 3H), 7.02 (t, J= 7.2 Hz, 2H), 6.88 (t, J= 7.6 Hz, 1H), 6.77 (d, J= 10 Hz, 1H), 4.78 (dd, J= 10.0, 6.0 Hz, 1H), 4.22 (m, 1H), 4.04 (t, J= 9.6 Hz, 1H), 3.93 (m, 1H), 3.86 10 (s, 3H), 3.64 (br. s, 1H), 3.36 (dd, J= 8.8, 5.6 Hz, 1H1), 3.25 (dd, J= 15.6, 9.6 Hz, 1H), 3.12 (dd, J= 14.0, 4.4 Hz, 1H), 3.07-3.01 (m, 2H), 2.87 (dd, J= 13.6, 6.4 Hz, 1H), 2.73 (dd, J 14.0, 10.8 Hz, 1H), 1.86 (m, 1H), 0.96 (d, J= 6.4 Hz, 3H), 0.90 (d, J= 6.4 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) M168.89, 160.23, 153.02, 139.53, 137.49, 137.37, 130.51, 129.49 (2C), 129.31 (2C), 128.59 (2C), 126.71, 124.82, 119.65, 119.16, 118.47 (2C), 112.65, 15 72.47, 69.82, 59.03, 55.91, 53.91, 53.56, 48.29, 35.70, 27.53, 20.31, 20.06. HRMS (ESI) m/z: C 3 1H 38

N

3 0 7 S (M + H) + calcd, 596.2430; found, 596.2435. (5S)-3-(4-Acetylphenyl)-N-[(1S,2R)- 1-benzyl-2-hydroxy-3-[isobutyl[(3 methoxyphenyl)-sulfonyl]amino]propyl]-2-oxo-oxazolidine-5-carboxamide (29f). lH NMR (400 MHz, CDC1 3 ) 68.0 (d, J= 8.8 Hz, 2H), 7.54 (d, J= 8.8 Hz, 2H), 7.43 (t, J= 7.6 Hz, 20 1H), 7.36 (d, J= 8.8 Hz, 1H), 7.30 (t, J= 2.4 Hz, 1H), 7.10 (d, J= 7.6 Hz, 3H), 6.97 (t, J= 7.6 Hz, 2H), 6.85 (d, J= 10.0 Hz, 1H), 6.80 (t, J= 7.6 Hz, 1H), 4.81 (dd, J= 9.6, 5.6 Hz, 1H), 4.25 (m, 1H), 4.06 (t, J= 9.6 Hz, 1H), 3.96 (m, 1H), 3.85 (s, 3H), 3.68 (br. s, 1H), 3.34 (dd, J= 9.2, 6.0 Hz, 1H), 3.23 (dd, J= 15.4, 9.2 Hz, 1H), 3.12-3.05 (m, 2H), 3.02 (dd, J= 13.6, 8.4 Hz, 1H), 2.89 (dd, J= 13.6, 7.2 Hz, 1H), 2.74 (dd, J= 14.0, 11.2 Hz, 1H), 2.61 (s, 25 3H), 1.87 (m, 1H), 0.93 (d, J= 6.4 Hz, 3H), 0.90 (d, J= 6.8 Hz, 3H); 13C NMR (100 MHz, CDC1 3 ) 196.97, 168.49, 160.19, 152.72, 141.54, 139.49, 137.46, 133.14, 130.50, 129.78 (2C), 129.50 (2C), 128.46 (2C), 126.61, 119.61, 119.06, 117.57 (2C), 112.70, 72.47, 69.84, 58.97, 55.89, 53.81, 53.47, 47.99, 35.49, 27.46, 26.65, 20.28, 20.05. HRMS (ESI) m/z:

C

33

H

40

N

3 0 8 S (M + H) calcd, 638.2536; found, 638.2538. 30 (5S)-N-[(1S,2R)- 1-Benzyl-3-[(cyclopropylmethyl)[(3 methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine 5-carboxamide (36b). 'H NMR (400 MHz, CDC1 3 ) 87.74 (d, J= 9.2 Hz, 2H), 7.38-7.32 -116- WO 2007/002173 PCT/US2006/024109 (m, 1H), 7.13 (d, J= 6.8 Hz, 2H), 7.09 (dd, J= 8.8, 2.0 Hz, 1H), 7.04-6.97 (m, 4H), 6.92 6.86 (m, 2H), 6.80 (d, J= 10.0 Hz, 1H), 4.79 (dd, J= 10.0, 5.6 Hz, 1H), 4.28 (m, 1H), 4.02 (t, J= 9.2 Hz, 2H), 3.87 (s, 3H), 3.62 (br. s, 1H), 3.36-3.10 (m, 5H), 2.96 (dd, J= 14.0, 7.2 Hz, 1H), 2.78 (dd, J= 14.0, 11.2 Hz, 1H), 0.87 (m, 1H), 0.56-0.53 (m, 2H), 0.18 (m, 2H); 5 3 C NMR (100 MHz, CDC1 3 ) 8168.63, 163.26, 163.20 (d, J= 244.2 Hz), 152.77, 139.03 (d, J= 10.6 Hz), 137.49, 130.53, 130.44, 129.57 (2C), 129.51 (2C), 128.54 (2C), 126.63, 114.61 (2C), 113.52 (d, J= 3.1 Hz), 111.51 (d, J= 21.2 Hz), 106.07 (d, J= 27.3 Hz), 72.36, 69.81, 55.82, 55.04, 53.40, 52.15, 48.21, 35.57, 10.07, 4.72, 4.26. HRMS (ESI) m/z:

C

31

H

35

FN

3 0 7 S (M + H) + calcd, 612.2179; found, 612.2180. 10 (5S)-N-[(1S,2R)-l1-Benzyl-3-[(cyclopropylmethyl)[(3 methoxyphenyl)sulfonyl]amino]-2-hydroxypropyl]-3-(3,4-difluorophenyl)-2-oxo oxazolidine-5-carboxamide (36c). 'H NMR (400 MHz, CDC1 3 ) 87.74 (d, J= 8.8 Hz, 2H), 7.54-7.48 (m, 1H), 7.19 (q, J= 9.6 Hz, 1H), 7.13 (d, J= 7.6 Hz, 2H), 7.05-6.96 (m, 5H), 6.90 (t, J= 7.6 Hz, 1H), 6.82 (d, J= 10.0 Hz, 1H), 4.80 (dd, J= 10.0, 5.6 Hz, 1H), 4.29 (m, 15 1H), 4.04 (m, 1H), 4.0 (t, J= 9.2 Hz, 1H), 3.87 (s, 3H), 3.60 (br. s, 1H) 3.35-3.24 (m, 3H), 3.21-3.10 (m, 2H), 2.96 (dd, J= 14.4, 7.6 Hz, 1H), 2.79 (dd, J= 14.0, 10.8 Hz, 1H), 0.91 0.83 (m, 1H), 0.54 (m, 2H), 0.18 (m, 2H); 13C NMR (100 MHz, CDC1 3 ) .6168.51, 163.27, 152.83, 150.46 (d, J= 246.4 Hz), 147.38 (d, J= 245.6 Hz), 137.57, 134.05 (m), 130.42, 129.56 (2C), 129.55 (2C), 128.51 (2C), 126.57, 117.59 (d, J= 17.4 Hz), 114.60 (2C), 20 113.87 (d, J= 3.8 Hz), 108.38 (d, J= 22.7 Hz), 72.38, 69.76, 55.82, 55.03, 53.37, 52.12, 48.28, 35.48, 10.05, 4.71, 4.26. HRMS (ESI) m/z: C 31

H

34

F

2

N

3 0 7 S (M + H) + calcd, 630.2086; found, 630.2077. (5S)-3-(4-Acetylphenyl)-N-[(1S,2R)- 1-Benzyl-3-[(cyclopropylmethyl)[(3-methoxy phenyl)sulfonyl]amino]-2-hydroxypropyl]-2-oxo-oxazolidine-5-carboxamide (36f). 'H 25 NMR (400 MHz, CDC1 3 ) 88.02 (d, J= 9.2 Hz, 2H), 7.74 (d, J= 8.8 Hz, 2H), 7.55 (d, J= 8.8 Hz, 2H), 7.12 (d, J= 7.6 Hz, 2H), 7.02-6.97 (m, 4H), 6.83 (t, J= 6.8 Hz, 1H), 6.69 (d, J = 9.6 Hz, 1H), 4.81 (dd, J= 10.4, 6.0 Hz, 1H), 4.28 (m, 1H), 4.08 (t, J= 9.6 Hz, 1H), 4.02 (m, 1H), 3.87 (s, 3H), 3.54 (d, J= 2.4 Hz, 1H), 3.39 (dd, J= 9.2, 5.6 Hz, 1H), 3.30 (dd, J= 15.2, 8.8 Hz, 1H), 3.23-3.18 (m, 2H), 3.12 (dd, J= 14.4, 4.8 Hz, 1H), 2.94 (dd, J= 14.0, 30 7.2 Hz, 1H), 2.78 (dd, J= 13.6, 10.4 Hz, 1H), 2.62 (s, 3H), 0.88 (m, 1H), 0.56 (d, J= 7.6 Hz, 2H), 0.23-0.15 (m, 2H); 1 3 C NMR (100 MHz, CDC1 3 ) .196.97, 168.50, 163.24, 152.74, 141.57, 137.58, 133.13, 130.44, 129.78 (2C), 129.54 (4C), 128.46 (2C), 126.58, -117- WO 2007/002173 PCT/US2006/024109 117.58 (2C), 114.59 (2C), 72.38, 69.89, 55.80, 55.0, 53.40, 52.09, 48.01, 35.49, 26.65, 10.02, 4.69, 4.26. HRMS (ESI) m/z: C 33

H

3 sN 3 OsS (M + H) + calcd, 636.2379; found, 636.2369. (5S)-N-[(1S,2R)- I -Benzyl-2-hydroxy-3-[[(3-methoxyphenyl)sulfonyl](2-thiophenyl 5 methyl)]amino]propyl]-2-oxo-3-phenyloxazolidine-5-carboxamnide (37a). 1H NMR (400 MHz, CDC1 3 ) 87.45-7.38 (m, 6H), 7.32 (d, J= 2.0 Hz, 1H), 7.22-7.17 (min, 2H), 7.13 (m, 1H), 7.08 (d, J= 8.0 Hz, 2H), 7.02 (t, J= 7.6 Hz, 2H), 6.93-6.88 (m, 3H), 6.57 (d, J= 9.6 Hz, 1H), 4.72 (dd, J= 10.0, 6.0 Hz, 1H), 4.65 (AB, d, J= 15.6 Hz, 1H), 4.59 (AB, d, J= 15.6 Hz, 1H), 4.10 (m, 1H), 4.05 (t, J= 9.6 Hz, 1H), 3.85 (s, 3H), 3.66 (dd, J= 11.2, 6.4 10 Hz, 1H), 3.48 (br. s, 1H), 3.43 (dd, J = 9.2, 6.0 Hz, 1H), 3.24 (m, 2H), 3.04 (dd, J= 14.0, 4.0 Hz, 1H), 2.68 (dd, J= 14.0, 10.4 Hz, 1H); 13C NMR (100 MHz, CDC1 3 ) 8168.97, 160.30, 153.01, 139.91, 138.26, 137.49, 137.29, 130.59, 129.50 (2C), 129.31 (2C), 128.59 (2C), 128.34, 127.21, 127.07, 126.67, 124.82, 119.68, 119.59, 118.47 (2C), 112.34, 71.96, 69.78, 55.91, 53.36, 51.68, 48.27,48.20, 35.61. HRMS (ESI) m/z: C 32

H

34

N

3 0 7

S

2 (M + ) + 15 calcd, 636.1838; found, 636.1864. (5S)-N-[(1S,2R)- 1 -Benzyl-2-hydroxy-3-[[(3-mnethoxyphenyl)sulfonyl](2-thiophenyl methy)]amino]propyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine-5-carboxamide (37b). 1H NMR (400 MHz, CDC1 3 ) 87.47-7.34 (m, 4H), 7.32 (t, J= 2.0 Hz, 1H), 7.24 (t, J= 3.2 Hz, 1H), 7.14 (m, 1H), 7.10-7.01 (m, 5H), 6.93-6.87 (m, 4H), 6.43 (d, J= 9.2 Hz, 1H), 4.72 20 (dd, J= 10.0, 5.6 Hz, 1H), 4.65 (AB d, J= 15.6 Hz, 1H), 4.58 (AB d, J= 15.6 Hz, 1H), 4.11 (min, 1H), 4.02 (t, J= 10.0 Hz, 1H), 3.86 (s, 3H), 3.63 (m, 1H), 3.38 (dd, J= 9.2, 5.6 Hz, 1H), 3.29-3.17 (m, 2H), 3.04 (dd, J= 14.0, 4.4, Hz, 1H), 2.67 (dd, J = 13.6, 10.4, Hz, 1H); 1 3 C NMR (100 MHz, CDC1 3 ) 8168.70, 163.19 (d, J= 244.1 Hz), 160.28, 152.76, 139.91, 139.01 (d, J= 10.6 Hz), 138.24, 137.32, 130.59, 130.51 (d, J= 9.8 Hz), 129.49 25 (2C), 128.53 (2C), 128.35, 127.18, 127.04, 126.62, 119.66, 119.56, 113.51 (d, J= 2.2 Hz), 112.37, 111.52 (d,J = 21.3 Hz), 106.05 (d, J= 26.5 Hz), 72.04, 69.74, 55.91, 53.30, 51.58, 48.16, 48.15, 35.56. HRMS (ESI) m/z: C 32

H

33

FN

3 0 7

S

2 (M + H) + calcd, 654.1744; found, 654.1766. (S)-3-(4-Acetylphenyl)-N-[(2S,3R)-l-benzyl-2-hydroxy-3-[[(3-methoxyphenyl) 30 sulfonyl](2-thiophenylmethyl)]amino]propyl]-2-oxo-oxazolidine-5-carboxamide (37f). 'H NMR (400 MHz, CDC1 3 ) 8.02 (d, J= 8.8 Hz, 2H), 7.55 (d, J= 9.2 Hz, 2H), 7.45 (t, J 7.6 Hz, 1H), 7.40 (d, J= 7.6 Hz, 1H), 7.32 (t, J= 2.4 Hz, 1H), 7.23 (dd, J= 4.4, 2.8 Hz, - 118- WO 2007/002173 PCT/US2006/024109 1H), 7.13 (m, 1H), 7.07 (d, J= 7.2 Hz, 2H), 6.99 (t, J= 7.6 Hz, 2H), 6.91 (m, 2H), 6.84 (t, J = 7.6 Hz, 1H), 6.54 (d, J= 9.6 Hz, 1H), 4.76 (dd, J= 10.0, 6.0 Hz, 1H), 4.65 (AB d, J= 15.2 Hz, 1H), 4.59 (AB d, J= 15.2 Hz, 1H), 4.14 (m, 1H), 4.07 (t, J= 9.6 Hz, 1H), 3.85 (s, 3H), 3.68 (m, 1H), 3.41 (m, 2H), 3.24 (m, 2H), 3.04 (dd, J= 14.0, 4.4, Hz, 1H), 2.67 (dd, J 5 = 13.6, 10.4, Hz, 1H), 2.62 (s, 3H); " 3 C NMR (100 MHz, CDC1 3 ) Mo196.98, 168.56, 160.31, 152.63, 141.54, 139.81, 138.25, 137.27, 133.20, 130.63, 129.84 (2C), 129.51 (2C), 128.52 (2C), 128.34, 127.22, 127.10, 126.66, 119.67, 119.58, 117.57 (2C), 112.41, 72.01, 69.75, 55.93, 53.28, 51.73, 48.29, 47.97, 35.58, 26.68. HRMS (ESI) m/z: C 34

H

36

N

3 0 8

S

2 (M + H) + calcd, 678.1944; found, 678.1953. 10 (5S)-N-[(1S,2R)- -Benzyl-2-hydroxy-3-[(2-thiophenylmethyl)[(2,4,5 trifluorophenyl)-sulfonyl]amino]propyl]-2-oxo-3-phenyloxazolidine-5-carboxamide (38a). 'H NMR (400 MHz, CDC1 3 ) 87.76-7.70 (m, 1H), 7.43-7.36 (m, 4H), 7.19-7.16 (m, 2H), 7.08-7.01 (m, 5H), 6.93-6.86 (m, 3H), 6.67 (d, J= 9.2 Hz, 1IH), 4.79-4.67 (m, 3H), 4.12 (m, 1H), 4.06 (t, J= 9.6 Hz, 1H), 3.79 (m, 1H), 3.49-3.33 (m, 4H), 3.02 (dd, J= 14.0, 4.4 15 Hz, 1H), 2.69 (dd, J= 14.0, 10.4 Hz, 1H); 1 3 C NMR (100 MHz, CDC1 3 ) f169.21, 154.8 (dd, J= 253.2, 10.6 Hz), 153.45 (dt, J= 257.0, 13.6 Hz), 153.05, 146.48 (dd, J= 253.2, 13.2 Hz), 137.57, 137.44, 137.14, 129.43 (2C), 129.34 (2C), 128.68 (2C), 127.20, 127.14, 126.81, 124.89, 119.64 (d, J= 22.0 Hz), 118.51 (2C), 107.72 (dd, J= 27.3, 21.2 Hz), 72.10, 69.81, 53.78, 51.05, 51.02, 48.29, 47.63, 35.45, 29.88. HRMS (ESI) m/z: C 3 1

H

29

F

3

N

3 0 6

S

2 20 (M +H) calcd, 660.1450; found, 660.1462. (5S)-N-[(1S,2R)-1 -Benzyl-2-hydroxy-3-[(2-thiophenylmethyl)[(2,4,5 trifluorophenyl)-sulfonyl]amino]propyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine-5 carboxamide (38b). 'H NMR (400 MHz, CDC1 3 ): 8 7.78-7.72 (m, 1H), 7.39-7.32 (m, 2H), 7.22 (d, J= 4.8, 1.2 Hz, 1H), 7.11-7.03 (m, 6H), 6.95-6.87 (m, 4H), 6.55 (d, J= 9.2 Hz, 25 1H), 4.79-4.69 (m, 3H), 4.14 (m, 1H), 4.05 (t, J= 9.6 Hz, 1H), 3.78 (m, 1H), 3.47-3.35 (m, 3H), 3.18 (d, J= 4.0 Hz, 1H), 3.04 (dd, J= 14.0, 4.8 Hz, 1H), 2.72 (dd, J= 14.0, 11.2 Hz, 1H); 1 3 C NMR (100 MHz, CDC1 3 ) 8 168.94, 164.42, 161.98, 154.75 (dd, J= 250.0, 10.6 Hz), 153.43 (dt, J= 248.0, 10.4 Hz)), 152.83, 146.32 (dd, J= 248.2, 10.4 Hz), 138.97 (d, J = 10.6 Hz), 137.51, 137.21, 130.52 (d, J= 9.5 Hz), 129.43 (2C), 128.72, 128.62 (2C), 30 127.17, 127.09, 126.74, 119.61 (d, J 22.0 Hz), 113.55, 111.58 (d, J= 21.2 Hz), 107.69 (dd, J= 27.3, 21.3 Hz), 106.10 (d, J 27.3 Hz), 72.24, 69.81, 53.71, 50.94, 48.21, 47.55, 35.40. HRMS (ESI) m/z: C3 1

H

28

F

4

N

3 0 6

S

2 (M + H) + calcd, 678.1355; found, 678.1377. -119- WO 2007/002173 PCT/US2006/024109 (S)-3-(4-Acetylphenyl)-N-[(2S,3R)-l1-Benzyl-2-hydroxy-3-[(2 thiophenylmethyl)[(2,4,5-trifluorophenyl)sulfonyl]amino]propyl]-2-oxo-oxazolidine-5 carboxamide (38f). 1H NMR (400 MHz, CDC13) 88.02 (d, J= 9.2 Hz, 2H), 7.78-7.72 (m, 1H), 7.55 (d, J= 9.2 Hz, 2H), 7.21 (dd, J= 5.2, 1.2 Hz, 1H), 7.10-6.99 (m, 5H), 6.93-6.85 5 (m, 3H), 6.67 (d, J= 8.8 Hz, 1H), 4.82-4.70 (m, 3H), 4.17 (m, 1H), 4.10 (t, J= 10 Hz, 1H), 3.84 (m, 1H), 3.50-3.36 (m, 3H), 3.30 (d, J= 4.0 Hz, 1H), 3.04 (dd, J= 14.0, 4.4 Hz, 1H), 2.71 (dd, J= 14.0, 10.8 Hz, 1H), 2.62 (s, 3H); 13C NMR (100 MHz, CDC1 3 ) 3196.97, 168.80, 154.50 (dd, J= 252.3, 10.8 Hz), 153.4 (dt, J= 255.6, 12.2 Hz), 152.68, 146.28 (dd, J= 252.4, 10.5 Hz), 141.51, 137.53, 137.17, 133.25, 129.84 (2C), 129.45 (2C), 128.71, 10 128.62 (2C), 127.21, 127.16, 126.78, 119.76 (d, J= 22.0 Hz), 117.61 (2C), 107.74 (dd, J 27.3, 21.2 Hz), 72.22, 69.81, 53.69, 51.09, 51.06, 48.0, 47.66, 35.43, 26.67. HRMS (ESI) m/z: C 33

H

3 1

F

3

N

3 0 7

S

2 (M + H) + calcd, 702.1555; found, 702.1561. (5S)-N-[(1S,2R)-1-Benzyl-2-hydroxy-3-[[(3-methoxyphenyl)sulfonyl][(R) (tetrahydro-2-furanyl)methyl]amino]propyl]-2-oxo-3-phenyloxazolidine-5-carboxamide 15 (39a). 'H NMR (400 MHz, CDC1 3 ) 87.47-7.38 (m, 5H), 7.35 (d, J= 7.6 Hz, 1H), 7.29 (d, J = 1.8 Hz, 1H), 7.19 (t, J= 7.2 Hz, 2H), 7.11 (m, 3H), 7.0 (t, J= 7.6 Hz, 2H), 6.89 (t, J= 7.6 Hz, 1H), 6.83 (d, J= 10 Hz, 1H), 5.27 (br. s, 1H), 4.81 (dd, J = 10.4, 6.0 Hz, 1H), 4.31 4.18 (m, 2H), 4.05 (t,J= 9.6 Hz, 1H), 4.0 (t,J= 10.0 Hz, 1H), 3.92-3.80 (m, 2H, overlapping signal), 3.88 (s, 3H, overlapping signal), 3.66 (dt, J= 15.2, 2.4 Hz, 1H), 3.43 20 (dd, J= 9.2, 6.0 Hz, 1H), 3.05 (dd, J = 14.0, 4.4 Hz, 1H), 2.88 (dd, J= 9.2, 4.8 Hz, 1H), 2.84 (dd, J= 9.6, 4.8 Hz, 1H), 2.72 (dd, J= 13.2, 10.0 Hz, 1H), 2.04 (m, 1H), 1.92 (m, 2H), 1.47 (m, 1H); 13C NMR (100 MHz, CDC1 3 ) .0168.53, 160.22, 153.13, 139.78, 137.65, 137.57, 130.53, 129.67 (2C), 129.28 (2C), 128.44 (2C), 126.55, 124.67, 119.45, 119.02, 118.44 (2C), 112.68, 80.49, 73.81, 69.87, 68.48, 56.48, 56.27, 55.91, 52.90, 48.29, 35.96, 25 29.22, 25.46. HRMS (ESI) m/z: C 32

H

38

N

3 0 8 S (M + H) + calcd, 624.2379; found, 624.2390. (5S)-N-[(1S,2R)- 1-Benzyl-2-hydroxy-3-[[(3-methoxyphenyl)sulfonyl][(R) (tetrahydro-2-furanyl)methyl]amino]propyl]-3-(3-fluorophenyl)-2-oxo-oxazolidine-5 carboxamide (39b). 'H NMR (400 MHz, CDC1 3 ) 87.42 (t, J= 7.6 Hz, 1H), 7.38-7.32 (im, 2H), 7.28 (t, J= 2.4 Hz, 1H), 7.11 (m, 4H), 7.0 (t, J= 7.2 Hz, 2H), 6.91-6.86 (m, 2H), 6.84 30 (d, J= 9.6 Hz, 1H), 5.28 (d, J= 2.8 Hz, 1H), 4.82 (dd, J= 10.0, 5.6 Hz, 1H), 4.31-4.19 (m, 2H), 4.02 (m, 2H), 3.92-3.80 (m, 2H, overlapping signal), 3.85 (s, 3H, overlapping signal), 3.69-3.64 (m, 2H), 3.39 (dd, J= 9.2, 5.6 Hz, 1H), 3.05 (dd, J= 14.0, 4.4 Hz, 1H), 2.89 -120- WO 2007/002173 PCT/US2006/024109 2.82 (m, 2H), 2.71 (dd, J= 14.0, 10.4 Hz, 1H), 2.04 (m, 1H), 1.92 (m, 2H), 1.46 (m, 1H);

"

3 C NMR (100 MHz, CDC1 3 ) 168.29, 163.21 (d, J= 243.4 Hz), 160.22, 152.86, 139.75, 139.17 (d, J= 10.6 Hz), 137.59, 130.54, 130.46 (d, J= 9.1 Hz), 129.67 (2C), 128.40 (2C), 126.50, 119.43, 118.99, 113.48 (d,J = 3.1 Hz), 112.71, 111.38 (d, J= 20.4 Hz),.106.03 (d, 5 J= 27.3 Hz), 80.51, 73.85, 69.84, 68.49, 56.53, 56.31, 55.90, 52.87, 48.20, 35.92, 29.23, 25.46. HRMS (ESI) m/z: C 32

H

37

FN

3 08S (M + H) + caled, 642.2285; found, 642.2289. EXAMPLE 9 BIOLOGICAL EVALUATION OF HIV-1 PROTEASE INHIBITORS HIV-1 protease inhibitor activities were determined by fluorescence resonance 10 energy transfer (FRET) method (Matayoshi, E. D.; Wang, G. T.; Krafft, G. A.; Erickson, J. Novel fluorogenic substrates for assaying retroviral proteases by resonance energy transfer. Science 1990, 247, 954-958.) Protease substrate (Arg-Glu(EDANS)-Ser-Gln-Asn-Tyr-Pro Ile-Val-Gln-Lys(DABCYL)-Arg) was purchased from Molecular Probe. The energy transfer donor (EDANS) and acceptor (DABCYL) were labeled at its two ends respectively 15 to perform FRET. Fluorescence measurements were carried out on PTI fluorescence spectrophotometer (Photon Technology International) at 30 oC. Excitation and emission wavelengths were set at 340 nm and 490 nm, respectively. Each reaction was recorded for about 10 min. Wide type HIV-1 protease (Q7K) and its MDR mutants Ml (L10I, G48V, I54V, L63P, V82A), M2 (D30N, L63P, N88D), and M3 (L10I, L63P, A71V, G73S, I84V, 20 L90M) were desalted through PD-10 columns (Amersham Biosciences). Sodium Acetate (20 mM, pH 5) was used as elution buffer. Apparent protease concentrations were around 50 nM estimated by UV spectrophotometer (Shimadzu) at 280 rnm. All inhibitors were dissolved in DMSO and diluted to appropriate concentrations. Protease (2 gL) and inhibitor (2 RL) or DMSO were mixed and incubated for 20-30 min at room temperature before 25 initialing substrate cleavage reaction. Throughout this work, 150 iL of 1 gM substrate was used. Substrate buffer is composite of 0.1 M sodium acetate, 1 M sodium chloride, 1 mM ethylenediaminetetraacetic acid (EDTA), 1 mM dithiothreitol (DTT), 2% dimethylsulfoxide (DMSO) and 1 mg/mL bovine serum albumin (BSA) with an adjusted pH 4.7. Inhibitor binding dissociation constant (Ki) was obtained by nonlinear regression fitting (GraFit 5, 30 Erithacus software) to the plot of initial velocity as a function of inhibitor concentrations based on Morrison equation. (Greco, W. R.; Hakala, M. T. Evaluation of methods for estimating the dissociation constant of tight binding enzyme inhibitors. J. Biol. Chem. 1979, - 121 - WO 2007/002173 PCT/US2006/024109 254, 12104-12109.) The initial velocities were derived from the linear range of reaction curves. INCORPORATION BY REFERENCE The contents of all cited references (including literature references, issued patents, 5 published patent applications and GenBank Accession numbers as cited throughout this application) are hereby expressly incorporated by reference. When definitions of terms in documents that are incorporated by reference herein conflict with those used herein, the definitions used herein govern. EQUIVALENTS 10 Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims. -122-

Claims

1. A compound, or a pharmaceutically acceptable salt thereof, of formula I: O0 R 2 n R 3 -NN NSO2R4 O R 1 R 5 I wherein, independently for each occurrence, n is 1 or 2; R 1 is -OH, -SH, or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

2. The compound of claim 1, wherein R 1 is -OH.

3. The compound of claim 1, wherein R 2 is arallkyl or heteroaralkyl.

4. The compound of claim 1, wherein R 2 is aralkyl.

5. The compound of claim 1, wherein R 3 is aryl or heteroaryl.

6. The compound of claim 1, wherein R 3 is aryl.

7. The compound of claim 1, wherein R 4 is aryl or heteroaryl. - 123- WO 2007/002173 PCT/US2006/024109

8. The compound of claim 1, wherein R 4 is aryl.

9. The compound of claim 1, wherein R 5 is alkyl, heterocyclyl, aralkyl or heteroaralkyl.

10. The compound of claim 1, wherein R 1 is -OH; R 2 is aralkyl or heteroaralkyl; R 3 is aryl or heteroaryl; and R 4 is aryl or heteroaryl.

11. The compound of claim 1, wherein R 1 is -OH; R 2 is aralkyl or heteroaralkyl; R 3 is aryl or heteroaryl; and R 5 is alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

12. The compound of claim 1, wherein R 1 is -OH; R 2 is aralkyl or heteroaralkyl; R 4 is aryl or heteroaryl; and R 5 is alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

13. The compound of claim 1, wherein R 1 is -OH; R 3 is aryl or heteroaryl; R 4 is aryl or heteroaryl; and R 5 is alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

14. The compound of claim 1, wherein R 1 is -OH; R 2 is aralkyl; R3 is aryl; R 4 is aryl; and R5 is alkyl.

15. The compound of claim 1, wherein R, is -OH; R 2 is aralkyl; R3 is aryl; R 4 is aryl; and R5 is aralkyl.

16. The compound of claim 1, wherein RI is -OH; R 2 is aralkyl; R 3 is aryl; R 4 is aryl; and R 5 is heteroaralkyl.

17. The compound of claim 1, wherein R 1 is -OH; R2 is aralkyl; R3 is aryl; R 4 is aryl; and R5 is (heterocyclyl)alkyl.

18. A compound, or a pharmaceutically acceptable salt thereof, of formula II: 0 R 3 -N N NSO2R4 H OH "R 6 II wherein, independently for each occurrence, R3 is alkyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; -124- WO 2007/002173 PCT/US2006/024109 R 4 is aryl, heteroaryl, aralkyl or heteroaralkyl; and R 6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl; or a pharmaceutically acceptable salt thereof.

19. The compound of claim 18, wherein R 3 is aryl or heteroaryl.

20. The compound of claim 18, wherein R 3 is aryl.

21. The compound of claim 18, wherein R 4 is aryl or heteroaryl.

22. The compound of claim 18, wherein R 4 is aryl.

23. The compound of claim 18, wherein R 6 is alkyl, heterocyclyl, aryl or heteroaryl.

24. The compound of claim 18, wherein R 6 is alkyl.

25. The compound of claim 18, wherein R 3 is aryl or heteroaryl; and R 4 is aryl or heteroaryl.

26. The compound of claim 18, wherein R 3 is aryl or heteroaryl; and R 6 is alkyl, heterocyclyl, aryl or heteroaryl.

27. The compound of claim 18, wherein R 4 is aryl or heteroaryl; and R 6 is alkyl, heterocyclyl, aryl or heteroaryl.

28. The compound of claim 18, wherein R 3 is aryl or heteroaryl; R 4 is aryl or heteroaryl; and R 6 is alkyl, heterocyclyl, aryl or heteroaryl.

29. The compound of claim 18, wherein R 3 is aryl; and R 4 is aryl.

30. The compound of claim 18, wherein R 3 is aryl; and R 6 is alkyl.

31. The compound of claim 18, wherein R 4 is aryl; and R 6 is alkyl.

32. The compound of claim 18, wherein R 3 is aryl; R 4 is aryl; and R 6 is alkyl. F

33. The compound of claim 18, wherein R 3 is .__ ,- , CH 3 , O F OCH 3 CH 3 CF 3 F OCH 3 - 125 - WO 2007/002173 PCT/US2006/024109 0 - OCF 3 C-, C l , , N 0 NH CH 3 OH C H3 CH3 CH3 or H 3 C H OCH 3 / \ OCH 3

34. The compound of claim 18, wherein R 4 is O C H3 F -O F _ F NH 2 , \/ OCH O F N-OH, N ~ , W c N C3O H N NW CH 3 YY H NY-N CH3 S 0 ; wherein, independently for each occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7 ) 2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. -126- WO 2007/002173 PCT/US2006/024109 CH 3 CH 3 -<S 0 CH3

35. The compound of claim 18, wherein R is CH 3 , , , CH 3 , OH Oo O or F

36. The compound of claim 18, wherein R 3 is , , H 3 , O F OCH 3 CH 3 _F 3 -F X-- CH OCH 3 0 OCF 3 CF3z ,-O C3 ci a P N 0 O CH3 NH OH 3 OH P 3 OCH 3 OCH3 F NH2 OCH3 F OOHN - - - F, & CF3 C3 C - H OH NOH-OH, N , NNN - 127-- WO 2007/002173 PCT/US2006/024109 H H S N N CH3 N N CH 3 or ; wherein, independently for each occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7 ) 2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive. F 0

37. The compound of claim 18, wherein R 3 is , , H 3 , O F OCH 3 CH 3 CF 3 C /F , ,/ OCH3 H 0 - OCF 3 C CF CH3~~ CH3NHC NH CH 3 OH CH 3 CH 3 CH 3 N o H 3 3 ;and R 6 is H 3 , CH3 3. O. , HOCH3 0 H OH 3 0 H 0 /\X '/ \N' \-- OH' 0 N 0 N, or /\ OCH 3

38. The compound of claim 18, wherein R 4 is -- OCH3 F -F 0 F ,--& NH 2 ) \/ OCH32 O -& F - 128 - WO 2007/002173 PCT/US2006/024109 - N- '-CH 3 / CF \/CF 3 3 H 0, N-OH, , N H N NW N N CH3 SOW or H NYOH 3 ; wherein, independently for each occurrence, W is selected, from the group consisting of -NHR 7 or -NHR(CH 2 )pN(R 7 ) 2 ; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; p is 1-10 inclusive; and R 6 i CO CH 3 O OH GH 3 o O is CH 3 , -C-H 3 0 0 HH 00 F

39. The compound of claim 18, wherein R 3 is , , / H 3 , O F OCH 3 CH 3 OF 3 1 F , 0 OCH 3 , / O 0 - OCF 3 CF 3 \/ 0 O 00CH3 CH 3 OH CH 3 N _ CH3 O-CH 3 N, C H3 H3 CH 3 or; R 4 is -129- WO 2007/002173 PCT/US2006/024109 F FF- F 3 O N-NOCH 3 CH3 F N NCH3 0 i__@ I or __ s O ; wherein, independently for each occurrence, W is ,selected, from the group consisting of -NHR 7 or -NHR(CH2)pN(R')2; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; pis 1-10 inclusive; and R6 is ,H3 , , - -H3 OH Oor O1 ,O CHO ,I -O~ I - -: o \-O -H ,C N I 5 CO N N:S: OH OHO O 0 10 H H3 N NC.HCH N N CH 3 H h p i e i , \O 0 N30 -- for ;- whriidpnetyfrec 40 o un, Wr is hnaetca cetbe atteef selected, from the group cnitn f-~E r-~RC 2 ~( 7 2 7isslcefrmtegpconsisting ofhdoeakl rlkl eeorly n 0 0H ,0\ \-, - , N N/-'N &CZ / J(NH\ 0 - ~~~orY OHO 40 Acopond o aparacutcalyacetalesat heeo, eecedfrm3hegru WO 2007/002173 PCT/US2006/024109 OMe F O 0~ 0 1 -N/1 Sib N N >0 / 0 H OH N HI 0~ 7- I OMe N N OCH 3 F\\ H NO N Ns OH b- 0 H N 7 OMe F 0 iF a N N-OeN NI b oH OH -o HH 0 0 F \' /\\ NS OCH 3 0T OH F- N H OH 0 s 0 OMe7 NN N N S OMe N'o H H OH 0 0o OMe F 0 1 0 10 -F N N N 0 N/N kfl 0H OH C/-O H N'~ F 0 H - 131 - WO 2007/002173 PCT/US2006/024109 F 0O F0e F N N S FN s O0 H OH 00 O OMe 0MeO 0 ~ H OH 0 H N l 00 I NH 2 IOCH 3 No 0 ,~ ja N NO 0 -A N' \\ H OH o NY OYH NOH 0 0 N f 0 00 N N 'SN/ - N H YHNOH 0- H OHO H O 1\ 0 0 OH C 0 7 0 0 Y 0 0 c0 H- \\ N N' N N \ 0 OY0 OH 7130 WO 2007/002173 PCT/US2006/024109 0 OCH 3 , OMe O o .. FC o o MeO N N NS N N SO O" W o H"'-N- H O "S1 0 0 OHO O OH O 0 " OF3 O N H 2 0 0 N N S O CNH N NNHO F N N N N N NS F 3 OON OH NOO OH toNH to\ FC FC N N OCH 3 -133I OH O OH N 1 NH 2 N 13 0 o - N N-/ H N0 r/ N 0 O CF 3 0 H~NH 2 0 0 Fo 0 qF\ N o - N N's \ N N N-- N N 0 o H O / C 0 H N NO FC 0 0 o 0 N\ 1 C \N N N 0 / N' NA\ 0 \/ H H >/ 0~ OH 0 ~0 - 133 - WO 2007/002173 PCT/US2006/024109 F 3 C F O H O0 OH 0 F N ~ ~ /s0OH 0 H' N ' O C H 3 U OHN 0~~ OH\/H F 3 C 0 N'3 HN N N 0 0 0 OH H o OHN o N/\ o- HHc N 0 NH~ sN0 O '1 OH \N\\'oN 0 0 N N o\ -b- F OH N 0 0\N \O 0 N N 0 N 0 - " NOH 0 \ N 3 8 ~ 0 N0 H 0/ 0S O\ 0N N 0 U H N'N O3 '-/ O>F 0 0 0r- N ZN- N 0 O \N N 8 N 0sC //\-o OH OH- 0 \/N N N 0 N' ~ H H O a O 00 OH OH 0~~ ~ ~ ~~ 134 Nt, \ WO 2007/002173 PCT/US2006/024109 FCO OCH3 O H N OHHN N N Y N 3 0'N os o o cs OOOH H/ N ,.' ,bo / " ' - -J "sq N H 'o F 3 CO / O O \ NI 0 ' 0N N O H H OH N F3 13 d'o H \,, N H , NAS N- r..S- o OOH N H 0 OH \/N 0 U "NA '0 0 OH 0 NN N oco 0 'N'3 / O H N 0 \ A' 0 O \H NN - N35 0 0 OH CO NJ:-o H N U\ N I OHOS 0 I~ 0 \0 N \\ ' NO 0 ' N U H N \' N N 0 H NN 0 0 O - 135- WO 2007/002173 PCT/US2006/024109 0 \ S S NN N N NO W O N O ,-O OH SN N F0C N >-w FC 0 N>-w N N SN O N O \ OO OH NO OH N N 6, 0 N O OH OO\ OHN 3O 0 )W F3O O OC -w N N NO~\\S ON NN' N, O l O H, and 3 OCHe N N N N H OH O O wherein, independently for each occurrence, W is selected, from the group consisting of -NH-R 7 or -NH--R(CH2)pN(R7)2; R 7 is selected from the group consisting of hydrogen, alkyl, aralkyl, heteroaralkyl and acyl; and p is 1-10 inclusive.

41. A compound, or a pharmaceutically acceptable salt thereof, of formula IIIA: -136 N~ ~ )%-0 HH OH-O aly0 arly, heeraa1y an acl anansd 1ncuie 41.ein Aicompoudetl rr aehracial cceptaeWi slteeo, fo fgoru cnistigo -136- WO 2007/002173 PCT/US2006/024109 0 R 2 R, 5 RF 4 nN X 2 O R I R 7 0 IIIA wherein, independently for each occurrence, n is 1 or 2; X 2 is absent, -0-, -S- or -NR-; R 1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 7 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

42. The compound of claim 41, wherein n is 1.

43. The compound of claim 41, wherein X 2 is absent.

44. The compound of claim 41, wherein R, is -OH.

45. The compound of claim 41, wherein R 2 is aralkyl or heteroaralkyl.

46. The compound of claim 41, wherein R 2 is aralkyl. - 137 - WO 2007/002173 PCT/US2006/024109

47. The compound of claim 41, wherein R 3 is alkenyl, (amino)alklcyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

48. The compound of claim 41, wherein R 3 is aryl or heteroaryl.

49. The compound of claim 41, wherein R 4 is alkyl, aryl or heteroaryl.

50. The compound of claim 41, wherein R 5 is hydrogen.

51. The compound of claim 41, wherein R 7 is alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

52. The compound of claim 41, wherein R 7 is alkyl, (cycloalkyl)alkyl or aralkyl.

53. The compound of claim 41, wherein X 2 is absent; RI is -OH; R 2 is aralkyl; R 3 is aryl or heteroaryl; R 4 is alkyl, aryl or heteroaryl; R 5 is hydrogen; and R 7 is alkyl, (cycloalkyl)alkyl or aralkyl.

54. A compound, or a pharmaceutically acceptable salt thereof, of formula IIIB: ,R4 n 14 0 R 2 R5 N R3'X, N H R 1 R 7 0 IIIB wherein, independently for each occurrence, nis 1 or2; XI is absent, -0-, -S- or -NR-; R 1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; - 138- WO 2007/002173 PCT/US2006/024109 R 4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalklyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 7 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

55. The compound of claim 54, wherein n is 1.

56. The compound of claim 54, wherein X 1 is absent.

57. The compound of claim 54, wherein R 1 is -OH.

58. The compound of claim 54, wherein R 2 is aralkyl or heteroaralkyl.

59. The compound of claim 54, wherein R 2 is aralkyl.

60. The compound of claim 54, wherein R 3 is alkyl, aryl or heteroaryl.

61. The compound of claim 54, wherein R 4 is aryl or heteroaryl.

62. The compound of claim 54, wherein R 5 is hydrogen.

63. The compound of claim 54, wherein R 7 is alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

64. The compound of claim 54, wherein R 7 is alkyl, (cycloalkyl)alkyl or aralkyl.

65. The compound of claim 54, wherein X 1 is absent; R 1 is -OH; R 2 is aralkyl; R3 is aryl or heteroaryl; R4 is alkyl, aryl or heteroaryl; R5 is hydrogen; and R7 is alkyl, (cycloalkyl)alkyl or aralkyl.

66. A compound, or a pharmaceutically acceptable salt thereof, of formula IVA: - 139- WO 2007/002173 PCT/US2006/024109 Ph 0 H R 3 N R 4 _O OH R 7 O O IVA wherein, independently for each occurrence, R 3 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl; R 7 is alkyl, cycloalkyl, (cycloalkyl)alkyl or aralkyl; and the stereochemical configuration at any undefined stereocenter is R or S.

67. The compound of claim 66, wherein R 3 is aryl or heteroaralkyl.

68. The compound of claim 66, wherein R 4 is aryl, (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl.

69. The compound of claim 66, wherein R 7 is alkyl, cycloalkyl or (cycloalkyl)alkyl.

70. The compound of claim 66, R 3 is aryl or heteroaryl; R 4 is aryl, (amino)allyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl; and R 7 is alkyl, cycloalkyl or (cycloalkyl)alkyl.

71. The compound of claim 66, wherein R 3 is -Ph.

72. The compound of claim 66, wherein R 7 is 73. A compound, or a pharmaceutically acceptable salt thereof, of formula IYB: -140- WO 2007/002173 PCT/US2006/024109 R4 Ph 0H N R 3 ON N H OH R 7 0 IVB wherein, independently for each occurrence, R 3 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl; R 4 is alkyl, alkenyl, (amino)alkyl, (amido)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 7 is alkyl, cycloalkyl, (cycloalkyl)alkyl or aralkyl; and the stereochemical configuration at any undefined stereocenter is R or S.

74. The compound of claim 73, wherein R 3 is (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

75. The compound of claim 73, wherein R 4 is aryl or heteroaryl.

76. The compound of claim 73, wherein R 7 is alkyl, cycloalkyl or (cycloalkyl)allkyl.

77. The compound of claim 73, R 4 is aryl or heteroaryl; R 3 is aryl, (amino)alkyl, (amido)alkyl, (keto)alkyl (heterocyclyl)alkyl or heterocyclyl; and R 7 is alkyl, cycloalkyl or (cycloalkyl)alkyl.

78. The compound of claim 73, wherein R 4 is -Ph.

79. The compound of claim 73, wherein R 7 is

80. A compound, or a pharmaceutically acceptable salt thereof, selected from the group OH, o OH N H CH, 0 H0H 0 consisting of - 141 - WO 2007/002173 PCT/US2006/024109 o H'C CN - H N 0 roH o--CH I NH O~H CH, H H O O OH 0 OCH 3 H OH 0 KO0 \0CNC H,CCH, 0'N H'N H ON =-0 OH CH O N OH OCz < H OH H OH o0 NoH OH 0~ NH0C- CH, 00 0 N OH:<0 N n- L\.-R H X2 is sent, --, -S- or -NR-;R 2 0 R 3 -Ne N ' N X 2 C 0R, R 5 VA wherein, independently for each occurrence, X 2 is absent, -0-, -S- or -INR-; R 1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; - 142- WO 2007/002173 PCT/US2006/024109 R 4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

82. The compound of claim 81, wherein n is 1.

83. The compound of claim 81, wherein X 2 is absent.

84. The compound of claim 81, wherein R 1 is -OH.

85. The compound of claim 81, wherein R 2 is aralkyl or heteroaralkyl.

86. The compound of claim 81, wherein R 2 is aralkyl.

87. The compound of claim 81, wherein R 3 is alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

88. The compound of claim 81, wherein R 3 is aryl or heteroaryl.

89. The compound of claim 81, wherein R 4 is (heterocyclyl)alkyl.

90. The compound of claim 81, wherein R 5 is alkyl.

91. The compound of claim 81, wherein X 2 is absent; R 1 is -OH; R2 is aralkyl; R 3 is aryl; R 4 is alkyl, aryl or heteroaryl; and R 5 is alkyl.

92. A compound, or a pharmaceutically acceptable salt thereof, of formula VB: 0 R 2 0 R 3 , 1_K X 1 N N N-R4 R 1 R5 O 0 VB wherein, independently for each occurrence, - 143 - WO 2007/002173 PCT/US2006/024109 Xi is absent, -0-, -S- or -NR-; R 1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

93. The compound of claim 92, wherein n is 1.

94. The compound of claim 92, wherein XI is absent.

95. The compound of claim 92, wherein R 1 is -OH.

96. The compound of claim 92, wherein R 2 is aralkyl or heteroaralkyl.

97. The compound of claim 92, wherein R 2 is aralkyl.

98. The compound of claim 92, wherein R 3 is alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl.

99. The compound of claim 92, wherein R 4 is aryl or heteroaryl.

100. The compound of claim 92, wherein R 5 is alkyl.

101. The compound of claim 92, wherein X 1 is absent; R 1 is -OH; R 2 is aralkyl; R 4 is aryl; R 3 is alkyl, aryl or heteroaryl; and R 5 is alkyl. -144- WO 2007/002173 PCT/US2006/024109

102. A compound, or a pharmaceutically acceptable salt thereof, of formula VIA: Ph 00 R 3 -N N N R 4 O R 1 KR VIA wherein, independently for each occurrence, R, is -OH or -NH 2 ; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl; R 6 is alkyl, cycloalkyl, or aryl; and the stereochemical configuration at any undefined stereocenter is R or S.

103. The compound of claim 102, wherein R 1 is -OH.

104. The compound of claim 102, wherein R 1 is -NH 2 .

105. The compound of claim 102, wherein X 2 is -0-.

106. The compound of claim 102, wherein R 4 is heterocyclyl. 0 0

107. The compound of claim 102, wherein R 4 is - or

108. The compound of claim 102, wherein X 2 is -0-; and R 4 is heterocyclyl. 0

109. The compound of claim 102, wherein X 2 is -0-; and R 4 is I- .

110. The compound of claim 102, wherein R 3 is aryl or heteroaryl.

111. The compound of claim 102, wherein R 3 is - . - 145 - WO 2007/002173 PCT/US2006/024109

112. The compound of claim 102, wherein R 6 is alkyl.

113. The compound of claim 102, wherein R 6 is -CH(CH 3 ) 2 .

114. A compound, or a pharmaceutically acceptable salt thereof, of formula VIB: Ph R 3 , , 1,K X 1 NH N-R 4 RI IR6 O 0 VIB wherein, independently for each occurrence, RI is -OH or -NH 2 ; R 3 is aryl, (amino)alkyl, (amido)alkyl, heterocyclyl, (heterocyclyl)alkyl, heteroaryl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 6 is alkyl, cycloalkyl, or aryl; and the stereochemical configuration at any undefined stereocenter is R or S.

115. The compound of claim 114, wherein R, is -OH.

116. The compound of claim 114, wherein R, is -NH 2 .

117. The compound of claim 114, wherein X 1 is -O-.

118. The compound of claim 114, wherein R 3 is heterocyclyl. 0 0

119. The compound of claim 114, wherein R 3 is or

120. The compound of claim 114, wherein Xi is -0-; and R 3 is heterocyclyl. 0

121. The compound of claim 114, wherein X 1 is -0-; and R 3 is

122. The compound of claim 114, wherein R 4 is aryl or heteroaryl. -146- WO 2007/002173 PCT/US2006/024109

123. The compound of claim 114, wherein R 4 is ~ .

124. The compound of claim 114, wherein R 6 is alkyl.

125. The compound of claim 114, wherein R 6 is -CH(CH 3 ) 2 .

126. A compound, or a pharmaceutically acceptable salt thereof, selected from the group N N 00 0 N N 0 0 N N 0 H OH CH3 H OH CH, OH CH, consisting of CH , CH 3 , CH, -Q -Q \/No o 0 o0 O NC)NO OfN N-'o O N o H HHLfH N" N _ H OH CH, H NH,2 CH, CH 3 , and CH,

127. A compound, or a pharmaceutically acceptable salt thereof, of formula VIIA: O R 2 H R4 N N X 2 R3-N N N 2 O R 1 R 5 O VIIA wherein, independently for each occurrence, X 2 is absent, -0-, -S- or -NR-; RI is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; - 147 - WO 2007/002173 PCT/US2006/024109 R 4 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

128. The compound of claim 127, wherein n is 1.

129. The compound of claim 127, wherein X 2 is absent.

130. The compound of claim 127, wherein R 1 is -OH or -NH 2 .

131. The compound of claim 127, wherein R 2 is aralkyl or heteroaralkyl.

132. The compound of claim 127, wherein R 2 is aralkyl.

133. The compound of claim 127, wherein R 3 is aryl or heteroaryl.

134. The compound of claim 127, wherein R 4 is (amido)alkyl or heterocyclyl.

135. The compound of claim 127, wherein R 5 is alkyl or aryl.

136. The compound of claim 127, wherein X 2 is absent; R 1 is -OH; R 2 is aralkyl; R 3 is aryl; R 4 is (amido)alkyl or heterocyclyl; and R 5 is alkyl or aryl.

137. A compound, or a pharmaceutically acceptable salt thereof, of formula VIIB: R4 0 R 2 'N 3'X 1 N NN 0 O H I R 1 R 5 O VIIB wherein, independently for each occurrence, X 1 is absent, -0-, -S- or -NR-; R 1 is -OH, -SH or -NHR; R is hydrogen, alkyl, aralkyl, heteroaralkyl or acyl; - 148- WO 2007/002173 PCT/US2006/024109 R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkcyl, aralkyl or heteroaralkyl; R 3 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 5 is hydrogen, alkyl, (cycloalkyl)alkyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

138. The compound of claim 137, wherein n is 1.

139. The compound of claim 137, wherein X 1 is absent.

140. The compound of claim 137, wherein R 1 is -OH or -NH2.

141. The compound of claim 137, wherein R 2 is aralkyl or heteroaralkyl.

142. The compound of claim 137, wherein R 2 is aralkyl.

143. The compound of claim 137, wherein R 3 is (amido)alkyl or heterocyclyl.

144. The compound of claim 137, wherein R 4 is aryl or heteroaryl.

145. The compound of claim 137, wherein R 5 is alkyl or aryl.

146. The compound of claim 137, wherein X 1 is absent; R 1 is -OH; R 2 is aralkyl; R 4 is aryl; R 3 is (amido)alkyl or heterocyclyl; and R 5 is alkyl or aryl.

147. A compound, or a pharmaceutically acceptable salt thereof, of formula VIIIA: Ph " ( _, H F4 R3-N/-- N - N 'N Y " x 2 O- O 0 OH R,3O VillA VIA149 - 149 - WO 2007/002173 PCT/US2006/024109 wherein, independently for each occurrence, X 2 is absent or -0-; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is aryl, heteroaryl, aralkyl or heteroaralkyl; R 6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R or S.

148. The compound of claim 147, wherein X 2 is absent.

149. The compound of claim 147, wherein R 3 is aryl or heteroaryl.

150. The compound of claim 147, wherein R 3 is - .

151. The compound of claim 147, wherein R 4 is (amino)alkyl, (amido)alkyl or heterocyclyl. OO OO N N / /

152. The compound of claim 147, wherein R 4 is W or W ; and W is aryl or heteroaryl. D 1 D 2 -O D3

153. The compound of claim 152, wherein W is D 5 D 4 ; and D 1 , D 2 , D 3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano.

154. The compound of claim 152, wherein W is - .

155. The compound of claim 147, wherein R 6 is alkyl or aryl. -150- WO 2007/002173 PCT/US2006/024109 CH 3 N

156. The compound of claim 147, wherein R 6 is CH 3 or

157. A compound, or a pharmaceutically acceptable salt thereof, of formula VIIIB: R4 Ph H R3'X N N 0 H OH O R VIIIB wherein, independently for each occurrence, X 1 is absent or -0-; R 3 is aryl, heteroaryl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 6 is alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R or S.

158. The compound of claim 157, wherein X 1 is absent.

159. The compound of claim 157, wherein R 4 is aryl or heteroaryl.

160. The compound of claim 157, wherein R4 is - .

161. The compound of claim 157, R 3 is (amino)alkyl, (amido)alkyl or heterocyclyl. N N / /

162. The compound of claim 157, wherein R 3 is W or W ; and W is aryl or heteroaryl. - 151 - WO 2007/002173 PCT/US2006/024109 D1 D2 Di 0D3

163. The compound of claim 162, wherein W is D5 D 4 ; and D 1 , D 2 , D 3 , D 4 and D 5 are independently selected from the group consisting of hydrogen, halogen, azide, alkyl, aralkyl, alkenyl, alkynyl, cycloalkyl, hydroxyl, alkoxyl, amino, nitro, sulfhydryl, imino, amido, phosphonate, phosphinate, carbonyl, carboxyl, silyl, ether, alkylthio, sulfonyl, sulfonamido, ketone, aldehyde, ester, heterocyclyl, aryl, heteroaryl, trifluoromethyl and cyano.

164. The compound of claim 162, wherein W is ~ .

165. The compound of claim 157, wherein R 6 is alkyl or aryl. CH 3 N

166. The compound of claim 157, wherein R 6 is CH 3 or .

167. A compound, or a pharmaceutically acceptable salt thereof, selected from the group 0H,C!j CH, I~ SH HCO N -- < H OHOJi N'~N N ) N 0 N "OH N 0 '", = OH N O CHC H3C'CHz Cil H~c CH, CH, consisting of 1-13ccii 3 HC and O \ C HaCH, 0 O N' N N CNH N OH O0 OCH 3 N

168. A compound, or a pharmaceutically acceptable salt thereof, of formula IX: - 152- WO 2007/002173 PCT/US2006/024109 0 0 n N N R 3 -N H H S0 OH R 2 OH 0 IX wherein, independently for each occurrence, n is 1 or 2; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, arallkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

169. The compound of claim 168, wherein n is 1.

170. The compound of claim 168, wherein R 2 is - .

171. A compound, or a pharmaceutically acceptable salt thereof, of formula X: 0 0 0 RN N NHR 4 R 3 -N H RH7 0 OH O S R 7 X wherein, independently for each occurrence, nis 1 or2; - 153 - WO 2007/002173 PCT/US2006/024109 R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 7 is hydrogen, allkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

172. The compound of claim 171, wherein n is 1.

173. A compound, or a pharmaceutically acceptable salt thereof, of formula XI: 0 R-N N N N-R 4 H OH 0 - 0 NHR 2 XI wherein, independently for each occurrence, nis 1 or2; R 2 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

174. The compound of claim 173, wherein n is 1. -154- WO 2007/002173 PCT/US2006/024109

175. A compound, or a pharmaceutically acceptable salt thereof, of formula XII: 0 n N N Z R 3 -N H OH NHR 4 XII wherein, independently for each occurrence, n is 1 or 2; Z is hydrogen, R 4 , or OR 4 ; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

176. The compound of claim 175, wherein n is 1.

177. A compound, or a pharmaceutically acceptable salt thereof, of formula XIII: O O OH m R 3 -N N N 0 n 0 O NHR 4 XIII wherein, independently for each occurrence, nis 1 or2; m is 1 or 2; - 155 - WO 2007/002173 PCT/US2006/024109 R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

178. The compound of claim 177, wherein n is 1.

179. A compound, or a phanrmaceutically acceptable salt thereof, of formula XIV: O 0 H OH R 3 -N N N S 0 NHR4 XIV wherein, independently for each occurrence, n is 1 or2; R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

180. The compound of claim 179, wherein n is 1.

181. A compound, or a pharmaceutically acceptable salt thereof, of formula XV: -156- WO 2007/002173 PCT/US2006/024109 0 H O OH H 3~ N N Kn 0I S 0 NHR 4 XV wherein, independently for each occurrence, R 3 is hydrogen, alkyl, alkenyl, (amino)alkyl, (amido)alkyl, (keto)alkyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; R 4 is hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, (heterocyclyl)alkyl, aralkyl or heteroaralkyl; and the stereochemical configuration at any undefined stereocenter is R, S, or a mixture of these configurations.

182. The compound of claim 181, wherein n is 1.

183. A pharmaceutical composition, comprising a pharmaceutical carrier and a therapeutically effective amount of a compound of any one of claims 1-182.

184. A method for treating an HIV infection, comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any one of claims 1-182.

185. A method for treating an HIV infection, comprising administering to a mammal in need thereof a therapeutically effective amount of a pharmaceutical composition of claim 183.

186. The method of claim 184, wherein the compound is administered as part of a highly active antiretroviral therapy (HAART) regimen.

187. The method of claim 185, wherein the pharmaceutical composition is administered as part of a highly active antiretroviral therapy (HAART) regimen.

188. The method of any one of claims 184-187, further comprising administering a second therapeutic agent. -157- WO 2007/002173 PCT/US2006/024109

189. The method of claim 188, wherein the second therapeutic agent is a non-nucleoside reverse transcriptase inhibitor (NNRTI), a nucleoside reverse transcriptase inhibitor (NRTI), a nucleotide reverse transcriptase inhibitor, an entry inhibitor, an integrase inhibitor, a fusion inhibitor, a protease inhibitor, or an inhibitor of a metabolic enzyme.

190. The method of claim 188, wherein the second therapeutic agent is selected from the group consisting of efavirenz (SustivaTM), nevirapine (ViramuneTM), delavirdine (RescriptorTm), AZT (zidovudine, RetrovirTM)/3TC (lamivudine, Epivir T M ), d4T (stavudine, ZeritTM)/3TC, ddl (didanosine, VidexTM/VidexECTM), ddC (zalcitabine, HividTM), d4T, tenofovir (VireadTM), and enfuvirtide (FuzeonTm).

191. The method of claim 188, wherein the second therapeutic agent is selected from the group consisting of amprenavir (Agenerase@; APV), tipranavir (Aptivus@; TPV), indinavir (Crixivan®; IDV), saquinavir (Invirase®; SQV), lopinavir and ritonavir (Kaletra®; LPV), fosamprenavir (Lexiva®; FPV), ritonavir (Norvir®; RTV), atazanavir (Reyataz®; ATZ), nelfinavir (Viracept®; NFV), brecanavir, and darunavir.

192. The method of claim 188, wherein the second therapeutic agent is ritonavir (Kaletra®; LPV).

193. The method of claim 188, wherein the second therapeutic agent is selected from the group consisting of zidovudine (AZT; Azidothymidine; Retrovir®), didanosine (Dideoxyinosine; ddl; Videx®), zalcitabine (Dideoxycytidine; ddC; Hivid®), lamivudine (3TC; Epivir®), stavudine (2',3'-didehydro-3'-deoxythymidine; D4T; Zerit®), abacavir succinate (1592U89 succinate; Ziagen® ABC), Combivir® (lamivudine & zidovudine; (-)-3TC & AZT), and Trizivir® (abacavir & lamivudine & zidovudine; ABC & (-)-3TC & AZT).

194. The method of claim 188, wherein the second therapeutic agent is selected from the group consisting of nevirapine (BI-RG-587; Viramune@), delavirdine (BHAP; U-90152; Rescriptor®), and (efavirenz; DMP-266; Sustiva@).

195. The method of claim 188, wherein the second therapeutic agent is T-20 (Fuzeon®; Enfuvirtide; DP-178; Pentafuside; GP41 127-162 AA).

196. The method of claim 188, wherein the second therapeutic agent is TMCC114. - 158- WO 2007/002173 PCT/US2006/024109

197. The method of claim 186, further comprising administering a reverse transcriptase inhibitor.

198. The method of claim 188, wherein the second therapeutic agent is lupinavir.

199. The method of claim 198, further comprising administering a reverse transcriptase inhibitor. - 159 -